<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2681333-A1" country="EP" doc-number="2681333" kind="A1" date="20140108" family-id="45852725" file-reference-id="318301" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586933" ucid="EP-2681333-A1"><document-id><country>EP</country><doc-number>2681333</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12709436-A" is-representative="NO"><document-id mxw-id="PAPP154849125" load-source="docdb" format="epo"><country>EP</country><doc-number>12709436</doc-number><kind>A</kind><date>20120301</date><lang>EN</lang></document-id><document-id mxw-id="PAPP198569529" load-source="docdb" format="original"><country>EP</country><doc-number>12709436.5</doc-number><date>20120301</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140557602" ucid="US-201161448137-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161448137</doc-number><kind>P</kind><date>20110301</date></document-id></priority-claim><priority-claim mxw-id="PPC140557586" ucid="US-2012027351-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012027351</doc-number><kind>W</kind><date>20120301</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989323266" load-source="docdb">C12Q   1/68        20060101AFI20120919BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1624975893" load-source="docdb" scheme="CPC">C12Q2600/118       20130101 LA20180616BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1624975894" load-source="docdb" scheme="CPC">C12Q2600/112       20130101 LA20180616BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1624975895" load-source="docdb" scheme="CPC">C12Q2600/158       20130101 LA20180616BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1713571022" load-source="docdb" scheme="CPC">G01N  33/57438     20130101 LA20180104BHEP        </classification-cpc><classification-cpc mxw-id="PCL2060962843" load-source="docdb" scheme="CPC">C12Q   1/6886      20130101 FI20140310BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365432" lang="DE" load-source="patent-office">VORHERSAGE VON GASTROENTEROPANKREATISCHEN NEUROENDOKRINEN NEOPLASMEN (GEP-NENS)</invention-title><invention-title mxw-id="PT132365433" lang="EN" load-source="patent-office">PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs)</invention-title><invention-title mxw-id="PT132365434" lang="FR" load-source="patent-office">PRÉDICTION DE NÉOPLASMES NEUROENDOCRINIENS GASTRO-ENTÉROPANCRÉATIQUES (GEP-NEN)</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919542270" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV YALE</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919504127" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>YALE UNIVERSITY</last-name></addressbook></applicant><applicant mxw-id="PPAR919006367" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Yale University</last-name><iid>100257140</iid><address><street>433 Temple Street</street><city>New Haven, CT 06511</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919521715" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>MODLIN IRVIN M</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919520032" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>MODLIN, Irvin, M.</last-name></addressbook></inventor><inventor mxw-id="PPAR919014762" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>MODLIN, Irvin, M.</last-name><address><street>11 Tulip Tree Lane</street><city>Woodbridge, CT 06525</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919011650" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Irvine, Jonquil Claire</last-name><iid>101207454</iid><address><street>Harrison Goddard Foote LLP 8th Floor 140 London Wall</street><city>London EC2Y 5DN</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012027351-W"><document-id><country>US</country><doc-number>2012027351</doc-number><kind>W</kind><date>20120301</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012119013-A1"><document-id><country>WO</country><doc-number>2012119013</doc-number><kind>A1</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549778623" load-source="docdb">AL</country><country mxw-id="DS549766507" load-source="docdb">AT</country><country mxw-id="DS549778624" load-source="docdb">BE</country><country mxw-id="DS549848623" load-source="docdb">BG</country><country mxw-id="DS549862514" load-source="docdb">CH</country><country mxw-id="DS549778633" load-source="docdb">CY</country><country mxw-id="DS549766873" load-source="docdb">CZ</country><country mxw-id="DS549917235" load-source="docdb">DE</country><country mxw-id="DS549778634" load-source="docdb">DK</country><country mxw-id="DS549778635" load-source="docdb">EE</country><country mxw-id="DS549848239" load-source="docdb">ES</country><country mxw-id="DS549848624" load-source="docdb">FI</country><country mxw-id="DS549848625" load-source="docdb">FR</country><country mxw-id="DS549917236" load-source="docdb">GB</country><country mxw-id="DS549778636" load-source="docdb">GR</country><country mxw-id="DS549917237" load-source="docdb">HR</country><country mxw-id="DS549766874" load-source="docdb">HU</country><country mxw-id="DS549862515" load-source="docdb">IE</country><country mxw-id="DS549778649" load-source="docdb">IS</country><country mxw-id="DS549848630" load-source="docdb">IT</country><country mxw-id="DS549778650" load-source="docdb">LI</country><country mxw-id="DS549917238" load-source="docdb">LT</country><country mxw-id="DS549766508" load-source="docdb">LU</country><country mxw-id="DS549848631" load-source="docdb">LV</country><country mxw-id="DS549848632" load-source="docdb">MC</country><country mxw-id="DS549766513" load-source="docdb">MK</country><country mxw-id="DS549766514" load-source="docdb">MT</country><country mxw-id="DS549848240" load-source="docdb">NL</country><country mxw-id="DS549846218" load-source="docdb">NO</country><country mxw-id="DS549848241" load-source="docdb">PL</country><country mxw-id="DS549848633" load-source="docdb">PT</country><country mxw-id="DS549766875" load-source="docdb">RO</country><country mxw-id="DS549848634" load-source="docdb">RS</country><country mxw-id="DS549848274" load-source="docdb">SE</country><country mxw-id="DS549862516" load-source="docdb">SI</country><country mxw-id="DS549846219" load-source="docdb">SK</country><country mxw-id="DS549846220" load-source="docdb">SM</country><country mxw-id="DS549766515" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99830192" ref-ucid="WO-2012119013-A1" lang="EN" load-source="patent-office"><p num="0000">Described are embodiments related to gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) biomarkers and agents, systems, and kits for detecting the same, and associated GEP-NEN diagnostic, prognostic, and predictive methods and uses thereof, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes.</p></abstract><abstract mxw-id="PA100327020" ref-ucid="WO-2012119013-A1" lang="EN" source="national office" load-source="docdb"><p>Described are embodiments related to gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) biomarkers and agents, systems, and kits for detecting the same, and associated GEP-NEN diagnostic, prognostic, and predictive methods and uses thereof, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes.</p></abstract><abstract mxw-id="PA99830193" ref-ucid="WO-2012119013-A1" lang="FR" load-source="patent-office"><p num="0000">Dans ses modes de réalisation, la présente invention se rapporte à des biomarqueurs et à des agents de néoplasmes neuroendocriniens gastro-entéropancréatiques (GEP-NEN, Gastroenteropancreatic Neuroendocrine Neoplasm). L'invention se rapporte d'autre part à des systèmes et à des kits pour leur détection. L'invention se rapporte par ailleurs à des procédés associés de diagnostic, de pronostic et de prédiction de GEP-NEN. L'invention se rapporte en outre à des utilisations de ces GEP-NEN comme, par exemple, la détection, la prédiction, la stadification, le profilage, la classification et la surveillance de l'efficacité du traitement ainsi que d'autres résultats cliniques.</p></abstract><abstract mxw-id="PA100327021" ref-ucid="WO-2012119013-A1" lang="FR" source="national office" load-source="docdb"><p>Dans ses modes de réalisation, la présente invention se rapporte à des biomarqueurs et à des agents de néoplasmes neuroendocriniens gastro-entéropancréatiques (GEP-NEN, Gastroenteropancreatic Neuroendocrine Neoplasm). L'invention se rapporte d'autre part à des systèmes et à des kits pour leur détection. L'invention se rapporte par ailleurs à des procédés associés de diagnostic, de pronostic et de prédiction de GEP-NEN. L'invention se rapporte en outre à des utilisations de ces GEP-NEN comme, par exemple, la détection, la prédiction, la stadification, le profilage, la classification et la surveillance de l'efficacité du traitement ainsi que d'autres résultats cliniques.</p></abstract><description mxw-id="PDES51232126" ref-ucid="WO-2012119013-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS </p><p id="p0002" num="0002"> (GEP-NENs) </p><p id="p0003" num="0003">Cross-Reference to Related Applications </p><p id="p0004" num="0004"> [0001]This application claims benefit of United States provisional application No. 61/448,137, filed on March 1, 2011, the disclosure of which is hereby incorporated by reference in its entirety for all purposes. </p><p id="p0005" num="0005">Reference to Sequence Listing Submitted Via EFS-Web </p><p id="p0006" num="0006"> [0002] The entire content of the following electronic submission of the sequence listing via the USPTO EFS-WEB server, as authorized and set forth in MPEP § 1730 II.B.2(a)(C), is incorporated herein by reference in its entirety for all purposes. The sequence listing is identified on the electronically filed text file as follows: 
<img id="imgf000002_0001" he="12" wi="125" file="imgf000002_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 </p><p id="p0007" num="0007"> Technical Field </p><p id="p0008" num="0008"> [0003] The invention described herein relates to gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) biomarkers and agents, systems, and kits for detecting the same, and associated GEP-NEN diagnostic and prognostic methods, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes. </p><p id="p0009" num="0009">Background Art </p><p id="p0010" num="0010"> [0004] Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN, also called </p><p id="p0011" num="0011">Gastroenteropancreatic (GEP) neuroendocrine tumor and neuoroendocrine tumor (NET)) is the second most prevalent malignant tumor of the gastrointestinal (GI) tract in the U.S., more prevalent than gastric, esophageal, pancreatic, and hepatobiliary neoplasms, with an incidence of about 2.5-5 cases per 100,000. Incidence and prevalence have increased between 100 and 600 percent in the U.S. over the last thirty years, with no increase in survival. 
<!-- EPO <DP n="3"/>-->
 [0005] Heterogeneity and complexity of GEP-NENs has made diagnosis, treatment, and classification difficult. These neoplasms lack several mutations commonly associated with other cancers; microsatellite instability is largely absent. See Tannapfel A, Vomschloss S, Karhoff D, et al., "BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors," Am J Clin Pathol 2005;123(2):256-60; Kidd M, Eick G, Shapiro MD, et al. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors," Cancer 2005;103(2):229-36. Individual histopathologic subtypes associate with distinct clinical behavior, yet there is no definitive, generally accepted pathologic classification or prediction scheme, hindering treatment development. </p><p id="p0012" num="0012"> [0006] Existing diagnostic and prognostic approaches include imaging {e.g., CT and MRI), histology, and detection of some gene products. Available methods are limited, for example, by low sensitivity and/or specificity, and inability to detect early-stage disease. GEP-NENs often go undiagnosed until they are metastatic and often untreatable. </p><p id="p0013" num="0013"> [0007] There is a need for specific and sensitive methods and agents for detection of GEP- NENs, including early-stage GEP-NENs, for example, for use in diagnosis, prognosis, prediction, staging, classification, treatment, monitoring, and risk assessment, and for investigating and understanding molecular factors of pathogenesis, malignancy, and </p><p id="p0014" num="0014">aggressiveness of this disease. For example, such methods and agents are needed that can be performed simply, rapidly, and at relatively low cost. Provided herein are methods, </p><p id="p0015" num="0015">compositions, and combinations that meet these needs. </p><p id="p0016" num="0016">Summary </p><p id="p0017" num="0017"> [0008] In one aspect, the present invention relates to gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) biomarkers, the detection of which may be used in diagnostic, prognostic and predictive methods. Among the provided objects are GEP-NEN biomarkers, panels of the biomarkers, agents for binding and detecting the biomarkers, kits and systems containing such agents, and methods and compositions for detecting the biomarkers, for example, in biological samples, as well as prognostic, predictive, diagnostic, and therapeutic uses thereof. </p><p id="p0018" num="0018"> [0009] Provided are agents, sets of agents, and systems containing the agents for GEP-NEN prognosis, detection and diagnosis. Typically, the systems include a plurality of agents (e.g., set of agents), where the plurality specifically binds to and/or detects a plurality of GEP-NEN biomarkers in a panel of GEP-NEN biomarkers. Typically, the agents are isolated polypeptides 
<!-- EPO <DP n="4"/>-->
 or polynucleotides which specifically bind to one or more GEP-NEN biomarkers. For example, provided are sets of isolated polynucleotides and polypeptides that bind to a panel of GEP-NEN biomarkers, and methods and uses of the same. </p><p id="p0019" num="0019"> [0010] Also provided are prognostic, diagnostic and predictive methods and uses of the agents, compositions, systems, and kits for GEP-NEN and associated conditions, syndromes and symptoms. For example, provided are methods and uses for detection, diagnosis, classification, prediction, therapeutic monitoring, prognosis, or other evaluation of GEP-NEN or an outcome, stage or level of aggressiveness or risk thereof, or associated condition. In some embodiments, the methods are performed by determining the presence, absence, expression levels, or expression profile of a GEP-NEN biomarker, more typically a plurality of GEP-NEN </p><p id="p0020" num="0020">biomarkers, such as a panel of biomarkers, and/or comparing such information with normal or reference expression levels or profiles or standards. Thus, in some embodiments, the methods are carried out by obtaining a biological test sample and detecting the presence, absence, expression levels, or expression profile of a GEP-NEN biomarker as described herein, more typically of a panel of at least two of the provided GEP-NEN biomarkers. For example, the methods can be performed with any of the systems of agents, e.g., polynucleotides or polypeptides, provided herein. For example, the methods generally are carried out using one or more of the provided systems. </p><p id="p0021" num="0021"> [0011] Provided are methods, agents and compositions for detection of and distinguishing between a number of different GEP-NEN types, stages, and sites (for example, pancreatic vs. small intestine GEP-NEN). In one aspect, differentiating between sites can provide prognostic information or help identify the GEP-NEN. Thus, in some embodiments, the methods distinguish between small intestine NENs (STNENs) and pancreatic NENs (PI-NENs). </p><p id="p0022" num="0022">Exemplary GEP-NEN types and stages include metastatic and primary GEP-NEN, GEP-NENs that are or are not responsive to various treatment approaches, and various GEP-NENs subtypes, including well-differentiated NET (WDNET), primary well differentiated nuroendocrine carcinoma (WDNEC), primary poorly differentiated neuroendocrine tumor (PDNET), primary poorly differentiated NEC (PDNEC), metastatic WDNET (WDNET MET), metastatic WDNEC (WDNEC MET) metastatic PDNEC (PDNEC MET) and metastatic PDNET (PDNET MET). </p><p id="p0023" num="0023"> [0012] In one aspect, the provided methods and compositions may be used to specifically and sensitively detect GEP-NENs, such as early-stage, primary, or asymptomatic GEP-NENs; in some aspects, the methods and compositions may be used to predict disease progression, 
<!-- EPO <DP n="5"/>-->
 treatment response, and metastasis. Methods and compositions provided herein are useful for diagnosis, prognosis, prediction (i.e., prediction of metastases in early-stage and primary GEP- NENs), staging, classification, treatment, monitoring, assessing risk, and investigating molecular factors associated with GEP-NEN disease. </p><p id="p0024" num="0024"> [0013] Provided are such methods capable of being carried out quickly, simply, and at relatively low cost, as compared to other diagnostic and prognostic methods. </p><p id="p0025" num="0025"> [0014] Provided are methods and compositions that are useful for defining gene expression- based classification of GEP-NENs, and thus are useful for allowing the prediction of malignancy and metastasis, such as in early stage disease or using histologically negative samples, providing accurate staging, facilitating rational therapy, and in developing large validated clinical datasets for GEP-NEN- specific therapeutics. </p><p id="p0026" num="0026"> [0015] The GEP-NEN biomarkers include biomarkers, the expression of which is different in or is associated with the presence or absence of GEP-NEN, or is different in or is associated with a particular classification, stage, aggressiveness, severity, degree, metastasis, symptom, risk, treatment responsiveness or efficacy, or associated syndrome. The panel of GEP-NEN biomarkers typically includes at least 2 GEP-NEN biomarkers, typically at least 3 biomarkers. In some embodiments, the panel of biomarkers includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, or 100 or more biomarkers, or includes at or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, or 100 GEP-NEN biomarkers, or more. </p><p id="p0027" num="0027"> [0016] For example, in some aspects, the panel of biomarkers includes at least 3, at least 11, at least 21, or at least 29 biomarkers, at least 51 biomarkers, or at least 75 more biomarkers. In a particular example, the panel contains at least 51 biomarkers or about 51 biomarkers or 51 biomarkers. Because the systems contain a plurality of agents (generally polypeptides or polynucleotides) that specifically bind to or hybridize to the biomarkers in the panel, the number of biomarkers generally relates to the number of agents in a particular system. For example, among the provided systems is a system that contains 51 agents, which specifically hybridize to or bind to a panel of 51 GEP-NEN biomarkers, respectively. 
<!-- EPO <DP n="6"/>-->
 [0017] In some aspects, the panel of biomarkers includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51, and/or all of the following groups of gene products, including polynucleotides (e.g. , transcripts) and polypeptides: </p><p id="p0028" num="0028"> [0018] AKAP8L, ATP6V1H, BNTP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS 13C, WDFY3, ZFHX3, ZXDC, ZZZ3, APLP2, CD59, ARAF1, BRAF1, KRAS, and RAF1 gene products; </p><p id="p0029" num="0029"> [0019] AKAP8L, ATP6V1H, BNTP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS 13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products; and </p><p id="p0030" num="0030"> [0020] APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT1, and VMAT2 gene products. </p><p id="p0031" num="0031"> [0021] In some examples, the panel of biomarkers includes AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, </p><p id="p0032" num="0032">MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS 13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </p><p id="p0033" num="0033"> [0022] In some examples, the panel of biomarkers includes APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT1, and VMAT2 gene products. </p><p id="p0034" num="0034"> [0023] In some examples, the panel of biomarkers includes AKAP8L, APLP2, ARAF1, ATP6V1H, BNIP3L, BRAF, C21orf7, CD59, COMMD9, CTGF, ENPP4, FAM13A, FLJ10357, FZD7, GLT8D1, HDAC9, HSF2, Ki67, KRAS, LEOl, MORF4L2, NAP1L1, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PNMA2, PQBPl, RAF1, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TPH1, TRMT112, VMAT1, VMAT2, VPS 13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </p><p id="p0035" num="0035"> [0024] In some examples, the panel of biomarkers includes an APLP2 gene product, a CD59 gene product, an ARAF1 gene product, a BRAF1 gene product, a KRAS gene product, or a RAF1 gene product. 
<!-- EPO <DP n="7"/>-->
 [0025] In some examples, the panel of GEP-NEN biomarkers includes APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAPILI, PNMA2, RAFl, TPHl, and VMAT2 gene products; or the panel of GEP-NEN biomarkers includes APLP2, ARAF1, BRAF1, CD59, KRAS, RAFl, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCKl, X2BTB48, CgA, CTGF, FZD7, Ki-67, Kissl, MAGE-D2, MTA1, NAPILI, NRP2, Tphl, VMAT1, VMAT2 and Survivin gene products. </p><p id="p0036" num="0036"> [0026] In some examples, it further includes further includes a gene product selected from the group consisting of MAGE-D2, MTA1, Survivin, Kissl, HOXC6, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, CTGF, PTPRN2, SPOCKl, and SCG5 gene products. </p><p id="p0037" num="0037"> [0027] In other examples, the panel of GEP-NEN biomarkers includes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 of, or includes each of, the biomarkers in one, more, or all of the following groups of gene products, including polynucleotides (e.g., transcripts) and polypeptides: </p><p id="p0038" num="0038"> [0028] (a) APLP2, ARAF1, BRAF1, CD59, KRAS, RAFl, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCKl, X2BTB48, CgA, CTGF, FZD7, Ki-67, Kissl, MAGE-D2, MTA1, NAPILI, NRP2, Tphl, VMAT1, VMAT2, and Survivin gene products; (b) MAGE-D2, MTA1, NAPILI, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCKl, HOXC6, CTGF, PTPRN2, SCG5, and Tph gene products; (c) ARAF1, BRAF, CTGF, FZD7, Ki67, KRAS, NAPILI, PNMA2, RAFl, TPHl, and VMAT2 gene products; (d) CXCL14, GRIA2, HOXC6, Ki-67, Kissl, MAGE-D2, MTA1, NAPILI, NKX2-3, OR51E1, PTPRN2, SCG5, SPOCKl, and X2BTB48 gene products; (e) CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCKl, and X2BTB48 gene products; (f) APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAPILI, PNMA2, RAFl, TPHl, and VMAT2 gene products; (g) APLP2, ARAF1, BRAF1, CD59, KRAS, and RAFl gene products; and/or (h) ARAF1, BRAF1, CD59, KRAS, RAFl, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCKl, X2BTB48, CgA, CTGF, FZD7, Ki-67, Kissl, MAGE-D2, MTA1, NAPILI, NRP2, Tphl, VMAT1, VMAT2 and Survivin gene products. </p><p id="p0039" num="0039"> [0029] In some examples, the biomarkers include at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51 of the following gene products (the term gene product including, for example, polynucleotides (e.g., transcripts) and polypeptides): AKAP8L, 
<!-- EPO <DP n="8"/>-->
 APLP2, ARAF1, ATP6V1H, BNIP3L, BRAF, C21orf7, CD59, COMMD9, CTGF, ENPP4, FAM13A, FLJ10357, FZD7, GLT8D1, HDAC9, HSF2, Ki67, KRAS, LEOl, MORF4L2, NAPILI, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PNMA2, PQBP1, RAF1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TPHl, TRMT112, VMATl, VMAT2, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </p><p id="p0040" num="0040"> [0030] In some aspects, the biomarkers include AKAP8L, APLP2, ARAF1, ATP6V1H, BNIP3L, BRAF, C21orf7, CD59, COMMD9, CTGF, ENPP4, FAM13A, FLJ10357, FZD7, GLT8D1, HDAC9, HSF2, Ki67, KRAS, LEOl, MORF4L2, NAPILI, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PNMA2, PQBP1, RAF1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TPHl, TRMT112, VMATl, VMAT2, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </p><p id="p0041" num="0041"> [0031] In some examples, the biomarkers include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38 of the following gene products (the term gene product including, for example, </p><p id="p0042" num="0042">polynucleotides {e.g., transcripts) and polypeptides): AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PQBP1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </p><p id="p0043" num="0043"> [0032] In some aspects, the biomarkers include AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PQBP1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3. </p><p id="p0044" num="0044"> [0033] In some examples, the biomarkers include at least two GEP-NEN biomarkers selected from among APLP2, ARAF1, BRAF1, CD59, KRAS, RAF1, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCK1, X2BTB48, CgA, CTGF, FZD, Ki-67, Kissl, MAGE-D2, MTAl, NAPILI, NRP2, Tphl, VMATl, VMAT2, and Survivin gene products. </p><p id="p0045" num="0045"> [0034] In one embodiment, the plurality of GEP-NEN biomarkers includes an APLP2 gene product or a CD59 gene product. In one embodiment, the GEP-NEN biomarkers include an APLP2 gene product. In one embodiment, they include a CD59 gene product. 
<!-- EPO <DP n="9"/>-->
 [0035] In one embodiment, the GEP-NEN biomarkers include an APLP2, CD59, ARAF1, BRAF1, KRAS or RAF1 gene product. </p><p id="p0046" num="0046"> [0036] In some embodiments, the panel of GEP-NEN biomarkers includes an APLP2, ARAF1, BRAF, CD59, KRAS, or RAF1 gene product or a GTGF, FZD7, Ki67, NAP1L1, PNMA2, TPH1, or VMAT2 gene product. In some embodiments, the panel of GEP-NEN biomarkers includes a PNMA2 gene product. In some embodiments, the panel of GEP-NEN biomarkers includes a VMAT2 gene product. In some embodiments, the panel of GEP-NEN biomarkers includes a CgA, CXCL14, GRIA2, HOXC6, Kissl, MAGE-D2, MTA1, NKX2-3, NRP2, OR51E1, PTPRN2, SCG5, SPOCK1, survivin, VMAT1, or X2BTB48 gene product. In other embodiments, the panel includes a PNMA2 biomarker. In some embodiments, the panel includes a VMAT2 biomarker. </p><p id="p0047" num="0047"> [0037] In some embodiments, the panel includes APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, and VMAT2 gene products; or includes MAGE-D2, MTA1, NAP1L1, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCK1, HOXC6, CTGF, PTPRN2, SCG5, CgA, and Tph gene products. In one aspect, the biomarkers includes at least one of or includes each of the following biomarkers: APLP2, ARAF1, BRAF1, CD59, KRAS, RAF1, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCK1, X2BTB48, CTGF, FZD7, Ki-67, Kissl, MAGE-D2, MTA1, NAP1L1, NRP2, Tphl, VMAT1, VMAT2, Survivin and X2BTB48 gene products. In one such embodiment, the biomarkers further include a CgA gene product. </p><p id="p0048" num="0048"> [0038] In one embodiment, the GEP-NEN biomarkers include one or more gene products having a nucleotide sequence with at least at or about or at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 % identity to or 100 % identity to (i.e., having a nucleotide sequence of) SEQ ID NO: 1, or to SEQ ID NO: 1, from nucleotide residues 158-2449; SEQ ID NO: 2, or to SEQ ID NO: 2 from nucleotide residues 195-2015 SEQ ID NO: 3 or to SEQ ID NO: 3, from nucleotide residues 62-2362; SEQ ID NO: 4 or to SEQ ID NO: 4, from nucleotide residues 278-664; SEQ ID NO: 5, or to SEQ ID NO: 5 from nucleotide residues 1 to 1374; SEQ ID NO: 6, or to SEQ ID NO: 6 from nucleotide residues 207-1256; SEQ ID NO: 7, or to SEQ ID NO: 7 from nucleotide residues 466-801; SEQ ID NO: 8, or to SEQ ID NO: 8 from nucleotide residues 62-1786; SEQ ID NO: 9, or to SEQ ID NO: 9 from nucleotide residues 460-3111; SEQ ID NO: 10, or to SEQ ID NO: 10 from nucleotide residues 113-820; SEQ ID NO: 11, or to SEQ ID NO: 11 from 
<!-- EPO <DP n="10"/>-->
 nucleotide residues 196-9966; SEQ ID NO: 12, or to SEQ ID NO: 12 from nucleotide residues 155-571; SEQ ID NO: 13, or to SEQ ID NO: 13 from nucleotide residues 182-751; SEQ ID NO: 14, or to SEQ ID NO: 14 from nucleotide residues 100-1920; SEQ ID NO: 15, or to SEQ ID NO: 15 from nucleotide residues 188-2335; S EQ ID NO: 16, or to SEQ ID NO: 16 from nucleotide residues 413-1588; SEQ ID NO: 17, or to SEQ ID NO: 17 from nucleotide residues 200-1294; SEQ ID NO: 18, or to SEQ ID NO: 18 from nucleotide residues 792-3587; SEQ ID NO: 19, or to SEQ ID NO: 19 from nucleotide residues 145-1101; SEQ ID NO: 20, or to SEQ ID NO: 20 from nucleotide residues 771-1865; SEQ ID NO: 21, or to SEQ ID NO: 21 from nucleotide residues 122-3169; SEQ ID NO: 22, or to SEQ ID NO: 22 from nucleotide residues 416-2362; or to SEQ ID NO: 22 SEQ ID NO: 23, or to SEQ ID NO: 23 from nucleotide residues 118-756; SEQ ID NO: 24, or to SEQ ID NO: 24 from nucleotide residues 152-1471; SEQ ID NO: 25, or to SEQ ID NO: 25 nucleotide residues 2811-2921, 3174-3283, 5158-5275, 11955- 12044, or to SEQ ID NO: 34; SEQ ID NO: 26, or to SEQ ID NO: 26 from nucleotide residues 27-1361; SEQ ID NO: 27, or to SEQ ID NO: 27 from nucleotide residues 472-2049; SEQ ID NO: 28, or to SEQ ID NO: 28 from nucleotide residues 32-1576; SEQ ID NO: 29, or to SEQ ID NO: 29 from nucleotide residues 467-1801; SEQ ID NO: 105, or to SEQ ID NO: 105 from nucleotide residues 122-1456; SEQ ID NO: 201, or to SEQ ID NO: 201 from nucleotide residues 100-2040; SEQ ID NO: 204, or to SEQ ID NO: 240, from nucleotide residues 293- 1744; SEQ ID NO: 205, or to SEQ ID NO: 205, from nucleotide residues 125-784; SEQ ID NO: 206, or to SEQ ID NO: 206 from nucleotide residues 278-1006; SEQ ID NO: 207, or to SEQ ID NO: 207 from nucleotide residues 38-508; SEQ ID NO: 208, or to SEQ ID NO: 208 from nucleotide residues 260-1621; SEQ ID NO: 209, or to SEQ ID NO: 209 from nucleotide residues 281-1126; SEQ ID NO: 210, or to SEQ ID NO: 210 from nucleotide residues 30-4589; SEQ ID NO: 211, or to SEQ ID NO: 211 from nucleotide residues 852-1967; SEQ ID NO: 212, or to SEQ ID NO: 212 from nucleotide residues 362-2128; SEQ ID NO: 213, or to SEQ ID NO: 213 from nucleotide residues 188-1798; SEQ ID NO: 215, or to SEQ ID NO: 215 from nucleotide residues 17-2017; SEQ ID NO: 217, or to SEQ ID NO: 217 from nucleotide residues 505-1371; SEQ ID NO: 218, or to SEQ ID NO: 218 from nucleotide residues 194-853; SEQ ID NO: 219, or to SEQ ID NO: 219 from nucleotide residues 319-837; SEQ ID NO: 220, or to SEQ ID NO: 220 from nucleotide residues 216-311 and 313-786; SEQ ID NO: 221, or to SEQ ID NO: 221 from nucleotide residues 312-1151; SEQ ID NO: 222, or to SEQ ID NO: 222 from nucleotide residues 625-2667; SEQ ID NO: 223, or to SEQ ID NO: 223 from nucleotide 
<!-- EPO <DP n="11"/>-->
 residues 210-13117, or to the sequence referenced at GenBank gi Number 205360961 or to that sequence from nucleotide residues 210-13118; SEQ ID NO: 224, or to SEQ ID NO: 224 from nucleotide residues 399-1871; SEQ ID NO: 225, or to SEQ ID NO: 225 from nucleotide residues 122-919; SEQ ID NO: 227, or to SEQ ID NO: 227 from nucleotide residues 320-1273; SEQ ID NO: 228, or to SEQ ID NO: 228 from nucleotide residues 121-4446; SEQ ID NO: 229, or to SEQ ID NO: 229 from nucleotide residues 229-1866; SEQ ID NO: 232, or to SEQ ID NO: 232 from nucleotide residues 102-1553; SEQ ID NO: 233, or to SEQ ID NO: 233 from nucleotide residues 176-1879; SEQ ID NO: 234, or to SEQ ID NO: 234 from nucleotide residues 618-1793; SEQ ID NO: 235, or to SEQ ID NO: 235 from nucleotide residues 526-1782; SEQ ID NO: 236, or to SEQ ID NO: 236 from nucleotide residues 65-1231; SEQ ID NO: 237, or to SEQ ID NO: 237 from nucleotide residues 89-1183; SEQ ID NO: 238, or to SEQ ID NO: 238 from nucleotide residues 227-4030; SEQ ID NO: 239, or to SEQ ID NO: 239 from nucleotide residues 104-1969; SEQ ID NO: 240, or to SEQ ID NO: 240 from nucleotide residues 94-612, SEQ ID NO: 243, or to SEQ ID NO: 243 from nucleotide residues 409-10988, SEQ ID NO: 244, or to SEQ ID NO: 244 from nucleotide residues 130-8499, SEQ ID NO: 245, or to SEQ ID NO: 245 from nucleotide residues 55-2187, and/or SEQ ID NO: 246, or to SEQ ID NO: 246 from nucleotide residues 477-3188. </p><p id="p0049" num="0049"> [0039] Among the provided methods, agents, and systems are those that are able to classify or detect a GEP-NEN in a human blood sample. In some embodiments, the provided systems and methods can identify or classify a GEP-NEN in a human blood sample; in some </p><p id="p0050" num="0050">embodiments, it can differentiate between a subject with GEP-NEN and a subject with another type of gastrointestinal (GI) cancer (or other cancer) or can determine the site of a GEP-NEN, e.g., by differentiating between a subject with small intestinal NEN and a subject with a pancreatic NEN. In some examples, the systems can provide such information with a </p><p id="p0051" num="0051">specificity, sensitivity, and/or accuracy of at least 75 , 80 , 85 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 % or 100 , e.g., at least 80 %. </p><p id="p0052" num="0052"> [0040] In some embodiments, the system can predict treatment responsiveness to, or determine whether a patient has become clinically stable following, or is responsive or non- responsive to, a GEP-NEN treatment, such as a surgical intervention or drug therapy (for example, somatostatin analog therapy). In some cases, the methods and systems do so with a specificity, sensitivity, and/or accuracy of at least 75 , 80 , 85 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 % or 100 , e.g., with at least 90 % accuracy. In some cases, 
<!-- EPO <DP n="12"/>-->
 it can differentiate between treated and untreated GEP-NEN with a specificity, sensitivity, and/or accuracy of at least 75 , 80 , 85 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 % or 100 , e.g., with a sensitivity and specificity of at least 85 %. </p><p id="p0053" num="0053"> [0041] In some cases, it can determine diagnostic or prognostic information regarding a subject previously diagnosed with GEP-NEN, for example, whether the subject has stable disease, progressive disease, or is in complete remission (for example, would be clinically categorized as having stable disease, progressive disease, or being in complete remission). </p><p id="p0054" num="0054"> [0042] In some embodiments, the agents for detecting the biomarkers {e.g., the sets of polynucleotide or polypeptide agents), and uses thereof, are capable of distinguishing between the presence and absence of GEP-NEN in a biological sample, between GEP-NEN and other intestinal and mucosal samples, such as enterochromaffin (EC) and small intestinal (SI) mucosal samples and GEP-NEN samples, between metastatic or aggressive and primary GEP-NEN samples, and/or between specific classes or subtypes of GEP-NENs. </p><p id="p0055" num="0055"> [0043] In some embodiments, the methods distinguish between GEP-NEN and other cancers, such as adenocarcinomas, including gastrointestinal adenocarcinoma or one of the breast, prostate, or pancreas, or a gastric or hepatic cancer, such as esophageal, pancreatic, gallbladder, colon, or rectal cancer. In other embodiments, the methods and systems </p><p id="p0056" num="0056">differentiate between GEP-NENs of different sites, such as between GEP-NENs of the small intestine and those of the pancreas. </p><p id="p0057" num="0057"> [0044] In one embodiment, the set of agents distinguishes between enterochromaffin (EC) and small intestinal (SI) mucosa. In one aspect, the panel of GEP-NEN biomarkers comprises CTGF, CXCL14, FZD7, Kissl, FZD, Kissl, NKX2-3, PNMA2, PTPRN2, SCG5, SPOCKl, and X2BTB48 gene products. In another embodiment, the system or set of agents distinguishes between Adenocarcinoma and GEP-NEN, such as an adenocarcinoma and a GEP-NEN sample. In one aspect, the panel of GEP-NEN biomarkers comprises at least sixteen GEP-NEN biomarkers, including a CgA gene product. In another embodiment, the system or set of agents distinguishes between primary and metastatic GEP-NEN disease. In one aspect of this embodiment, the panel of GEP-NEN biomarkers includes at least eighteen GEP-NEN </p><p id="p0058" num="0058">biomarkers. </p><p id="p0059" num="0059"> [0045] In some embodiments, the system or set of agents or use of the same distinguishes between one or more various sub-types of GEP-NEN, and/or contains agents that bind to or detect a set of biomarkers the expression profile of which or the summed expression (e.g. 
<!-- EPO <DP n="13"/>-->
 vectorally summed expression) of which differs significantly between the various sub-types. In one aspect of this embodiment, the system distinguishes between primary PDNEC and primary WDNET; in one example, the panel of biomarkers includes CXCL14 and MAGE-D2 gene products. In another embodiment, the system distinguishes between primary PDNEC and primary WDNEC; in one example, the panel of GEP-NEN biomarkers includes three biomarkers, including a PTPRN2 gene product. In another embodiment, the system </p><p id="p0060" num="0060">distinguishes between primary PDNEC and primary PDNET; in one example, the panel of biomarkers includes MTA1 and PNMA2 gene products. In another embodiment, the system distinguishes between primary PDNET and primary WDNET; in one example, the panel of NE biomarkers includes at least four biomarkers. In another embodiment, the system distinguishes between primary WDNEC and primary WDNET; in one example, the set contains at least 21 biomarkers. </p><p id="p0061" num="0061"> [0046] In another embodiment, the system distinguishes between metastatic sub-types of GEP-NEN, such as between metastatic WDNEC and metastatic WDNET, for example, where the panel contains at least three biomarkers, including a CXCL14 gene product; between metastatic PDNEC and metastatic WDNEC, for example, where the set of biomarkers includes at least four biomarkers, including a NAP 1 LI gene product; between metastatic PDNEC and metastatic WDNET, for example, where the panel of GEP-NEN biomarkers includes at least six biomarkers, for example, including a NRP2 gene product. </p><p id="p0062" num="0062"> [0047] In one aspect, the system is able to classify or detect a GEP-NEN in a human blood sample or human saliva sample. In one aspect, the human sample is whole blood or nucleic acid or protein prepared from whole blood, without first sorting or enriching for any particular population of cells. In one aspect, the system includes agents that bind to biomarkers in a panel of at least 29 GEP-NEN biomarkers. </p><p id="p0063" num="0063"> [0048] In some aspects, the methods and systems provide such diagnostic, differentiation, detection, predictive, or prognostic information or determination as described above with a greater sensitivity, specificity, or accuracy compared with another diagnostic method, such as available detection or diagnosis method, such as the detection of circulating CgA levels. </p><p id="p0064" num="0064"> [0049] In some embodiments, in addition to the agents that bind the GEP-NEN biomarkers, the provided systems contain one or more agents that bind to gene products for use in normalization or as controls, for example, housekeeping gene products, including any one or more of: ACTB, TOX4, TPT1 and TXNIP gene products; 
<!-- EPO <DP n="14"/>-->
 [0050] housekeeping gene products, including any one or more of: 18S, GAPDH, ALG9, SLC25A3, VAPA, TXNIP, ADD3, DAZAP2, ACTG1, ACTB, ACTG4B, ARF1, HUWE1, MORF4L1 RHOA, SERP1, SKP1, TPT1, TOX4, TFCP2, and ZNF410, gene products; </p><p id="p0065" num="0065"> [0051] housekeeping genes including any one or more of 18S, GAPDH, ALG9, SLC25A3, VAPA, TXNIP, ADD3, DAZAP2, ACTG1, ACTB, ACTG4B, ARF1, HUWE1, MORF4L1 RHOA, SERP1, SKP1, TPT1, and TOX4 gene products; or </p><p id="p0066" num="0066"> [0052] housekeeping genes including any one or more of: ALG9, TFCP2, ZNF410, 18S, and GAPDH gene products. </p><p id="p0067" num="0067"> [0053] In some embodiments, the system distinguishes between enterochromaffin (EC) and small intestinal (SI) mucosa and the panel of GEP-NEN biomarkers further includes CTGF, CXCL14, FZD7, Kissl, FZD, Kissl, NKX2-3, PNMA2, PTPRN2, SCG5, SPOCK1, and X2BTB48 gene products. In another embodiment, the panel of GEP-NEN biomarkers includes MAGE-D2, MTA1, NAP1L1, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCK1, HOXC6, CgA, CTGF, PTPRN2, SCG5, and Tphl gene products. In another embodiment, the system distinguishes between </p><p id="p0068" num="0068">Adenocarcinoma and GEP-NEN and includes a set of polynucleotides or polypeptides that specifically hybridize to a panel of sixteen or more GEP-NEN biomarkers, including a CgA gene product. </p><p id="p0069" num="0069"> [0054] In some embodiments, the methods and systems determine the presence, absence, expression levels, or expression profile indicates the presence, absence, classification, prognosis, risk, responsiveness to treatment, aggressiveness, severity, or metastasis of the GEP-NEN. For example, in one aspect, the presence, absence, expression levels, or expression profile detected in the test sample indicates the efficacy of a GEP-NEN treatment. In one aspect, the detected presence, absence, expression levels, or expression profile distinguishes between primary PDNEC and primary WDNET and the panel of biomarkers includes CXCL14 and MAGE-D2 gene products; in other aspects, it distinguishes between primary PDNEC and primary WDNEC and the panel of biomarkers includes three biomarkers, including a PTPRN2 gene product; in another aspect, it distinguishes between primary PDNEC and primary PDNET, and the panel of biomarkers includes MTA1 and PNMA2 gene products; in another aspect, it distinguishes between primary PDNET and primary WDNET or in primary PDNET and primary WDNEC, and the panel of biomarkers includes at least four biomarkers; in another aspect, it distinguishes between primary WDNEC and primary WDNET, the panel of biomarkers includes twenty-one 
<!-- EPO <DP n="15"/>-->
 biomarkers; in another aspect, it distinguishes between metastatic WDNEC and metastatic WDNET and the panel of biomarkers includes at least three biomarkers, including a CXCL14 gene product; in another aspect, it distinguishes between metastatic PDNEC and metastatic WDNEC and the panel comprises at least four biomarkers, including a NAP1L1 gene product; in another aspect, it distinguishes between metastatic PDNEC and metastatic WDNET and the panel comprises at least six biomarkers, including a NRP2 gene product. </p><p id="p0070" num="0070"> [0055] The biological test sample used with the methods can be any biological sample, such as tissue, biological fluid, or other sample, including blood samples, such as plasma, serum, whole blood, buffy coat, or other blood sample, tissue, saliva, serum, urine, or semen sample. In some aspects, the sample is obtained from blood. Often, the test sample is taken from a GEP- NEN patient. </p><p id="p0071" num="0071"> [0056] In some embodiments, the methods further include comparing the expression levels or expression profile or presence or absence of the biomarkers detected in the test sample to a normal or reference level of expression or a normal or reference expression profile, or a standard value of expression level, amount, or expression profile, or the presence (or more typically the absence) of detection in a reference or normal sample. </p><p id="p0072" num="0072"> [0057] In some such embodiments, the methods include a step of obtaining a normal or reference sample and detecting the presence, absence, expression levels, or expression profile of the panel of GEP-NEN biomarkers in the normal sample, typically carried out prior to the comparison step. In one aspect, this further step determines a normal or reference level of expression or a normal or reference expression profile, which can be compared to the expression level or profile detected in the test biological sample. </p><p id="p0073" num="0073"> [0058] In some cases, statistical analysis is performed to determine whether there is a difference, such as a significant difference, between the expression levels detected in the test biological sample and the normal or reference sample, or other standard or reference expression level. For example, a difference may be considered significant where there is a p value of less than 0.05 or where there is a + 2 standard deviation. Other methods for determining significance are known in the art. </p><p id="p0074" num="0074"> [0059] The normal or reference sample may be from a healthy patient or a patient who has GEP-NEN. Where the test sample is from a patient with GEP-NEN, the normal or reference sample or level may be from the same or a different patient. For example, the normal or reference sample may be from the GEP-NEN patient from a tissue, fluid or cell not expected to 
<!-- EPO <DP n="16"/>-->
 contain GEP-NEN or GEP-NEN cells. On another aspect, the normal or control sample is from the GEP-NEN patient before or after therapeutic intervention, such as after surgery or chemical intervention. In another aspect, the reference or normal sample is from a tissue or fluid that corresponds to the GEP-NEN or metastasis of the test sample, from a healthy individual, such as normal EC or SI sample, or normal liver, lung, bone, blood, saliva, or other bodily fluid, tissue, or biological sample. In another embodiment, the test sample is from a metastatis, plasma, or whole blood or other fluid of a GEP-NEN patient and the reference sample is from primary tumor or sorted tumor cells. </p><p id="p0075" num="0075"> [0060] In one aspect, the test biological sample is from a GEP-NEN patient prior to treatment and the normal or reference sample is from the GEP-NEN patient after treatment. In another aspect, the normal or reference sample is from a non-metastatic tissue of the GEP-NEN patient. </p><p id="p0076" num="0076"> [0061] In other aspects, the test sample is from blood and the test biological sample is from the GEP-NEN patient after treatment and the reference sample is from the same GEP-NEN patient as the test biological sample, prior to treatment; the reference sample is from a tissue or fluid not containing GEP-NEN cells; the reference sample is from a healthy individual; the reference sample is from a cancer other than GEP-NEN; the reference sample is from an EC cell or SI tissue; the test biological sample is from a metastatic GEP-NEN and the reference sample is from a non-metastatic GEP-NEN; or the reference sample is from a GEP-NEN of a different classification compared to the GEP-NEN patient from which the test biological sample is obtained. </p><p id="p0077" num="0077"> [0062] The agents can be any agents for detection of biomarkers, and typically are isolated polynucleotides or isolated polypeptides or proteins, such as antibodies, for example, those that specifically hybridize to or bind to a panel of GEP-NEN biomarkers including at least 21 GEP- NEN biomarkers. </p><p id="p0078" num="0078"> [0063] In some embodiments, the methods are performed by contacting the test sample with one of the provided agents, more typically with a plurality of the provided agents, for example, one of the provided systems, such as a set of polynucleotides that specifically bind to the panel of GEP-NEN biomarkers. In some embodiments, the set of polynucleotides includes DNA, RNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides. In some embodiments, the methods include the step of isolating RNA from the test sample prior to detection, such as by RT-PCR, e.g., QPCR. Thus, in some embodiments, detection of the GEP-NEN biomarkers, 
<!-- EPO <DP n="17"/>-->
 such as expression levels thereof, includes detecting the presence, absence, or amount of RNA. In one example, the RNA is detected by PCR or by hybridization. </p><p id="p0079" num="0079"> [0064] In one aspect, the polynucleotides include sense and antisense primers, such as a pair of primers that is specific to each of the GEP-NEN biomarkers in the panel of biomarkers. In one aspect of this embodiment, the detection of the GEP-NEN biomarkers is carried out by PCR, typically quantitative or real-time PCR. For example, in one aspect, detection is carried out by producing cDNA from the test sample by reverse transcription; then amplifying the cDNA using the pairs of sense and antisense primers that specifically hybridize to the panel of GEP-NEN biomarkers, and detecting products of the amplification. In some embodiments, the GEP-NEN biomarkers include mRNA, cDNA, or protein. </p><p id="p0080" num="0080"> [0065] In some embodiments, the methods are capable of detecting low-volume GEP-NENs, early-stage GEP-NENs, micrometastes, circulating GEP-NEN cells, and/or other instances of GEP-NEN that are difficult to detect by available methods, such as imaging or detection of available biomarkers such as GEP-NEN. For example, in some embodiments, the sample is a blood sample, such as a whole blood sample, and the method detects at least at or about three GEP-NEN cells per milliliter (mL) of whole blood. </p><p id="p0081" num="0081"> [0066] In some aspects the methods further comprise statistical analysis and analysis using predictive models such as mathematical algorithms. In one example, the methods include computing a mean expression level for the panel of GEP-NEN biomarkers in the test biological sample. In one aspect of this embodiment, the computing is carried out by vectorally summing the detected expression levels for each of the plurality of GEP-NEN biomarkers. In some aspects, the mean expression level is compared to a reference mean expression level, such as one obtained by performing the methods on a reference or normal sample. Often the comparison reveals a significant difference in the mean expression levels in the test sample compared to the mean reference expression levels. In some aspects, the detected expression or expression profiles are sufficiently different, such as significantly different or sufficiently up or down- regulated, where there is a p value of less than at or about 0.05, or a difference of + standard deviation, or an S value of +0.4, with S &lt; -0.4 or S &gt; 0.4, or other known method, such as those described herein. In some aspects, the expression, such as mean expression, mean summed expression or expression profile detected and/or determined in the test biological sample correlates with that of another GEP-NEN sample, such as where the test sample is a whole blood or other biological fluid sample, and the amount correlates with that of a GEP-NEN tissue or 
<!-- EPO <DP n="18"/>-->
 purified cell population. For example, with an R of at least about 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1. </p><p id="p0082" num="0082"> [0067] In one embodiment, the method identifies the presence or absence, classification, or stage of GEP-NEN with between 80 % to 100 , such as at or about or at least at or about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 % predictive value, sensitivity, or specificity. In some embodiments, the methods include a step of compressing the detected expression levels of the biomarkers from the test biological sample. Typically, the compression is carried out to determine the expression profile of the panel of biomarkers. </p><p id="p0083" num="0083"> [0068] In some embodiments, the test biological sample is a whole blood or saliva sample from a GEP-NEN patient and expression levels or expression profile detected or determined for the test biological sample correlate(s) with the expression levels or expression profile for the same GEP-NEN biomarkers for a GEP-NEN tissue sample or purified GEP-NEN cell sample obtained from the same patient, with an R of at least about 0.4. </p><p id="p0084" num="0084"> [0069] In some embodiments, the methods include steps for analyzing the data using a predictive algorithm, model, and/or topographical analysis. In some examples, the predictive algorithm is support vector machines (SVM), linear discriminant analysis (LDA), K-nearest neighbor (KNN) or naive Bayes (NB). In some examples, the predictive algorithm is support vector machines (SVM), linear discriminant analysis (LDA), or K-nearest neighbor (KNN). In other examples, the algorithm is decision tree, SVM, RDA, or Perceptron, or other model known in the art or described herein. In one aspect, the model or algorithm determines the presence, absence, metastatic or non-metastatic nature of a GEP-NEN, or distinguishes between two or more classes of GEP-NEN with a misclassification rate of between 0.05 to 0. </p><p id="p0085" num="0085"> [0070] Also among the provided are methods are methods for detecting neuroendocrine tumor cells in blood, by obtaining a blood sample; and contacting the blood sample with one or more agents, which specifically binds to a panel of GEP-NEN biomarkers, which includes at least two GEP-NEN biomarkers, wherein the method detects at least at or about one, two, three, four, or five cells per mL of blood. GEP-NEN cells per mL blood. </p><p id="p0086" num="0086"> [0071] Also among the provided embodiments are methods for enriching or isolating GEP- NEN cells from fluids and mixtures of cells, such as plasma, blood, buffy coat, cell culture, biological fluid, or other cell preparation. In one aspect of this embodiment the method is carried out by contacting the mixture of cells with an agent that specifically binds to a GEP-NEN 
<!-- EPO <DP n="19"/>-->
 biomarker and purifying cells which bind to the agent. In one aspect of this embodiment, the biomarker is CD 164. In one aspect, the biomarker is a polypeptide biomarker. In one such aspect, the agent is an antibody that specifically binds to the biomarker, such as a CD 164 antibody. In some embodiments, the purification is by FACS or column purification or any other known method for purifying cells based on affinity. In one aspect, the contacting further includes contacting the cells with another GEP-NEN-specific agent. In some aspects, the method enriches or isolates at least at or about one, two, three, four, or five cells per mL of blood. </p><p id="p0087" num="0087"> [0072] Also provided are methods and uses of the provided biomarkers, agents, systems and detection methods for use in GEP-NEN treatment and treatment monitoring. For example, provided are methods using the diagnostic, predictive, and detection methods described above in conjunction with GEP-NEN treatment, such as to assay a sample obtained from a subject undergoing treatment or who was previously undergoing treatment for GEP-NEN. In one embodiment, such methods are carried out by obtaining a sample from such a patient and detecting or determining the presence or absence of expression, expression levels, or expression profile of a GEP-NEN biomarker, typically a panel of GEP-NEN biomarkers, in the sample. In one aspect, the method includes first providing a treatment to the patient. In such methods, the biomarker or panels generally is or are detected using an agent or system as provided herein, such as those described above. In some aspects, the method further includes, prior to providing the treatment, determining a pre-treatment amount, presence, absence, expression levels, or expression profile in a sample from the patient of the biomarker or panel of biomarkers. Thus, in some examples, the pre-treatment amount, presence, absence, expression levels, or expression profile is or are compared to the amount, presence, absence, expression levels, or expression profile determined or detected in the patient after treatment. </p><p id="p0088" num="0088"> [0073] In some cases, this analysis determines that there is a difference in expression levels between the pre-treatment expression levels and the post-treatment expression levels, which can indicate the efficacy of the treatment. In some cases, the method further includes determining expression amount, presence, absence, levels, or profiles of the biomarkers in the patient or a sample from the patient at a later time. Such methods can further include comparing the information from the later time to that originally detected or determined. This information, for example, a difference between the expression amounts, presence, absence, levels, or profiles levels can indicate information about whether the individual has been responsive to treatment, 
<!-- EPO <DP n="20"/>-->
 for example, can indicate recurrence, lack of treatment responsiveness, stable disease, or progressive disease. </p><p id="p0089" num="0089"> [0074] In some embodiments, such methods provide the advantage of providing more sensitive, specific, or accurate information compared to available diagnostic methods, such as detection of CgA levels in the serum or other sample. Thus, in one example, the methods provide the indicated diagnostic, prognostic, or predictive information in a case where the CgA expression levels are not significantly different in the samples assayed, for example, between the pre-treatment and post-treatment samples and/or the sample taken at a later timepoint, or between the test sample and the normal sample. </p><p id="p0090" num="0090"> [0075] In some cases, the treatment is discontinued or modified based on the determination from the methods. The methods may be performed in an iterative fashion, with treatment reevaluated or modified according to the expression levels or profiles or comparisons. Thus, in some embodiments, the methods further include discontinuing the treatment or modifying the treatment provided to the patient, for example, based on the information determined by the diagnostic approach. In some cases, the comparison and/or expression amount, presence, absence, levels, or profile indicates the presence of a GEP-NEN micrometastasis in the patient. In one example, one or more of the samples taken from the patient is or was determined to be free of GEP-NEN, GEP-NEN metastases, or GEP-NEN recurrence by another diagnostic method, such as by histology or detection of CgA alone. </p><p id="p0091" num="0091"> [0076] In other embodiments, the treatment methods are carried out by obtaining a first sample from a GEP-NEN patient and detecting expression levels of a panel of GEP-NEN biomarkers in the first sample; providing a treatment to the patient; obtaining a second sample from the GEP-NEN patient and detecting expression levels of the panel of GEP-NEN </p><p id="p0092" num="0092">biomarkers in the second sample; and comparing the expression levels detected in the first sample to those detected in the second sample. In one aspect, the method further includes determining whether there is a difference in expression levels between the first and second samples, for example, determining that there is such a difference. In one example the difference indicates the efficacy of the treatment. In a further embodiment, the method further includes obtaining a third sample from the patient, detecting the expression levels in the third sample and comparing them to the expression levels in the first or second sample. In some cases, the comparison indicates the presence of a metastasis, such as micrometastasis. In some </p><p id="p0093" num="0093">embodiments, one or more of the samples is taken from a patient determined to be free of GEP- 
<!-- EPO <DP n="21"/>-->
 NEN, GEP-NEN metastases, or GEP-NEN recurrence by another assay, such as detection of CgA alone, imaging, or histology, yet the methods detect the presence of GEP-NEN, GEP-NEN metastases, or GEP-NEN recurrence in the same sample. </p><p id="p0094" num="0094"> [0077] In one example, the method further includes determining that there is a difference between expression levels detected in the second and third samples, where the difference indicates a recurrence or lack of treatment responsiveness. In some aspects, the levels of CgA expression in the second sample are not significantly different compared to those in the first sample or the third sample. </p><p id="p0095" num="0095">Brief Description of the Drawings </p><p id="p0096" num="0096">[0078] FIG. 1. Gene expression distribution across Normal, Localized and Malignant tissues. Expression of individual genes (listed above individual graphs) across samples was compared to average expression in the normal enterochomaffin (EC) cell and assigned to Upregulated, Downregulated, or Baseline class. Each graph shows results for normal, malignant, and localized tissues, from left to right. Ellipsoids correspond to a +2 Standard Deviations (SD) threshold. All p-values: p &lt; 0.05. </p><p id="p0097" num="0097"> [0079] FIG. 2. Principal Component (PC) Analysis of primary Small Intestinal Neuroendocrine Tumors, metastases and normal EC cells. Ln-normalized real-time PCR expression levels of indicated biomarkers, reduced to 3 PCs, representing 75.6% variance in primary tumor subtypes and normal EC cell preparations (2A) and 73.2% variance in primary tumor subtypes and corresponding metastases (2C). For primary tumors and normal EC cells, three groups of genes with similar expression patterns were observed (2B), with two groups identified in corresponding metastases (2D). </p><p id="p0098" num="0098"> [0080] FIG. 3: Similarity Matrix using Pearson Correlation of the marker gene expressions in primary Small Intestinal Neuroendocrine Tumors and normal EC cells. Ln- normalized real-time PCR expression levels of indicated genes plotted onto X- and Y-axis. </p><p id="p0099" num="0099"> [0081] FIG. 4: Density Map of distributions between normal EC cells and Small Intestinal Neuroendocrine Tumors. Expression levels of indicated transcripts as identified by FS plotted on X- and Y-axes, with normal and neoplastic samples scattered according to respective gene pair expressions, distribution densities based on average Euclidean distance (difference in expression) between samples were colorized green (normal) and red (neoplastic). Blue areas indicate a region of transition between normal and neoplastic groups. 
<!-- EPO <DP n="22"/>-->
 [0082] FIG. 5: Decision Tree classifying primary Small Intestinal Neuroendocrine Tumors. Expression levels of NAP1L1 and Ki-67 were identified as principle discriminators in the Decision Tree classifier using Feature Selection. The model was constructed by correlating values of NAP1L1 and Ki-67 to primary tumor subtypes. Percentages in parenthesis indicate the occurrence frequencies of primary small intestinal neuroendocrine tumor subtypes. </p><p id="p0100" num="0100"> [0083] FIG. 6: Density Map of distributions between primary Small Intestinal </p><p id="p0101" num="0101">Neuroendocrine Tumors and their metastases. Expression levels of Kissl, NAP1L1, MAGE- D2, and CgA transcripts as identified by the FS algorithm plotted on X- and Y-axis. Primary Small Intestinal Neuroendocrine tumor subtypes (WDNETs, WDNECs, PDNECs) and respective metastases (METs) scattered according to their respective gene pair expressions (6A- C). Distribution densities based on the average Euclidean distance (difference in expression) between samples were colorized blue (primary tumors) and red (metastases). Green areas indicate a region of transition between primary tumor subtypes and respective metastases. </p><p id="p0102" num="0102"> [0084] FIG. 7: Evaluation of the classifier performance in the test and training sets. Graph shows percentage of correctly- validated samples in training and test sets, showing Normal EC cells cross-validated with the 77% accuracy and predicted in an independent test set with 76% accuracy (p = 0.84). Localized NETs were cross-validated with 78% accuracy and predicted with 63% accuracy in the test set (p = 0.25). Malignant NETs were cross-validated with 83% accuracy and predicted with 83% accuracy in an independent set (p = 0.80) </p><p id="p0103" num="0103"> [0085] FIG. 8: Principal component analysis (PCA) and expression of marker genes in NETs, adenocarcinomas and normal tissues. 8A. Transcript expressions of the 21 marker gene panel reduced to 3 principal components that capture most of the variance (83%) within the dataset. Each centroid (average expression) corresponds to the transcript expression profile of the sample as given by its principal component vector. In this representation, proximity of separation between centroids is indicative of the degree of similarity. Thus, the marker gene panel can successfully distinguish adenocarcinomas (breast, colon, pancreas), normal SI mucosa, normal EC cells, and primary and metastatic NET subtypes. Of note, normal EC cells have a substantially different genetic profile to normal SI mucosa and neoplastic tissue. 8B. An analysis of the proportion of samples that express each of the marker genes, demonstrated that significantly more NET samples (&gt;95%) were positive for 16 of the marker genes compared to adenocarcinomas (AC). Genes highly expressed in both tumor types included CTGF, FZD7, NRP2, PNMA2 and survivin. NML=normal SI mucosa, NML_EC=normal EC cell, 
<!-- EPO <DP n="23"/>-->
 MET=metastasis, WDNET=well differentiated NET; WDNEC=well differentiated neuroendocrine carcinoma; PDNET=poorly differentiated NET; PDNEC=poorly differentiated NEC. */?&lt;0.002 SI NETs versus adenocarcinomas (Fisher's exact test). </p><p id="p0104" num="0104"> [0086] FIG. 9: Heatmap of correlation coefficients and relationship network of highly correlated gene pairs. 9A. Pearson's correlation coefficients (R<sup>2</sup>) for each gene across all tissue types were calculated and represented as a heatmap with the lowest value (-0.03) represented in black, medium (0.4) in dark grey, and highest (1) in light grey. 9B. A network of co-expression was constructed such that transcript pairs with R 2 &gt;0.40 were connected by an edge. Actual R 2 values are superimposed on every edge. </p><p id="p0105" num="0105"> [0087] FIG. 10: Volcano plots of gene ranks and significance (p) values for a t-test. 10A.</p><p id="p0106" num="0106">A two-sample t-test was computed to identify differentially expressed genes in 1) EC cells, normal SI mucosa, and primary and metastatic tissues; 2) primary NET subtypes; 3) metastatic NET subtypes. In normal EC cells compared to normal SI mucosa, transcript expression of the classic neuroendocrine marker Tphl, was significantly higher (p&lt;0.001, S=0.7). 10B. Compared to normal SI mucosa, neoplastic tissue expressed higher transcript levels of CgA and GRIA-2, however CgA expression was not significantly altered (p=0.07, S=0.39) between neoplastic tissue and normal EC cells. IOC. There were no differentially expressed genes between all metastases as a group and all the different primary NET subtypes when analyzed as a group. 10D. There were no differentially expressed transcripts between PDNET-PDNEC and WDNET- PDNEC, and in WDNEC-PDNEC, MAGE-D2 was the only significant marker (p=0.009, S=1.03). CgA, Kissl, NRP2, and Tphl were differentially expressed between all metastasis subtypes. </p><p id="p0107" num="0107"> [0088] FIG. 11: Transcript expression in whole blood. Housekeeping genes (ALG-9, TFCP2, ZNF410) identified in plasma after Trizol mRNA isolation (11A) and the QIAamp RNA Blood Mini Kit approach (11B), showing identification of housekeeping genes in significantly more samples (8/15 versus 2/15, p=0.05) after isolation with the QIAamp RNA Blood Mini Kit approach. Transcript expression levels of the same 3 housekeeping genes and 11 NET biomarker genes were evaluated by PCR in mRNA prepared from whole blood from 3 healthy donors (normal samples), showing highly correlated detected gene expression levels across samples (11C). </p><p id="p0108" num="0108"> [0089] FIG. 12. Average combined transcript expression of each gene (12A). Transcripts exhibited a low variability: 0.04-0.45 (median 0.12). Principal component analysis of average 
<!-- EPO <DP n="24"/>-->
 marker gene expression for all samples (12B). The mathematical algorithms (SVM, LDA, KNN and NB) identified that the correct calls were made for times 0, 30mins, 1 hr, 2 hr and 4 hr. Inconsistent call rates occurred between 8 - 48 hrs indicating the optimal time for storage in a refrigerator prior to freezing is 0-4 hrs. </p><p id="p0109" num="0109"> [0090] FIG. 13: Identification of the most appropriate housekeeping gene and determination of the effect of feeding on ALG-9 transcripts in whole blood. Transcript expression of 5 housekeeping genes was evaluated in 5 healthy controls. ALG-9 was identified to have the least variation (13A). ALG-9 expression was measured as a function of time after feeding, showing no significant alteration after feeding (up to 4 hrs) (13B). </p><p id="p0110" num="0110">[0091] FIG. 14: Topological analysis of candidate house-keeping genes mapped to the blood interactome (7,000 genes, 50,000 interactions): Degree (14A), Betweeness (14B) and Clustering (14C). Genes with the lowest values in each category included TXNIP, ACTB, TOX4 and TPT1. Analysis of blood- and tissue-associated house-keeping genes identified potential candidate genes for normalization protocols. </p><p id="p0111" num="0111"> [0092] FIG. 15: Raw CT values plotted as a function of either tissue-derived or blood- derived candidate house-keeping genes. Genes with the least variation included ALG9, ARF1, ATG4B, RHDA, and SKP1. Mean and SD are included. A value of 40 was assigned to samples with no amplification. Samples with no gene expression are given a value of 40 (e.g., 4 samples amplified using MORF4L1). Analysis of candidate house-keeping genes identified a relatively small number (n=6) that exhibited low variability and were candidates for development of normalization protocols. </p><p id="p0112" num="0112"> [0093] FIG. 16: M- values for each of the candidate house -keeping genes calculated using the geNorm program. ALG9 was the most stable of the tissue-derived genes. Nine of the 10 blood-derived genes (except SERP1) were considered robust. Robust markers (dotted boxes). </p><p id="p0113" num="0113"> [0094] FIG. 17: PCR efficiency curves plotted for each of the candidate house-keeping genes. Efficient amplification occurs between 0.9-1.0. Values lower than 0.9 indicate sub- optimal primer binding and inefficient amplification. Values above 1.0 identify over- amplification, presumably through less than specific primer binding. Genes with appropriate efficiency included 18S, ALG9, and TPT1. Mean +SD, n=3. A small number of candidates (n=3) exhibited efficacy as house-keeping genes. </p><p id="p0114" num="0114"> [0095] FIG. 18: Variance in amplification kinetics for the house-keeping and target genes. Values -0.1 demonstrate similar PCR efficiencies and indicate the house-keeper can be used in 
<!-- EPO <DP n="25"/>-->
 comparative C<sub>T</sub> methods. ALG9 was the only house-keeping gene to exhibit an acceptable efficiency for normalization protocols. </p><p id="p0115" num="0115"> [0096] FIG. 19: Variance in target gene expression in normal samples using either a geNorm protocol (using 18S, ALG9 and GAPDH as house-keeping genes) or AAC<sub>T</sub> with ALG9. The latter exhibited a significantly lower co-efficient of variation for each of the target genes and -60% of genes exhibited a normal distribution. *p&lt;0.004 (Mann-Whitney test). The optimal method for normalization was AAC<sub>T.</sub> </p><p id="p0116" num="0116"> [0097] FIG. 20: Identification of tissue-associated genes from U133A and HUGE arrays. PCA of GEP-NENs compared to other neoplasia (breast, colon, prostate and liver) identified the transcriptome was most similar to Crohn's Disease (20A). Subtraction of transcript expression associated with other neoplasia identified a specific GEP-NEN gene signature (modeled as an interactome - 20B). Back-analysis to the tissue arrays identified 21 novel markers which differentiated control from GEP-NENs both by hierarchical cluster analysis (20C) and principal component analysis (PCA) (20D). STNENs exhibit a different transcript spectrum to other cancers. A NEN-specific gene signature is identifiable, which can differentiate these tumors from control samples. </p><p id="p0117" num="0117"> [0098] FIG. 21: Gene expression profiles in the Blood (21A,D), "In-house" (21B, E), and Public datasets (21C, F). Analysis of transcript expression identified that samples from both GEP-NEN tissue and blood could be differentiated from controls. This indicates that each of these compartments contain a definable GEP-NEN molecular fingerprint that can be measured and used to distinguish tumors from controls. </p><p id="p0118" num="0118"> [0099] FIG. 22: Correlation profiles of transcript changes in blood and tissue samples. Both tissue databases were highly correlated (R=0.59, 22A) but lower correlations were noted between blood transcriptomes and either the "In-house" dataset (R=-0.11, 22B) or the Public dataset (R=-0.05, 22C). The common genes identified in both the tissue and blood samples provided a group of candidate marker transcripts which we then examined in blood. </p><p id="p0119" num="0119"> [00100] FIG. 23: A: Correlated and anti-correlated biological processes in GEP-NEN transcriptomes from peripheral blood and tumor tissue samples. B &amp; C: Eighty-five genes associated with tumor function (intracellular signaling and transcription and regulation of cell death), were up-regulated in both tissue and blood samples. This group was considered to represent evaluable candidate circulating biomarkers. 
<!-- EPO <DP n="26"/>-->
 [00101] FIG. 24: Expression of the 22 genes with low paralog numbers (0-3) are ~3 times more central in the blood interactome compared to all other genes (-6,000 genes). This group of specific genes, with few relatives, is present in blood and can be considered as potential markers of neuroendocrine neoplasia. </p><p id="p0120" num="0120"> [00102] FIG. 25: FACS of AO/APC-CD164 dual stained whole blood from a patient with metastatic NETs. Flow cytometric analysis following AO (acridine orange) /APC-CD164 dual- staining of whole blood from a patient with metastatic NET showed a distinct population of cells consistent in size with NET cells (PI, arrow: 25A) exhibiting the characteristic AO/APC positivity of NETs (25B). This population of cells was collected (25C); immuno staining with anti-TPH confirmed that the cells were NET cells (25C-inset). </p><p id="p0121" num="0121"> [00103] FIG. 26: Relationship between whole blood PCR marker levels and FACS- collected circulating NETs and tissue. Whole blood expression levels of biomarker transcripts were highly correlated (p&lt;0.0001) with FACS-sorted samples (representing circulating tumor cells (26A)) and with tissue (26B), confirming that whole blood is an appropriate compartment for measuring NET transcripts. </p><p id="p0122" num="0122"> [00104] FIG. 27: ROCs and sensitivity and specificities for predicting NETs. ROCs and AUCs for selected genes (top 3 panels) and summed transcripts (VI) (bottom left) were calculated in Yale samples (NETs and controls) as described in Example 5D. Use of predicted cut-offs were tested in NETs from Berlin and Uppsala and sensitivities and specificities are provided (bottom right). </p><p id="p0123" num="0123"> [00105] FIG. 28: Reproducibility studies of target genes in blood. The reproducibility of the marker gene ALG9 and the target gene, FZD7, demonstrated high correlation: R : 0.92-0.97, /?&lt;0.0001 (28A-B). Intra- and inter-assay reproducibilities were high for normalized FDZ7 </p><p id="p0124" num="0124">(28C-D, CV = 2.28-3.95%); no differences were noted between normalized FZD7 in controls and tumor samples (28D), demonstrating the significant reproducibility of blood measurements. </p><p id="p0125" num="0125"> [00106] FIG. 29: Performance of the marker gene panel in differentiating Normal tissue from GEP-NENs (Treated and Untreated). All four mathematical algorithms exhibited similar performance metrics of -88%. </p><p id="p0126" num="0126"> [00107] FIG. 30: Correct call rates for each of the mathematical algorithms (SVM, LDA, KNN and Bayes) in each of the four independent sets. The 51 marker panel had significantly more correct calls (20% better) than either the 25 or 13 panel subsets. Increasing the number of the marker genes increased the sensitivity of detecting GEP-NENs in blood. Mean+SEM. 
<!-- EPO <DP n="27"/>-->
 *p&lt;0.008 vs. 13 and 25 panels (Yates value 6.8-14.7; Fishers 2-tailed exact probability test &lt;0.005). </p><p id="p0127" num="0127"> [00108] FIG. 31: Alterations in blood PCR marker levels and CgA during surgical resection. Tumor excision significantly reduced expression levels of a panel of biomarkers ("PCR") as described in Example 5H, when measured 2 weeks post-operation (31A). CgA levels were variable (31B). horizontal = mean. n=9 patients. </p><p id="p0128" num="0128"> [00109] FIG. 32: Alterations in blood PCR marker levels and CgA during Octreotide LAR therapy. Octreotide LAR significantly reduced blood expression levels of the panel of biomarkers ("PCR") as described in Example 5H; expression remained suppressed over the time course (32A). CgA levels were variable before being reduced by 6 months (32B). *p&lt;0.02 versus BEFORE. #p=0.06 vs. 1 MONTH. Horizontal line = mean. MON = month. n=S patients. </p><p id="p0129" num="0129"> [00110] FIG. 33: Alterations in blood PCR marker levels and CgA after CryoAblation. Expression levels of CgA and a 13-biomarker panel (PCR+) in patient SK before and at various times following cryoablation, as described in Example 5H, with changes in biomarker expression correlating with the appearance of micrometastases. </p><p id="p0130" num="0130"> [00111] FIG. 34: Alterations in blood PCR marker levels and CgA during surgical resection and Octreotide LAR therapy. Expression levels of CgA and an NET biomarker panel levels in patient BG, as described in Example 5H, measured out to 2 weeks post-operation and following Octreotide LAR. </p><p id="p0131" num="0131"> [00112] FIG. 35: Overall percentage correct calls for patients in complete remission (Group I: complete responders [CR], n=l2), considered clinically as exhibiting stable disease (SD) following surgery («=42, Group II - SD-Sx) or after treatment with long-acting somatostatin analogs (LAR: «=78, Group III - SD-LAR). *This includes pasireotide: n=l and everolimus: n=4). The PCR test exhibited between 90-100% correct call rates for treated samples. </p><p id="p0132" num="0132"> [00113] FIG. 36: Mathematical analyses including SVM, LDA, KNN and Bayes </p><p id="p0133" num="0133">demonstrated that the 13 marker panel could differentiate between stable and progressive disease with sensitivities of -73%. </p><p id="p0134" num="0134"> [00114] FIG. 37: Comparison of CgA DAKO levels across control and GEP-NEN (both untreated and treated) blood samples (w=130). Differences were noted between untreated and treated samples using the Student's t-test (37A) or non-parametric analyses (37B). Red crosses represent outliers (37A) and the y-scale is transformed logarithmically for visualization purposes 
<!-- EPO <DP n="28"/>-->
 (37A, B). CgA levels can consistently distinguish between normal and untreated groups but exhibit significant overlap with treated samples. </p><p id="p0135" num="0135"> [00115] FIG. 38: Utility of CgA ELISA for correctly detecting GEP-NENs and </p><p id="p0136" num="0136">differentiating treated from untreated samples. Using 19 U/L as a cut-off (as per DAKO criteria), the overall percentage correct calls for GEP-NENs and controls was 70%, and the performance metrics were better in untreated patients compared to treated patients (sensitivity 63% vs. 45%). CgA levels best identify untreated patients and samples from individuals with no disease (controls). </p><p id="p0137" num="0137"> [00116] FIG. 39: Comparison of correct call rates for circulating CgA DAKO levels and the individual algorithms using the PCR-based approach across control and GEP-NEN (both untreated and treated) blood samples (w=130). Call rates were significantly higher for the PCR- based test (-90-95% for each of the algorithms) compared to -50% of CgA (FIG. 39A). </p><p id="p0138" num="0138">Inclusion of CgA values in the algorithm did not increase the correct call rates, and was associated with a decrease in correct calls for the KNN algorithm (FIG. 39B). </p><p id="p0139" num="0139"> [00117] FIG. 40: PCR score for a blood sample obtained from a normal control (black dotted line: PCR Score = 15, called "normal") and from Case 1 presenting with mesenteric metastases (red dotted line: PCR Score 68: called "tumor untreated". The population distributions are in solid lines. This provides an illustration of the relationship between the algorithm calls and a Score (Transcript index). </p><p id="p0140" num="0140"> [00118] FIG. 41: PCA of SI-NENs (w=46) and PNENs (n=lS) identified that the 51 marker panel could differentiate between pancreatic NENs and small bowel NENs. (41A). A variety of mathematical algorithms including SVM, LDA, KNN and Bayes demonstrated these two tumor groups could be differentiated with an overall sensitivity of -92% (FIG. 41B). The signature for SI-NENs is different to PNENs. </p><p id="p0141" num="0141"> [00119] FIG. 42: PCA of GEP-NENs (w=64) and GI cancers (n=42) identified that the 51 marker panel could differentiate between the two neoplasia types (FIG. 42A). Mathematical analyses including SVM, LDA, KNN and Bayes demonstrated these two tumor types could be differentiated with sensitivities of -83% (FIG. 42B). The signature for GEP-NENs is different to GI cancers. </p><p id="p0142" num="0142"> [00120] FIG. 43: Comparison of the PCR-based approach and CgA DAKO levels across control and GEP-NEN (both untreated and treated) blood samples (w=130). Call rates were significantly higher for the PCR-based test for identifying either a GEP-NEN or for 
<!-- EPO <DP n="29"/>-->
 differentiating between treated and untreated samples. *p&lt;0.0005 vs. CgA, p&lt;0.02 vs. CgA. The PCR blood test is significantly more accurate than measurement of CgA levels to detect tumors and differentiate treated from non-treated patients. </p><p id="p0143" num="0143">Detailed description A. Definitions </p><p id="p0144" num="0144"> [00121] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et ah, Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted. </p><p id="p0145" num="0145"> [00122] As used herein, the term "GEP-NEN biomarker" and "NET biomarker" refer synonymously to a biological molecule, such as a gene product, the expression or presence of which (e.g., the expression level or expression profile) on its own or as compared to one or more other biomarkers {e.g., relative expression) differs (i.e., is increased or decreased) depending on the presence, absence, type, class, severity, metastasis, location, stage, prognosis, associated symptom, outcome, risk, likelihood of treatment responsiveness, or prognosis of GEP-NEN disease, or is associated positively or negatively with such factors or the prediction thereof. </p><p id="p0146" num="0146"> [00123] As used herein, the term "polynucleotide" or nucleic acid molecule means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA. As used herein, a nucleic acid molecule or nucleic acid sequence of the invention that serves as a probe in a microarray analysis preferably 
<!-- EPO <DP n="30"/>-->
 comprises a chain of nucleotides, more preferably DNA and/or RNA. In other embodiments a nucleic acid molecule or nucleic acid sequence of the invention comprises other kinds of nucleic acid structures such as for instance a DNA/RNA helix, peptide nucleic acid (PNA), locked nucleic acid (LNA) and/or a ribozyme. Hence, as used herein the term "nucleic acid molecule" also encompasses a chain comprising non-natural nucleotides, modified nucleotides and/or non- nucleotide building blocks which exhibit the same function as natural nucleotides. </p><p id="p0147" num="0147"> [00124] As used herein, the term "polypeptide" means a polymer of at least 10 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used. </p><p id="p0148" num="0148"> [00125] As used herein, the terms "hybridize," "hybridizing," "hybridizes," and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6XSSC/0.1% SDS/100 μ^πύ ssDNA, in which temperatures for hybridization are above 37 degrees C and temperatures for washing in O.lXSSC/0.1% SDS are above 55 degrees C, and most preferably to stringent hybridization conditions. </p><p id="p0149" num="0149"> [00126] In the context of amino acid sequence comparisons, the term "identity" is used to express the percentage of amino acid residues at the same relative position which are the same. Also in this context, the term "homology" is used to express the percentage of amino acid residues at the same relative positions which are either identical or are similar, using the conserved amino acid criteria of BLAST analysis, as is generally understood in the art. Further details regarding amino acid substitutions, which are considered conservative under such criteria, are provided below. </p><p id="p0150" num="0150"> [00127] Additional definitions are provided throughout the subsections which follow. </p><p id="p0151" num="0151">B. GEP-NEN disease and biomarkers </p><p id="p0152" num="0152"> [00128] Diagnosis and prognosis of GEP-NEN has been difficult, in part due to the prosaic symptoms and syndromes of the disease, such as carcinoid syndrome, diarrhea, flushing, sweating, bronchioconstruction, GI bleeding, cardiac disease, intermittent abdominal pain, which often remain silent for years. Available diagnostic methods include anatomical localization, such as by imaging, e.g., X-ray, gastrointestinal endoscopy, abdominal computed tomography (CT), combined stereotactic radiosurgery (SRS) / CT, and MRI, and detection of some gene products. Known methods are limited, for example by low specificity and/or sensitivity and/or 
<!-- EPO <DP n="31"/>-->
 in the ability to detect early-stage disease. Detection of single biomarkers has not been entirely satisfactory, for example, to identify malignancy in human blood samples and predict complex outcomes like fibrosis and metastasis. See Michiels S, Koscielny S, Hill C, "Interpretation of microarray data in cancer," Br J Cancer 2007;96(8): 1155-8. Limitations in available methods have contributed to difficulties in pathological classification, staging, and prediction, treatment developing and monitoring therapeutic effects. Among the embodiments provided herein are methods and compositions that address these limitations. </p><p id="p0153" num="0153"> [00129] In one aspect, the provided invention relates to the detection and identification of GEP-NEN biomarkers and panels of such biomarkers, for example, in biological samples. </p><p id="p0154" num="0154">Provided are methods and compositions {e.g., agents, such as polynucleotides), for detecting, determining expression levels of, and recognizing or binding to the biomarkers, in biological samples, typically blood samples, and for detecting and analyzing expression profiles </p><p id="p0155" num="0155">(signatures) of panels of biomarkers. Also provided are compositions and combinations containing the agents, including sets (panels) of agents, systems, and kits, for use in the provided methods. </p><p id="p0156" num="0156"> [00130] Also provided are methods and compositions for the detection, enrichment, isolation, and purification of GEP-NEN cells, e.g., circulating GEP-NEN cells (CNCs), for example, from a blood sample, culture, cell mixture, fluid, or other biological sample, based on the expression of one or more of the GEP-NEN biomarkers. </p><p id="p0157" num="0157"> [00131] Also provided are models and biomathematical algorithms, e.g., supervised learning algorithms, and methods using the same, for prediction, classification, and evaluation of GEP- NEN and associated outcomes, for example, predicting degree of risk, responsiveness to treatment, metastasis or aggressiveness, and for determining GEP-NEN sub-type. </p><p id="p0158" num="0158"> [00132] Detection of the biomarkers using the provided embodiments is useful for improving GEP-NEN diagnostics and prognostics, and to inform treatment protocols. In some aspects, detection of the biomarkers and/or expression levels by the provided embodiments confirms or indicates the presence, absence, stage, class, location, sub-type, aggressiveness, malignancy, metastasis, prognosis, or other outcome of GEP-NEN, or a GEP-NEN cell, such as a circulating GEP-NEN cell (CNC). The provided methods and compositions may be used for tumor localization, and for predicting or detecting metastases, micrometastases, and small lesions, and/or for determining degree of risk, likelihood of recurrence, treatment responsiveness or remission, and informing appropriate courses of treatment. For example, detecting the 
<!-- EPO <DP n="32"/>-->
 biomarkers, e.g., in circulation may be used to detect early- stage and primary GEP-NENs (e.g., to identify GEP-NEN disease or metastases in a patient previously deemed "negative" by another approach, such as anatomic localization). </p><p id="p0159" num="0159"> [00133] The provided methods and compositions may be used for designing, implementing, and monitoring treatment strategies, including patient- specific treatment strategies. In one example, detected expression levels of the GEP-NEN biomarkers serve as surrogate markers for treatment efficacy, e.g. , to monitor the effects of surgical therapy (e.g. , removal of tumors), targeted medical therapy (e.g. , inhibition of tumor secretion/ proliferation), and other therapeutic approaches, by detecting remission or recurrence of tumors, even in the form of small micrometastases. The methods also may be used in evaluating clinical symptoms and outcomes, and for histological grading and molecular characterization of GEP-NENs. </p><p id="p0160" num="0160">C. GEP-NEN biomarkers </p><p id="p0161" num="0161">[00134] The provided biomarkers including GEP-NEN biomarkers, and panels (sets) of the same. Among the provided GEP-NEN biomarkers are gene products, such as DNA, RNA, e.g., transcripts, and protein, which are differentially expressed in GEP-NEN disease, and/or in different stages or sub-types of GEP-NEN, or in different GEP-NEN tumors, such as gene products differentially expressed in metastatic versus primary tumors, tumors with different degrees of aggressiveness, high versus low-risk tumors, responsive versus non-responsive tumors, tumors exhibiting different pathological classifications and/or likelihood of response to particular courses of treatment, as well as those associated with features of GEP-NEN disease, stage, or type, or with neuroendocrine cells or related cell-types. </p><p id="p0162" num="0162"> [00135] For example, the biomarkers include gene products whose expression is associated with or implicated in tumorogenicity, metastasis, or hormone production, or a phenotype of primary or metastatic GEP-NEN, such as adhesion, migration, proliferation, apoptosis, metastasis, and hormone secretion, and those associated with neoplasia or malignancy in general. The biomarkers also include gene products expressed in related normal tissues, such as neuroendocrine cells, the small intestine (SI) mucosa, and enterochromaffin (EC) cells. </p><p id="p0163" num="0163"> [00136] Among the biomarkers are GEP-NEN cell secretion products, including hormones and amines, e.g. , gastrin, ghrelin, pancreatic polypeptide, substance P, histamine, and serotonin, and growth factors such as tumor growth factor-beta (TGF-β) and connective tissue growth 
<!-- EPO <DP n="33"/>-->
 factor (CTGF), which are detectable in the circulation. Secretion products can vary with tumor sub-type and origin. </p><p id="p0164" num="0164"> [00137] In one example, the biomarkers are gene products associated with regulatory genotypes (i.e., adhesion, migration, proliferation, apoptosis, metastasis, and/or hormone secretion) that underlay various GEP-NEN subtypes, stages, degrees of aggressiveness, or treatment responsiveness. </p><p id="p0165" num="0165"> [00138] Also among the GEP-NEN biomarkers are gene products differentially expressed in primary GEP-NENs and hepatic metastases as compared to normal small bowel mucosa and pure preparations of EC cells See Modlin et ah, "Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed," Ann Surg 2006;244(l):52-60; Kidd M, et ah, "The role of genetic markers, NAP1L1, MAGE-D2 and MTA1, in defining small intestinal carcinoid neoplasia," Annals of Surgical Oncology 2006;13:253-62; Kidd M et ah, "Q RT-PCR detection of Chromogranin A: A new standard in the identification of neuroendocrine tumor disease," Annals of Surgery 2006;243:273-80. </p><p id="p0166" num="0166"> [00139] The GEP-NEN biomarkers include: AKAP8L (A kinase (PRKA) anchor protein 8- like), ATP6V1H (ATPase, H+ transporting, lysosomal 50/57kDa, VI subunit H), BNIP3L (BCL2/adenovirus E1B 19kDa interacting protein 3-like), C21orf7 (chromosome 21 open reading frame 7), COMMD9 (COMM domain containing 9), ENPP4 (ectonucleotide </p><p id="p0167" num="0167">pyrophosphatase/phosphodiesterase 4). FAM13A (family with sequence similarity 13, member A), FLJ 10357 (Rho guanine nucleotide exchange factor 40), GLT8D1 (glycosyltransferase 8 domain containing 1), HDAC9 (histone deacetylase 9), HSF2 (heat shock transcription factor 2), LEOl (Pafl/RNA polymerase II complex component, homolog (S. cerevisiae)), MORF4L2 (MORF4L2 mortality factor 4 like 2), NOL3 (nucleolar protein 3 (apoptosis repressor with CARD domain)), NUDT3 (nudix (nucleoside diphosphate linked moiety X)-type motif 3), OAZ2 (ornithine decarboxylase antizyme 2), PANK2 (pantothenate kinase 2), PHF21A (PHD finger protein 21A), PKD1 (polycystic kidney disease 1 (autosomal dominant)), PLD3 </p><p id="p0168" num="0168">(phospholipase D family, member 3), PQBP1 (polyglutamine binding protein 1), RNF41 (polyglutamine binding protein 1), RSFl (remodeling and spacing factor 1), RTN2 (reticulon 2), SMARCD3 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3p), SPATA7 (spermatogenesis associated 7), SSTl (somatostatin receptor 1), SST3 (somatostatin receptor 3), SST4 (somatostatin receptor 4), SST5 (somatostatin receptor 5), TECPR2 (tectonin beta-propeller repeat containing 2), TRMT112 (tRNA methyltransferase 
<!-- EPO <DP n="34"/>-->
 11-2 homolog (S. cerevisiae)), VPS13C (vacuolar protein sorting 13 homolog C (S. cerevisiae)), WDFY3 (WD repeat and FYVE domain containing 3), ZFHX3 (zinc finger homeobox 3), ZXDC (ZXD family zinc finger C), ZZZ3 (zinc finger, ZZ-type containing 3), Amyloid beta (A4) precursor- like protein 2 (APLP2); v-raf murine sarcoma 3611 viral oncogene homolog (ARAF1); v-raf murine sarcoma viral oncogene homolog Bl (BRAF1); CD59; Chromogranin A (CgA, also called parathyroid secretory protein 1, CHGA); connective tissue growth factor (CTGF); chemokine (C-X-C motif) ligand 14 (CXCL14); frizzled homolog 7 (FZD7); glutamate receptor, ionotropic, AMPA 2 (GRIA2); homeobox C6 (HOXC6); Ki-67; KiSS-1 metastasis- suppressor (Kissl); v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS); melanoma antigen family D, 2 (MAGE-D2); metastasis associated 1 (MTA1); nucleosome assembly protein 1-like 1 (NAP1L1); NK2 transcription factor related, locus 3 (e.g., Homo Sapiens NK2 transcription factor related, locus 3 (Drosophila)) (NKX2-3); neuropilin 2 (NRP2); olfactory receptor, family 51, subfamily E, member 1 (OR51E1); paraneoplastic antigen MA2 (PNMA2); protein tyrosine phosphatase, receptor type, N polypeptide 2 (PTPRN2); v-raf- 1 murine leukemia viral oncogene homolog 1 (RAF1); secretogranin V (7B2 protein) (SCG5); </p><p id="p0169" num="0169">sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 (SPOCK1); apoptosis inhibitor survivin gene (BIRC5; API4; EPR-1) (Survivin); tryptophan hydroxylase 1 (TPH1), solute carrier family 18 (vesicular monoamine), member 1 (VMAT1); solute carrier family 18 (vesicular monoamine), member 2 (VMAT2); and X2BTB48 (serpin peptidase inhibitor, clade A (alpha- 1 antiproteinase, antitrypsin), member 10), including gene products typically human gene products, including transcripts, mRNA, cDNA, coding sequences, proteins and polypeptides, as well as polynucleotides (nucleic acids) encoding the proteins and polypeptides, including naturally occurring variants, e.g., allelic variants, splice variants, transcript variants, and single nucleotide polymorphism (SNP) variants. For example, the biomarkers include polynucleotides, proteins, and polypeptides having the sequences disclosed herein, and naturally occurring variants thereof. </p><p id="p0170" num="0170"> [00140] The GEP-NEN biomarkers further include CD 164. In another aspect, the biomarkers include NALP, e.g., products of the caspase-3 activating apoptosis gene and apoptotic marker, NALP. </p><p id="p0171" num="0171"> [00141] APLP2 biomarkers include human APLP2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the APLP2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 1 (referenced at 
<!-- EPO <DP n="35"/>-->
 GenBank gi number 214010177) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 158-2449 of SEQ ID NO: 1), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0172" num="0172"> [00142] The ARAF1 biomarkers include human ARAF1 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ARAF1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 2 </p><p id="p0173" num="0173">(referenced at GenBank gi number 283484007), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 195-2015 of SEQ ID NO: 2), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0174" num="0174"> [00143] The BRAFl biomarkers include BRAFl gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the BRAFl biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 (referenced at GenBank gi number 187608632), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 62-2362 of SEQ ID NO: 3), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0175" num="0175"> [00144] The CD59 biomarkers include human CD59 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the CD59 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 4 </p><p id="p0176" num="0176">(referenced at GenBank gi number 187829037), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 278-664 of SEQ ID NO: 4), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0177" num="0177"> [00145] The CgA biomarkers include human CGA or CHGA gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the CgA biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 5 </p><p id="p0178" num="0178">(referenced at GenBank gi number 33990769), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 1 to 1374 of SEQ ID NO: 5), a natural variant thereof, or a protein encoded by such a polynucleotide. Human CgA encodes a water soluble acidic glycoprotein stored in the secretory granules of neuroendocrine cells and detectable in plasma. </p><p id="p0179" num="0179"> [00146] The CTGF biomarkers include human CTGF gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the CTGF biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 6 
<!-- EPO <DP n="36"/>-->
 (referenced at GenBank gi number 98986335), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 207-1256 of SEQ ID NO: 6), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0180" num="0180"> [00147] The CXCL14 biomarkers include human CXCL14 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the CXCL14 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 7 </p><p id="p0181" num="0181">(referenced at GenBank gi number 208022628), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 466-801of SEQ ID NO: 7), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0182" num="0182"> [00148] The FZD7 biomarkers include human FZD7 gene products, e.g., Homo sapiens frizzled homolog 7 (Drosophila) (FDZ7), including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the FDZ7 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 8 (referenced at GenBank gi number 4503832), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 62- 1786of SEQ ID NO: 8 a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0183" num="0183"> [00149] The GRIA2 biomarkers include human GRIA2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the GRIA2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 9 </p><p id="p0184" num="0184">(referenced at GenBank gi number 134304849), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 460-3111 of SEQ ID NO: 9), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0185" num="0185"> [00150] The homeobox C6 (HOXC6) biomarkers include human HOXC6 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the HOXC6 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 10 (referenced at GenBank gi number 93141222) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 113-820 of SEQ ID NO: 10), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0186" num="0186"> [00151] The Ki67 biomarkers include human Ki67 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the Ki67 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 11 (referenced at GenBank gi number 225543213)or containing the coding region thereof (e.g., nucleotides 196- 
<!-- EPO <DP n="37"/>-->
 9966) of SEQ ID NO: 11), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0187" num="0187"> [00152] The Kissl biomarkers include human KISS1 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the KISS1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 12 (referenced at GenBank gi number 116829963), or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 155-571 of SEQ ID NO: 12), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0188" num="0188"> [00153] The KRAS biomarkers include human KRAS gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the KRAS biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 13 (referenced at GenBank gi number 34485724) or containing the coding region thereof (e.g., nucleotides 182-751 of SEQ ID NO: 13), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0189" num="0189"> [00154] The MAGE-D2 biomarkers include human MAGE-D2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the MAGE-D2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 14 (referenced at GenBank gi number 29171703) or containing a protein-coding portion thereof, (e.g. , the open reading frame at nucleotides 100-1920 of SEQ ID NO: 14), a natural variant thereof, or a protein encoded by such a polynucleotide. MAGE-D2 encodes an adhesion- associated protein. </p><p id="p0190" num="0190"> [00155] The MTA1 biomarkers include human MTA1 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the MTA1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 15 (referenced at GenBank gi number 115527079) or containing the coding region thereof (e.g., nucleotides 188-2335 of SEQ ID NO: 15), a natural variant thereof, or a protein encoded by such a polynucleotide. MTA, an estrogen-antagonistic breast cancer malignancy gene, has been used to identify progressive (metastatic) disease in other tumors including breast, hepatocellular, esophageal, gastric, and colorectal carcinomas. </p><p id="p0191" num="0191"> [00156] The NAP1L1 biomarkers include human NAP1L1 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the NAP1L1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 16 
<!-- EPO <DP n="38"/>-->
 (referenced at GenBank gi number 219842231) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 413-1588 of SEQ ID NO: 16), a natural variant thereof, or a protein encoded by such a polynucleotide. NAP 1 LI is a mitosis-regulatory gene encoding a nuclear protein involved in chromatin assembly and DNA replication. </p><p id="p0192" num="0192"> [00157] The NKX2-3 biomarkers include human NKX2-3 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the NKX2-3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 17 (referenced at GenBank gi number 148746210) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 200-1294 of SEQ ID NO: 17), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0193" num="0193"> [00158] The NRP2 biomarkers include human NRP2 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the NRP2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 18 (referenced at GenBank gi number 41872561) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 792-3587 of SEQ ID NO: 18), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0194" num="0194"> [00159] The OR51E1 biomarkers include human OR51E1 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the OR51E1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 19 (referenced at GenBank gi number 205277377) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 145-1101 of SEQ ID NO: 19), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0195" num="0195"> [00160] The PNMA2 biomarkers include human PNMA2 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the PNMA2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 20 (referenced at GenBank gi number 156766040) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 771-1865 of SEQ ID NO: 20), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0196" num="0196"> [00161] The PTPRN2 biomarkers include human PTPRN2 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the PTPRN2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 21 (referenced at GenBank gi number 194097439) or containing a protein-coding portion thereof, 
<!-- EPO <DP n="39"/>-->
 (e.g., the open reading frame at nucleotides 122-3169 of SEQ ID NO: 21), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0197" num="0197"> [00162] The RAF1 biomarkers include human RAF1 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the RAF1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 22 (referenced at GenBank gi number 189458830) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 416-2362 of SEQ ID NO: 22), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0198" num="0198"> [00163] The SCG5 biomarkers include human SCG5 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SCG5 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 23 (referenced at GenBank gi number 221139784) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 118-756 of SEQ ID NO: 23), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0199" num="0199"> [00164] The SPOCKl biomarkers include human SPOCKl gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SPOCKl biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 24 (referenced at GenBank gi number 82659117) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 152-1471 of SEQ ID NO: 24), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0200" num="0200"> [00165] The Survivin biomarkers include human Survivin gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the Survivin biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 25 (referenced at GenBank gi number 59859877) or containing a protein-coding portion thereof, (e.g., the open reading frame at nucleotides 122-550 of SEQ ID NO: 25) or a polynucleotide having the protein-coding sequence (SEQ ID NO: 34) of nucleotides 2811-2921, 3174-3283, 5158-5275, 11955-12044 of GenBank gi number 2315862), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0201" num="0201"> [00166] The TPH1 biomarkers include human TPH1 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the TPH1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 26 (referenced at GenBank gi number 226342925) or containing a protein-coding portion thereof 
<!-- EPO <DP n="40"/>-->
 (e.g., the open reading frame at nucleotides 27-1361 of SEQ ID NO: 26), a natural variant thereof, or a protein encoded by such a polynucleotide. TPH1 encodes an enzyme produced by enterochromaffin (EC) cells of the GI tract, important for the production of serotonin. </p><p id="p0202" num="0202"> [00167] The VMAT1 biomarkers include human VMAT1 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the VMAT1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 27 (referenced at GenBank gi number 215272388) or containing the coding region thereof (e.g., nucleotides 472-2049 of SEQ ID NO: 27), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0203" num="0203"> [00168] The VMAT2 biomarkers include human VMAT2 gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the VMAT2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 28 (referenced at GenBank gi number 141803164) or containing the coding region thereof (e.g., nucleotides 32-1576 of SEQ ID NO: 28), a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0204" num="0204"> [00169] The X2BTB48 biomarkers include human serpin peptidase inhibitor, clade A (alpha- 1 antiproteinase, antitrypsin), member 10) gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the X2BTB48 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 29 (referenced at GenBank gi number 154759289) or containing the coding region thereof (e.g., nucleotides 467- 1801 of SEQ ID NO: 29), a natural variant thereof, such as the nucleotide sequence referenced at GenBank gi number 154759290 (SEQ ID NO: 105) or a coding sequence thereof, e.g., the coding sequence thereof at nucleotides 122-1456, or a protein encoded by such polynucleotides, such as the protein having the amino acid sequence referenced at GenBank gi number 7705879. </p><p id="p0205" num="0205"> [00170] The AKAP8L (A kinase (PRKA) anchor protein 8 -like) biomarkers include human AKAP8L gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the AKAP8L biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 201 (referenced at GenBank gi number 49472840), or containing a protein-coding portion thereof, e.g., the coding sequence thereof of nucleotides 100-2040 of SEQ ID NO: 201, a natural variant thereof, or a protein encoded by such a polynucleotide. 
<!-- EPO <DP n="41"/>-->
 [00171] The ATP6V1H (ATPase, H+ transporting, lysosomal 50/57kDa, VI subunit H) biomarkers include human ATP6V1H gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ATP6V1H biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 204 (referenced at GenBank gi number 47717103), or containing a protein-coding portion thereof, e.g., the coding sequence thereof of nucleotides 293-1744, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0206" num="0206"> [00172] The BNIP3L (BCL2/adenovirus E1B 19kDa interacting protein 3-like) biomarkers include human BNIP3L gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the BNIP3L biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 205 (referenced at GenBank gi number 47078259), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 125-784 of SEQ ID NO: 205, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0207" num="0207"> [00173] The C21orf7 (chromosome 21 open reading frame 7) biomarkers include human C21orf7 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the C21orf7 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 206 (referenced at GenBank gi number 31542267), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 278-1006 of SEQ ID NO: 206, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0208" num="0208"> [00174] The COMMD9 (COMM domain containing 9) biomarkers include human ATP6V1H gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the COMMD9 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 207 (referenced at GenBank gi number 156416006), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 38- 508 of SEQ ID NO: 207, a natural variant thereof, or a protein encoded by such a </p><p id="p0209" num="0209">polynucleotide. </p><p id="p0210" num="0210"> [00175] The ENPP4 (ectonucleotide pyrophosphatase/phosphodiesterase 4) biomarkers include human ENPP4 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ENPP4 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 208 (referenced at GenBank gi number 
<!-- EPO <DP n="42"/>-->
 194688140), or containing a protein-coding portion thereof, e.g., the coding sequence thereof of nucleotides 260-1621 of SEQ ID NO: 208, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0211" num="0211"> [00176] The FAM13A (family with sequence similarity 13, member A) biomarkers include human FAM13A gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the FAM13A biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 209 (referenced at GenBank gi number </p><p id="p0212" num="0212">283806631), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 281-1126 of SEQ ID NO: 209, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0213" num="0213"> [00177] The FLJ 10357 (Rho guanine nucleotide exchange factor 40) biomarkers include human ARHGEF40 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the FLJ 10357 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 210 (referenced at GenBank gi number 50843836), or containing a protein-coding portion thereof, e.g., the coding sequence thereof of nucleotides 30-4589 of SEQ ID NO: 210, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0214" num="0214"> [00178] The GLT8D1 (glycosyltransferase 8 domain containing 1) biomarkers include human GLT8Dlgene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the GLT8D1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 211 (referenced at GenBank gi number 58331224), or containing a protein-coding portion thereof, e.g., the coding sequence thereof of nucleotides 852-1967 of SEQ ID NO: 211, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0215" num="0215"> [00179] The HDAC9 (histone deacetylase 9) biomarkers include human HDAC9 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the HDAC9 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 212 (referenced at GenBank gi number 323423043), or containing a protein- coding portion thereof, e.g., the coding sequence thereof at nucleotides 362-2128 of SEQ ID NO: 212, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0216" num="0216"> [00180] The HSF2 (heat shock transcription factor 2) biomarkers include human HSF2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In 
<!-- EPO <DP n="43"/>-->
 one example, the HSF2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 213 (referenced at GenBank gi number 207113145), or containing a protein- coding portion thereof, e.g., the coding sequence thereof of nucleotides 188-1798 of SEQ ID NO: 213, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0217" num="0217"> [00181] The LEOl (Paf 1/RNA polymerase II complex component, homolog (S. cerevisiae)) biomarkers include human LEOl gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the LEOl biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 215 (referenced at GenBank gi number 37059738), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 17-2017 of SEQ ID NO: 215, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0218" num="0218"> [00182] The MORF4L2 (MORF4L2 mortality factor 4 like 2) biomarkers include human MORF4L2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the MORF4L2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 217 (referenced at GenBank gi number </p><p id="p0219" num="0219">215490020, or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 505-1371, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0220" num="0220"> [00183] The NOL3 (nucleolar protein 3 (apoptosis repressor with CARD domain)) biomarkers include human NOL3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the NOL3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 218 (referenced at GenBank gi number 297632351), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 194-853, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0221" num="0221"> [00184] The NUDT3 (nudix (nucleoside diphosphate linked moiety X)-type motif 3) biomarkers include human NUDT3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the NUDT3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 219 (referenced at GenBank gi number 322302838), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 319-837 of SEQ ID NO: 219, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0222" num="0222"> [00185] The OAZ2 (ornithine decarboxylase antizyme 2) biomarkers include human OAZ2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs 
<!-- EPO <DP n="44"/>-->
 thereof. In one example, the OAZ2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 220 (referenced at GenBank gi number 161377456), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 216- 311 and 313-786, or a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0223" num="0223"> [00186] The PANK2 (pantothenate kinase 2) biomarkers include human PANK2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the PANK2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 221 (referenced at GenBank gi number 85838514), or containing a protein- coding portion thereof, e.g., the coding sequence thereof at nucleotides 312-1151, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0224" num="0224"> [00187] The PHF21A (PHD finger protein 21 A) biomarkers include human PHF21A gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the PHF21A biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 222 (referenced at GenBank gi number 156546893), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 625-2667, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0225" num="0225"> [00188] The PKDl (polycystic kidney disease 1 (autosomal dominant)) biomarkers include human PKDl gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the PKDl biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 223, or the sequence referenced at GenBank gi Number 205360961, or containing a protein-coding portion thereof of such a sequence, e.g., the coding sequence thereof at nucleotides 210-13118 or nucleotides 210-13117 of GenBank gi Number 205360961 or SEQ ID NO: 223, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0226" num="0226"> [00189] The PLD3 (phospholipase D family, member 3) biomarkers include human PLD3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the PLD3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 224 (referenced at GenBank gi number 166197669), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 399- 1871 of SEQ ID NO: 224, a natural variant thereof, or a protein encoded by such a </p><p id="p0227" num="0227">polynucleotide. 
<!-- EPO <DP n="45"/>-->
 [00190] The PQBP1 (polyglutamine binding protein 1) biomarkers include human PQBP1 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the PQBP1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 225 (referenced at GenBank gi number 74027246), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 122- 919, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0228" num="0228"> [00191] The RNF41 (polyglutamine binding protein 1) biomarkers include human RNF41 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the RNF41 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 227 (referenced at GenBank gi number 338827617), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 320- 1273 of SEQ ID NO: 227, a natural variant thereof, or a protein encoded by such a </p><p id="p0229" num="0229">polynucleotide. </p><p id="p0230" num="0230"> [00192] The RSFl (remodeling and spacing factor 1) biomarkers include human RSFl gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the RSFl biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 228 (referenced at GenBank gi number 38788332), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 121-4446 of SEQ ID NO: 228, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0231" num="0231"> [00193] The RTN2 (reticulon 2) biomarkers include human RTN2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the RTN2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 229 (referenced at GenBank gi number 46255010), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 229-1866 of SEQ ID NO: 229, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0232" num="0232"> [00194] The SMARCD3 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3p) biomarkers include human SMARCD3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SMARCD3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 232 (referenced at GenBank gi number 51477701), or containing a protein- coding portion thereof, e.g., the coding sequence thereof at nucleotides 102-1553, a natural variant thereof, or a protein encoded by such a polynucleotide. 
<!-- EPO <DP n="46"/>-->
 [00195] The SPATA7 (spermatogenesis associated 7) biomarkers include human SPATA7 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SPATA7 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 233 (referenced at GenBank gi number 295789142), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 176- 1879 of SEQ ID NO: 233, a natural variant thereof, or a protein encoded by such a </p><p id="p0233" num="0233">polynucleotide. </p><p id="p0234" num="0234"> [00196] The SST1 (somatostatin receptor 1) biomarkers include human SST1 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SST1 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 234 (referenced at GenBank gi number 33946330), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 618-1793 of SEQ ID NO: 234, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0235" num="0235"> [00197] The SST3 (somatostatin receptor 3) biomarkers include human SST3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SST3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 235 (referenced at GenBank gi number 44890055), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 526-1782 of SEQ ID NO: 235, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0236" num="0236"> [00198] The SST4 (somatostatin receptor 4) biomarkers include human SST3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SST3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 236 (referenced at GenBank gi number 149944553), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 65-1231, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0237" num="0237"> [00199] The SST5 (somatostatin receptor 5) biomarkers include human SST3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SST3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 237 (referenced at GenBank gi number 289547751), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 89-1183, a natural variant thereof, or a protein encoded by such a polynucleotide. 
<!-- EPO <DP n="47"/>-->
 [00200] The TECPR2 (tectonin beta-propeller repeat containing 2) biomarkers include human TECPR2 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the TECPR2 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 238 (referenced at GenBank gi number </p><p id="p0238" num="0238">289547516), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 227-4030 of SEQ ID NO: 238, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0239" num="0239"> [00201] The TRMT112 (tRNA methyltransferase 11-2 homolog (S. cerevisiae)) biomarkers include human TRMT112 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the TRMT112 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 241 (referenced at GenBank gi number 7705476), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 36-413 of SEQ ID NO: 241, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0240" num="0240"> [00202] The VPS13C (vacuolar protein sorting 13 homolog C (S. cerevisiae)) biomarkers include human VPS13C gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the VPS13C biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 242 (referenced at GenBank gi number 308081495), or containing a protein-coding portion thereof, e.g., the coding sequence thereof at nucleotides 92-10978, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0241" num="0241"> [00203] The WDFY3 (WD repeat and FYVE domain containing 3) biomarkers include human WDFY3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the WDFY3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 243, or the sequence referenced at GenBank gi number 195972885, or containing a protein-coding portion thereof, e.g., the coding sequence at nucleotides 409-10988 of SEQ ID NO: 243 or GenBank gi number 195972885, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0242" num="0242"> [00204] The ZFHX3 (zinc finger homeobox 3) biomarkers include human ZFHX3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ZFHX3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 244 (referenced at GenBank gi number 258613986), or containing a protein- 
<!-- EPO <DP n="48"/>-->
 coding portion thereof, e.g., the coding sequence thereof at nucleotides 130-8499 of SEQ ID NO: 244, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0243" num="0243"> [00205] The ZXDC (ZXD family zinc finger C) biomarkers include human ZXDC gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ZXDC biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 245 (referenced at GenBank gi number 217035098), or containing a protein- coding portion thereof, e.g., the coding sequence thereof at nucleotides 55-2187 of SEQ ID NO: 245, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0244" num="0244"> [00206] The ZZZ3 (zinc finger, ZZ-type containing 3) biomarkers include human ZZZ3 gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ZZZ3 biomarker is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 246 (referenced at GenBank gi number 141803158), or containing a protein- coding portion thereof, e.g., the coding sequence thereof at nucleotides 477-3188 of SEQ ID NO: 246, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0245" num="0245"> [00207] In some aspects, the provided methods and compositions detect a GEP-NEN biomarker; in some examples, the provided methods and compositions detect panels of GEP- NEN biomarkers, including two or more GEP-NEN biomarkers, such as at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, or 100 or more biomarkers. </p><p id="p0246" num="0246"> [00208] For example, provided are methods and compositions that detect at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51, and/or all of the following sets of biomarkers: </p><p id="p0247" num="0247"> [00209] AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, ZZZ3, APLP2, CD59, ARAF1, BRAF1, KRAS, and RAF1 gene products; </p><p id="p0248" num="0248"> [00210] AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, 
<!-- EPO <DP n="49"/>-->
 PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products; and </p><p id="p0249" num="0249"> [00211] APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT1, and VMAT2 gene products. </p><p id="p0250" num="0250"> [00212] Also provided are methods and compositions that detect at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 of the following sets of biomarkers: </p><p id="p0251" num="0251"> [00213] APLP2, ARAF1, BRAF1, CD59, CgA, CTGF, CXCL14, FZD7, GRIA2, HOXC6, Ki-67; Kissl, KRAS, MAGE-D2, MTA1, NAP1L1, NKX2-3, NRP2, OR51E1, PNMA2, PTPRN2, RAF1, SCG5, SPOCK1, Survivin, TPH1, VMAT1, VMAT2); and X2BTB48; </p><p id="p0252" num="0252"> [00214] APLP2, ARAF1, BRAF1, CD59, KRAS, RAF1, CXCL14, GRIA2, HOXC6, NKX2- 3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCK1, and X2BTB48; </p><p id="p0253" num="0253"> [00215] CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCK1, and X2BTB48; or CgA (chromogranin A), CTGF, FZD7 (frizzled homolog 7), Ki-67 (a marker of proliferation), Kissl (Kissl metastasis suppressor), MAGE-D2 (melanoma antigen family D2), MTA1 (metastasis-associated 1), NAP1L1, NRP2 (neuropilin 2), Tphl, VMAT1, VMAT2, and Survivin. </p><p id="p0254" num="0254"> [00216] In some aspects, the panels further include CD 164. </p><p id="p0255" num="0255"> [00217] In some aspects, they further include NALP or other known biomarkers. </p><p id="p0256" num="0256"> [00218] In some embodiments, the panel of polynucleotides further includes one or more polynucleotide able to specifically hybridize to "housekeeping," or reference genes, for example, genes for which differences in expression is known or not expected to correlate with differences in the variables analyzed, for example, with the presence or absence of GEP-NEN or other neoplastic disease, differentiation of various GEP-NEN sub-types, metastasis, mucosal or other tissue types, prognostic indications, and/or other phenotype, prediction, or outcome. In some aspects, expression levels of such housekeeping genes are detected and used as an overall expression level standards, such as to normalize expression data obtained for GEP-NEN biomarkers across various samples. </p><p id="p0257" num="0257"> [00219] Housekeeping genes are well known in the art. Typically, the housekeeping genes include one or more genes characterized as particularly appropriate for analyzing GEP-NEN samples, such as ALG9, TFCP2 and ZNF410. See Kidd M, et al., "GeneChip, geNorm and Gastrointestinal tumors: novel reference genes for real-time PCR." Physiol Genomics 
<!-- EPO <DP n="50"/>-->
 2007;30:363-70. Other housekeeping genes and polynucleotides are well known in the art and include glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine </p><p id="p0258" num="0258">phosphoribosyltransferase (HPRT) and 18S RNA. </p><p id="p0259" num="0259"> [00220] The ALG9 housekeeping genes include human ALG9 (asparagine-linked </p><p id="p0260" num="0260">glycosylation 9, alpha- 1,2-mannosyltransferase homolog) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ALG9 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 35 and referenced at GenBank gi no.: 118026920or containing the coding region thereof of nucleotides 100-1956 of SEQ ID NO: 35, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0261" num="0261"> [00221] The TFCP2 housekeeping genes include human TFCP2 (transcription factor CP2) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the TFCP2 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 36 and referenced at GenBank gi no. 291219872, or containing the coding region thereof at nucleotides 722-2230 of SEQ ID NO: 36, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0262" num="0262"> [00222] The ZNF410 housekeeping genes include human ZNF410 (zinc finger protein 410) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ZNF410 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 37 and referenced at GenBank gi no. 10863994, or containing the coding region thereof at nucleotides 183-1619 of SEQ ID NO: 37, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0263" num="0263"> [00223] The GAPDH housekeeping genes include human GAPDH (glyceraldehyde-3- phosphate dehydrogenase) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the GAPDH housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 38 and referenced at GenBank gi number 83641890 or containing the coding region thereof at nucleotides 103-1110 of SEQ ID NO: 38, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0264" num="0264"> [00224] The 18S housekeeping genes include human 18S (Eukaryotic 18S rRNA), including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the 18S housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 39 and referenced at GenBank gi number 36162 or a natural variant thereof. 
<!-- EPO <DP n="51"/>-->
 [00225] The HPRT housekeeping genes include human HPRT gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the HPRT housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 40, and referenced at GenBank gi no. 164518913, or containing the coding region thereof at nucleotides 168-824 of SEQ ID NO: 40, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0265" num="0265"> [00226] The SLC25A3 housekeeping genes include human SLC25A3 (solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SLC25A3 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 247 and referenced at GenBank gi no.: 223718119, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 121-1209 of SEQ ID NO: 247, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0266" num="0266"> [00227] The VAPA housekeeping genes include human VAPA ((vesicle-associated membrane protein)-associated protein A) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the VAPA housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 248 and referenced at GenBank gi no.: 94721249, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 300-1184 of SEQ ID NO: 248, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0267" num="0267"> [00228] The TXNIP housekeeping genes include human TXNIP (thioredoxin interacting protein) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the TXNIP housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 249 and referenced at GenBank gi no.: 171184420, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 342-1517 of SEQ ID NO: 249, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0268" num="0268"> [00229] The ADD3 housekeeping genes include human ADD3 (adducin 3 (gamma)) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ADD3 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 250 and referenced at GenBank gi no.: 62912451, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 377-2497 of SEQ ID NO: 250, a natural variant thereof, or a protein encoded by such a polynucleotide. 
<!-- EPO <DP n="52"/>-->
 [00230] The DAZAP2 housekeeping genes include human DAZAP2 (DAZ-associated protein 2) gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the DAZAP2 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 251 and referenced at GenBank gi no.: 211904132 or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 185-691, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0269" num="0269"> [00231] The ACTG1 housekeeping genes include human ACTG1 (actin, gamma 1) gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the ACTG1 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 252 and referenced at GenBank gi no.: 316659408, or containing a coding region thereof, e.g., the e.g., the coding sequence thereof at nucleotides 259-1386 of SEQ ID NO: 252, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0270" num="0270"> [00232] The ACTB housekeeping genes include human ACTB (actin, beta) gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the ACTB housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 200 and referenced at GenBank gi no.: 168480144, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 85- 1212 of SEQ ID NO: 200, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0271" num="0271"> [00233] The ATG4B housekeeping genes include human ACG4B (autophagy related 4 homolog B (S. cerevisiae)) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the ACTG4B housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 203, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 104- 1285 of SEQ ID NO: 203, or the sequence referenced at GenBank gi no.: 47132610, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0272" num="0272"> [00234] The ARF1 housekeeping genes include human ARF1 (ADP-ribosylation factor 1) gene products, including natural variants, e.g. , allelic variants, and homologs and analogs thereof. In one example, the ARF1 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 202 and referenced at GenBank gi no.: 66879659 or containing a coding region thereof, e.g., the coding sequence thereof at nucleotide residues 229- 774, a natural variant thereof, or a protein encoded by such a polynucleotide. 
<!-- EPO <DP n="53"/>-->
 [00235] The HUWE1 housekeeping genes include human HUWE1 (HECT, UBA and WWE domain containing 1) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the HUWE1 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 214 and referenced at GenBank gi no.: 195963314, or containing the coding region thereof, e.g., the coding sequence thereof at nucleotides 403-13527, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0273" num="0273"> [00236] The MORF4L1 housekeeping genes include human MORF4L1 (mortality factor 4 like 1) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the MORF4L1 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 216 and referenced at GenBank gi no.: 45643136, or containing a coding region thereof, e.g., the coding sequence at nucleotides 189-1160, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0274" num="0274"> [00237] The RHOA housekeeping genes include human RHOA (ras homolog gene family, member A) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the RHOA housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 226 and referenced at GenBank gi no.: 50593005, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 277-858, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0275" num="0275"> [00238] The SERP1 housekeeping genes include human SERP1 (stress-associated </p><p id="p0276" num="0276">endoplasmic reticulum protein 1) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SERP1 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 230 and referenced at GenBank gi no.: 109809760, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 507-707, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0277" num="0277"> [00239] The SKP1 housekeeping genes include human SKP1 (S-phase kinase- associated protein 1) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the SKP1 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 231 and referenced at GenBank gi no.: 160420325, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 180-662, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0278" num="0278"> [00240] The TOX4 housekeeping genes include human TOX4 (TOX high mobility group box family member 4) gene products, including natural variants, e.g., allelic variants, and homologs 
<!-- EPO <DP n="54"/>-->
 and analogs thereof. In one example, the TOX4 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 239 and referenced at GenBank gi no.: 99077116, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 104-1969, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0279" num="0279"> [00241] The TPT1 housekeeping genes include human TPT1 (tumor protein, translationally- controlled 1) gene products, including natural variants, e.g., allelic variants, and homologs and analogs thereof. In one example, the TPT1 housekeeper is a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 240 and referenced at GenBank gi no.: 141801911, or containing a coding region thereof, e.g., the coding sequence thereof at nucleotides 94-612, a natural variant thereof, or a protein encoded by such a polynucleotide. </p><p id="p0280" num="0280">D. Methods and agents for detecting the GEP-NEN biomarkers, tumors, and cells </p><p id="p0281" num="0281"> [00242] Also provided are methods, compositions, and systems, for the detection of the GEP- NEN biomarkers and for identifying, isolating, and enriching tumors and cells that express the GEP-NEN biomarkers. For example, provided are agents, sets of agents, and systems for detecting the GEP-NEN biomarkers and methods for use of the same, including for diagnostic and prognostic uses. </p><p id="p0282" num="0282"> 1. Agents and systems for detecting the biomarkers </p><p id="p0283" num="0283"> [00243] In one embodiment, the agents are proteins, polynucleotides or other molecules which specifically bind to or specifically hybridize to the GEP-NEN biomarkers. The agents include polynucleotides, such as probes and primers, e.g. sense and antisense PCR primers, having identity or complementarity to the polynucleotide biomarkers, such as mRNA, and proteins, such as antibodies, which specifically bind to such biomarkers. Sets and kits containing the agents, such as agents specifically hybridizing to or binding the panel of biomarkers, also are provided. </p><p id="p0284" num="0284"> [00244] Thus, the systems, e.g., microarrays, sets of polynucleotides, and kits, provided herein include those with nucleic acid molecules, typically DNA oligonucleotides, such as primers and probes, the length of which typically varies between 15 bases and several kilo bases, such as between 20 bases and 1 kilobase, between 40 and 100 bases, and between 50 and 80 nucleotides or between 20 and 80 nucleotides. In one aspect, most (i.e. at least 60% of) nucleic acid molecules of a nucleotide microarray, kit, or other system, are capable of hybridizing to GEP-NEN biomarkers. 
<!-- EPO <DP n="55"/>-->
 [00245] In one example, systems containing polynucleotides that specifically hybridize to the biomarkers, e.g., nucleic acid microarrays, are provided to detect and measure changes in expression levels and determine expression profiles of the biomarkers according to the provided methods. Among such systems, e.g., microarrays, are those comprising polynucleotides able to hybridize to at least as at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, or 100 or more biomarkers, such as to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51, and/or all of the following sets of biomarkers: </p><p id="p0285" num="0285"> [00246] AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PQBP1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SST1, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, ZZZ3, APLP2, CD59, ARAF1, BRAF1, KRAS, and RAF1 gene products; </p><p id="p0286" num="0286"> [00247] AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PQBP1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SST1, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products; and </p><p id="p0287" num="0287"> [00248] APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT1, and VMAT2 gene products; or </p><p id="p0288" num="0288"> [00249] at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 of APLP2, ARAF1, BRAF1, CD59, CgA, CTGF, CXCL14, FZD7, GRIA2, HOXC6, Ki-67; Kissl, KRAS, MAGE-D2, MTA1, NAP1L1, NKX2-3, NRP2, OR51E1, PNMA2, PTPRN2, RAF1, SCG5, SPOCKl, Survivin, TPH1, VMAT1, VMAT2); and </p><p id="p0289" num="0289">X2BTB48; or of the biomarkers APLP2, ARAF1, BRAF1, CD59, KRAS, RAF1, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCKl, and X2BTB48; or of the biomarkers CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCKl, and X2BTB48. </p><p id="p0290" num="0290"> [00250] In some aspects, at least 60%, or at least 70%, at least 80%, or more, of the nucleic acid molecules of the system, e.g., microarray, are able to hybridize to biomarkers in the panel of 
<!-- EPO <DP n="56"/>-->
 biomarkers. In one example, probes immobilized on such nucleotide microarrays comprise at least 2, and typically at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, or 100 or more biomarkers, such as to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51, or more nucleic acid molecules able to hybridize to at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, or 100 or more biomarkers, such as to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51, or more of the biomarkers, where each of the nucleic acid molecules is capable of specifically hybridizing to a different one of the biomarkers, such that at least that many different biomarkers can be bound. </p><p id="p0291" num="0291"> [00251] In one example, the remaining nucleic acid molecules, such as 40% or at most 40% of the nucleic acid molecules on the microarray or in the set of polynucleotides are able to hybridize to a set of reference genes or a set of normalization genes (such as housekeeping genes), for example, for normalization in order to reduce systemic bias. Systemic bias results in variation by inter-array differences in overall performance, which can be due to for example inconsistencies in array fabrication, staining and scanning, and variation between labeled RNA samples, which can be due for example to variations in purity. Systemic bias can be introduced during the handling of the sample in a microarray experiment. To reduce systemic bias, the determined RNA levels are preferably corrected for background non-specific hybridization and normalized. </p><p id="p0292" num="0292"> [00252] The use of such reference probes is advantageous but not mandatory. In one embodiment a set of polynucleotides or system, e.g., microarray, is provided wherein at least 90% of the nucleic acid sequences are able to hybridize to the GEP-NEN biomarkers; further embodiments include such systems and sets in which at least 95% or even 100% of the polynucleotides hybridize to the biomarkers. </p><p id="p0293" num="0293"> [00253] Disclosed in the Examples are exemplary suitable polynucleotides, such as PCR primers. Other nucleic acid probes and primers, able to hybridize to different regions of the 
<!-- EPO <DP n="57"/>-->
 biomarkers are of course also suitable for use in connection with the provided systems, kits and methods. </p><p id="p0294" num="0294"> 2. Detection of the biomarkers </p><p id="p0295" num="0295"> [00254] Also provided are methods for detecting and quantifying the biomarkers, including detecting the presence, absence, amount or relative amount, such as expression levels or expression profile of the biomarkers. Typically, the methods are nucleic acid based methods, for example, measuring the presence, amount or expression levels of biomarker mRNA expression. Such methods typically are carried out by contacting polynucleotide agents to biological samples, such as test samples and normal and reference samples, for example, to quantify expression levels of nucleic acid biomarkers (e.g., mRNA) in the samples. </p><p id="p0296" num="0296"> [00255] Detection and analysis of biomarkers according to the provided embodiments can be performed with any suitable method known in the art. For example, where the biomarkers are RNA biomarkers, RNA detection and quantification methods are used. </p><p id="p0297" num="0297"> [00256] Exemplary methods for quantifying or detecting nucleic acid expression levels, e.g., mRNA expression, are well known, and include northern blotting and in situ hybridization (Parker and Barnes, Methods in Molecular Biology 106:247-283, 1999); RNAse protection assays (Hod, Biotechniques 13:852-854, 1992); and quantitative or semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264, 1992), representative methods for sequencing -based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPSS). </p><p id="p0298" num="0298"> [00257] Therefore, in one embodiment, expression of the biomarker or biomarker panel includes RNA expression; the methods include determining levels of RNA of the biomarkers, such as RNA obtained from and/or present in a sample of a patient, and performing analysis, diagnosis, or predictive determinations based upon the RNA expression levels determined for the biomarkers or panel of biomarkers. </p><p id="p0299" num="0299"> [00258] RNA samples can be processed in numerous ways, as is known to those in the art. Several methods are well known for isolation of RNA from samples, including guanidinium thiocyanate-phenol-chloroform extraction, which may be carried out using the TRIZOL® reagent, a proprietary formulation (see Chomczynski P, Sacchi N (2006). "The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: </p><p id="p0300" num="0300">twenty- something years on". Nat Protoc 1 (2): 581-5). In this method, TRIZOL® is used to 
<!-- EPO <DP n="58"/>-->
 extract RNA and DNA; chloroform and centrifugation are used to separate RNA from other nucleic acids, followed by a series of washes with ethanol for cleanup of the RNA sample. </p><p id="p0301" num="0301"> [00259] The RNA samples can be freshly prepared from cells or tissues at the moment of harvesting; alternatively, they can be prepared from samples that stored at -70°C until processed for sample preparation. Alternatively, tissues or cell samples can be stored under and/or subjected to other conditions known in the art to preserve the quality of the RNA, including fixation for example with formalin or similar agent; and incubation with RNase inhibitors such as RNAsin® (Pharmingen) or RNasecure® (Ambion); aqueous solutions such as RNAlater® (Assuragen), Hepes-Glutamic acid buffer mediated Organic solvent Protection Effect (HOPE), and RCL2 (Alphelys); and non-aqueous solutions such as Universal Molecular Fixative (Sakura Finetek USA Inc.). A chaotropic nucleic acid isolation lysis buffer (Boom method, Boom et al. J Clin Microbiol. 1990; 28:495-503) may also be used for RNA isolation. </p><p id="p0302" num="0302"> [00260] In one embodiment, RNA is isolated from buffy coat by incubating samples with TRIZOL®, followed by RNA clean-up. RNA is dissolved in diethyl pyrocarbonate water and measured spectrophotometrically, and an aliquot analyzed on a Bioanalyzer (Agilent </p><p id="p0303" num="0303">Technologies, Palo Alto, CA) to assess the quality of the RNA (Kidd M, et al. "The role of genetic markers— NAP 1L1, MAGE-D2, and MTA1— in defining small-intestinal carcinoid neoplasia," Ann Surg Oncol 2006;13(2):253-62). In another embodiment, RNA is isolated from plasma using the QIAamp RNA Blood Mini Kit; in some cases, this method allows better detection by real-time PCR of significantly more housekeeping genes from plasma compared to the TRIZOL® approach. In another embodiment, RNA is isolated directly from whole blood, for example, using the QIAamp RNA Blood Mini Kit in a similar manner. </p><p id="p0304" num="0304"> [00261] Methods for isolating RNA from fixed, paraffin-embedded tissues as the RNA source are well-known and generally include mRNA isolation, purification, primer extension and amplification (for example: T. E. Godfrey et al,. /. Molec. Diagnostics 2: 84-91 [2000]; K. Specht et al., Am. J. Pathol. 158: 419-29 [2001]). In one example, RNA is extracted from a sample such as a blood sample using the QIAamp RNA Blood Mini Kit RNA. Typically, RNA is extracted from tissue, followed by removal of protein and DNA and analysis of RNA concentration. An RNA repair and/or amplification step may be included, such as a step for reverse transcription of RNA for RT-PCR. </p><p id="p0305" num="0305"> [00262] Expression levels or amounts of the RNA biomarkers may be determined or quantified by any method known in the art, for example, by quantifying RNA expression relative 
<!-- EPO <DP n="59"/>-->
 to housekeeping gene or with relation to RNA levels of other genes measured at the same time. Methods to determine RNA levels of genes are known to a skilled person and include, but are not limited to, Northern blotting, (quantitative) PCR, and microarray analysis. </p><p id="p0306" num="0306"> [00263] Northern blotting may be performed for quantification of RNA of a specific biomarker gene or gene product, by hybridizing a labeled probe that specifically interacts with the RNA, following separation of RNA by gel electrophoresis. Probes are for example labeled with radioactive isotopes or chemiluminescent substrates. Quantification of the labeled probe that has interacted with said nucleic acid expression product serves as a measure for determining the level of expression. The determined level of expression can be normalized for differences in the total amounts of nucleic acid expression products between two separate samples with for instance an internal or external calibrator by comparing the level of expression of a gene that is known not to differ in expression level between samples or by adding a known quantity of RNA before determining the expression levels. </p><p id="p0307" num="0307"> [00264] For RT-PCR, biomarker RNA is reverse transcribed into cDNA. Reverse </p><p id="p0308" num="0308">transcriptase polymerase chain reaction (RT-PCR) is, for example, performed using specific primers that hybridize to an RNA sequence of interest and a reverse transcriptase enzyme. </p><p id="p0309" num="0309">Furthermore, RT-PCR can be performed with random primers, such as for instance random hexamers or decamers which hybridize randomly along the RNA, or oligo d(T) which hybridizes to the poly(A) tail of mRNA, and reverse transcriptase enzyme. </p><p id="p0310" num="0310"> [00265] In some embodiments, RNA expression levels of the biomarkers in a sample, such as one from a patient suffering from or suspected of suffering from GEP-NEN or associated symptom or syndrome, are determined using quantitative methods such as by real-time rt-PCR (qPCR) or microarray analysis. In some embodiments, quantitative Polymerase Chain Reaction (QPCR) is used to quantify the level of expression of nucleic acids. In one aspect, detection and determining expression levels of the biomarkers is carried out using RT-PCR, GeneChip analysis, quantitative real-time PCR (Q RT-PCR), or carcinoid tissue microarray (TMA) immunostaining/quantitation, for example, to compare biomarker RNA, e.g., mRNA, or other expression product, levels in different sample populations, characterize patterns of gene expression, to discriminate between closely related mRNAs, and to analyze RNA structure. </p><p id="p0311" num="0311"> [00266] In one example, QPCR is performed using real-time PCR (RTPCR), where the amount of product is monitored during the amplification reaction, or by end-point </p><p id="p0312" num="0312">measurements, in which the amount of a final product is determined. As is known to a skilled 
<!-- EPO <DP n="60"/>-->
 person, rtPCR is for instance performed by the use of a nucleic acid intercalator, such as for example ethidium bromide or SYBR® Green I dye, which interacts which all generated double stranded products resulting in an increase in fluorescence during amplification, or for instance by the use of labeled probes that react specifically with the generated double stranded product of the gene of interest. Alternative detection methods that can be used are provided by amongst other things dendrimer signal amplification, hybridization signal amplification, and molecular beacons. </p><p id="p0313" num="0313"> [00267] In one embodiment, reverse transcription on total RNA is carried out using the High Capacity cDNA Archive Kit (Applied Biosystems (ABI), Foster City, CA) following the manufacturer's suggested protocol (briefly, using 2 micrograms of total RNA in 50 microliters water, mixing with 50 uL of 2XRT mix containing Reverse Transcription Buffer, </p><p id="p0314" num="0314">deoxynucleotide triphosphate solution, random primers, and Multiscribe Reverse Transcriptase). RT reaction conditions are well known. In one example, the RT reaction is performed using the following thermal cycler conditions: 10 mins, 25°C; 120 min., 37°C {see Kidd M, et al., "The role of genetic markers— NAP 1 LI, MAGE-D2, and MTA1— in defining small-intestinal carcinoid neoplasia," Ann Surg Oncol 2006;13(2):253-62). </p><p id="p0315" num="0315"> [00268] For measurement of individual transcript levels, in one embodiment, Assays-on- Demand™ products are used with the ABI 7900 Sequence Detection System according to the manufacturer's suggestions {see Kidd M, Eick G, Shapiro MD, et al. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005;103(2):229-36). In one example, cycling is performed under standard conditions, using the TaqMan® Universal PCR Master Mix Protocol, by mixing cDNA in 7.2 uL water, 0.8 uL 20· Assays-on-Demand primer and probe mix and 8 uL of 2X TaqMan Universal Master mix, in a 384-well optical reaction plate, under the following conditions: 50°C, 2 min.; 95°C; 10 min.; 50 cycles at 95°C for 15 min., 60° for 1 min {see Kidd M, et al, "The role of genetic markers— NAP 1 LI, MAGE-D2, and MTA1— in defining small-intestinal carcinoid neoplasia," Ann Surg Oncol 2006;13(2):253-62). </p><p id="p0316" num="0316"> [00269] Typically, results from real-time PCR are normalized, using internal standards and/or by comparison to expression levels for housekeeping genes. For example, in one embodiment, Raw AC<sub>T</sub> (delta C<sub>T</sub> = change in cycle time as a function of amplification) data from QPCR as described above is normalized using well-known methods, such as geNorm {see Vandesompele 
<!-- EPO <DP n="61"/>-->
 J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol </p><p id="p0317" num="0317"> 2002;3(7):RESEARCH0034). Normalization by house-keeping gene expression levels is also well-known. See Kidd M, et al., "GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR," Physiol Genomics 2007;30(3):363-70. </p><p id="p0318" num="0318"> [00270] Microarray analysis involves the use of selected nucleic acid molecules that are immobilized on a surface. These nucleic acid molecules, termed probes, are able to hybridize to nucleic acid expression products. In a preferred embodiment the probes are exposed to labeled sample nucleic acid, hybridized, washed and the (relative) amount of nucleic acid expression products in the sample that are complementary to a probe is determined. Microarray analysis allows simultaneous determination of nucleic acid expression levels of a large number of genes. In a method according to the invention it is preferred that at least 5 genes according to the invention are measured simultaneously. </p><p id="p0319" num="0319"> [00271] Background correction can be performed for instance according to the "offset" method that avoids negative intensity values after background subtraction. Furthermore, normalization can be performed in order to make the two channels on each single array comparable for instance using global loess normalization, and scale normalization which ensures that the log-ratios are scaled to have the same median-absolute-deviation (MAD) across arrays. </p><p id="p0320" num="0320"> [00272] Protein levels may, for example, be measured using antibody-based binding assays. Enzyme labeled, radioactively labeled or fluorescently labeled antibodies may be used for detection of protein. Exemplary assays include enzyme-linked immunosorbent assays (ELISA), radio-immuno assays (RIA), Western Blot assays and immunohistochemical staining assays. Alternatively, in order to determine the expression level of multiple proteins simultaneously protein arrays such as antibody-arrays are used. </p><p id="p0321" num="0321"> [00273] Typically, the biomarkers and housekeeping markers are detected in a biological sample, such as a tissue or fluid sample, such as a blood, such as whole blood, plasma, serum, stool, urine, saliva, tears, serum or semen sample, or a sample prepared from such a tissue or fluid, such as a cell preparation, including of cells from blood, saliva, or tissue, such as intestinal mucosa, tumor tissue, and tissues containing and/or suspected of containing GEP-NEN metastases or shed tumor cells, such as liver, bone, and blood. In one embodiment, a specific cell preparation is obtained by fluorescence-activated cell sorting (FACS) of cell suspensions or fluid from tissue or fluid, such as mucosa, e.g., intestinal mucosa, blood or buffy coat samples. 
<!-- EPO <DP n="62"/>-->
 [00274] In some embodiments, the sample is taken from a GEP-NEN patient, a patient suspected of having GEP-NEN, a patient having and/or suspected of having cancer generally, a patient exhibiting one or more GEP-NEN symptoms or syndromes or determined to be at-risk for GEP-NEN, or a GEP-NEN patient undergoing treatment or having completed treatment, including patients whose disease is and/or is thought to be in remission. </p><p id="p0322" num="0322"> [00275] In other embodiments, the sample is taken from a human without GEP-NEN disease, such as a healthy individual or an individual with a different type of cancer, such as an adenocarcinoma, for example, a gastrointestinal adenocarcinoma or one of the breast, prostate, or pancreas, or a gastric or hepatic cancer, such as esophageal, pancreatic, gallbladder, colon, or rectal cancer. </p><p id="p0323" num="0323"> [00276] In some examples, the methods and systems distinguish between GEP-NEN and other cancers, such as adenocarcinomas, including gastrointestinal adenocarcinoma or one of the breast, prostate, or pancreas, or a gastric or hepatic cancer, such as esophageal, pancreatic, gallbladder, colon, or rectal cancer. In other embodiments, the methods and systems </p><p id="p0324" num="0324">differentiate between GEP-NENs of different sites, such as between GEP-NENs of the small intestine and those of the pancreas. Such embodiments are useful, for example, to determine the primary location of a tumor where it is unknown and to determine prognosis (particularly because GEP-NEN tumors can exhibit significantly different prognosis depending upon site of origin). In some embodiments, the methods and systems differentiate between GEP-NENs of different sites, e.g., pancreatic and small intestinal tumors, with at least 80, 85, 90, 91, 92, or greater accuracy. In other embodiments, the methods can diagnose or detect adenocarcinomas with neuroendocrine components. </p><p id="p0325" num="0325"> [00277] In some embodiments, the sample is taken from the GEP-NEN tumor or metastasis. In other embodiments, the sample is taken from the GEP-NEN patient, but from a tissue or fluid not expected to contain GEP-NEN or GEP-NEN cells; such samples may be used as reference or normal samples. Alternatively, the normal or reference sample may be a tissue or fluid or other biological sample from a patient without GEP-NEN disease, such as a corresponding tissue, fluid or other sample, such as a normal blood sample, a normal small intestinal (SI) mucosa sample, a normal enterochromaffin (EC) cell preparation. </p><p id="p0326" num="0326"> [00278] In some embodiments, the sample is a whole blood sample. As neuroendocrine tumors metastasize, they typically shed cells into the blood. Accordingly, detection of the panels of GEP-NEN biomarkers provided herein in plasma and blood samples may be used for 
<!-- EPO <DP n="63"/>-->
 identification of GEP-NENs at an early time point and for predicting the presence of tumor metastases, e.g., even if anatomic localization studies are negative. Accordingly, the provided agents and methods are useful for early diagnosis. </p><p id="p0327" num="0327"> [00279] Thus, in some embodiments, the methods can identify a GEP-NEN molecular signature or expression profile in 1 mL or about 1 mL of whole blood. In some aspects, the molecular signature or expression profile is stable for up to four hours (for example, when samples are refrigerated 4-8 °C following phlebotomy) prior to freezing. In one aspect, the approach able to diagnose, prognose or predict a given GEP-NEN-associated outcome using a sample obtained from tumor tissue is also able to make the same diagnosis, prognosis, or prediction using a blood sample. </p><p id="p0328" num="0328"> [00280] A number of existing detection and diagnostic methodologies require 7 to 10 days to produce a possible positive result, and can be costly. Thus, in one aspect, the provided methods and compositions are useful in improving simplicity and reducing costs associated with GEP- NEN diagnosis, and make early-stage diagnosis feasible. </p><p id="p0329" num="0329"> [00281] Thus in one example, the biomarkers are detected in circulation, for example by detection in a blood sample, such as a serum, plasma, cells, e.g., peripheral blood mononuclear cells (PBMCs), obtained from buffy coat, or whole blood sample. </p><p id="p0330" num="0330"> [00282] Tumor- specific transcripts have been detected in whole blood in some cancers. See Sieuwerts AM, et al., "Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR," Breast Cancer Res Treat </p><p id="p0331" num="0331">2009;118(3):455-68 and Mimori K, et al, "A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases," Ann Surg Oncol 2008;15(10):2934-42. </p><p id="p0332" num="0332"> [00283] The CellSearch™ CTC Test (Veridex LLC) (described by Kahan L., "Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule," Fed Regist 2004;69:26036- 8) uses magnetic beads coated with EpC AM- specific antibodies that detects epithelial cells (CK- 8/18/19) and leukocytes (CD45), as described by Sieuwerts AM, Kraan J, Bolt-de Vries J, et al., "Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR," Breast Cancer Res Treat 2009;118(3):455-68. This method has been used to detect circulating tumor cells (CTCs), and monitoring disease progression and therapy efficacy in metastatic prostate (Danila DC, Heller G, Gignac GA, et al. 
<!-- EPO <DP n="64"/>-->
 Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13(23):7053-8), colorectal (Cohen SJ, Alpaugh RK, Gross S, et al. </p><p id="p0333" num="0333">Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;6(2): 125-32. and breast (Cristofanilli M, Budd GT, Ellis MJ, et al., Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351(8):781-91). </p><p id="p0334" num="0334"> [00284] This and other existing approaches have not been entirely satisfactory for detection of GEP-NEN cells, which can exhibit variable expression and/or not express cytokeratin (See Van Eeden S, et al, Classification of low-grade neuroendocrine tumors of midgut and unknown origin," Hum Pathol 2002;33(11): 1126-32; Cai YC, et al., "Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors," Hum Pathol 2001;32(10): 1087-93, and studies described herein, detecting EpCAM transcript expression in two of twenty-nine GEP-NEN samples). </p><p id="p0335" num="0335"> [00285] Factors to consider in the available detection methods for circulating tumor cells are relatively low numbers of the cells in peripheral blood, typically about 1 per 10<sup>6</sup> peripheral blood mononuclear cells (PBMCs) (see Ross AA, et al. "Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques," Blood 1993;82(9):2605-10), and the potential for leukocyte contamination. See Sieuwerts AM, et al. "Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR," Breast Cancer Res Treat 2009;118(3):455-68; Mimori K, et al) and technical complexity of available approaches. These factors can render available methods not entirely satisfactory for use in the clinical laboratory. </p><p id="p0336" num="0336"> [00286] In some embodiments, Neuroendocrine cells are FACS-sorted to heterogeneity, using known methods, following acridine orange (AO) staining and uptake, as described Kidd M, et al., "Isolation, Purification and Functional Characterization of the Mastomys EC cell," Am J Physiol 2006;291:G778-91; Modlin EVI, et al., "The functional characterization of normal and neoplastic human enterochromaffin cells," / Clin Endocrinol Metab 2006;91(6):2340-8. </p><p id="p0337" num="0337"> [00287] In some embodiments, the provided detection methods are used to detect, isolate, or enrich for the GEP-NEN cells and/or biomarkers in two to three mL of blood or less. The methods are performed using standard laboratory apparatuses and thus are easily performed in 
<!-- EPO <DP n="65"/>-->
 the clinical laboratory setting. In one example, a readout is obtained within 12 hours, at an average cost of approximately 20-30 per sample. </p><p id="p0338" num="0338">E. Diagnostic, Prognostic, and Predictive Uses </p><p id="p0339" num="0339"> [00288] Also provided are diagnostic, prognostic, and predictive uses for the agents and detection methods provided herein, such as for the diagnosis, prognosis, and prediction of GEP- NEN, associated outcomes, and treatment responsiveness. For example, available GEP-NEN classification methods are limited, in part due to incorrect classifications and that individual lesions or tumors can evolve into different GEP-NEN sub-types or patterns, and/or contain more than one GEP-NEN sub-type. Known classification frameworks are limited, for example, in the ability to predict response to treatment or discriminate accurately between tumors with similar histopathologic features that may vary substantially in clinical course and treatment response, and to predict treatment responsiveness. </p><p id="p0340" num="0340"> [00289] For example, the World Health Organization (WHO) classification criteria, adopted in 2000, distinguish between well differentiated NETs (WDNETs) (benign behavior or uncertain malignant potential), well differentiated neuroendocrine carcinomas (low-grade malignancy) (WDNECs), poorly differentiated neuroendocrine tumors (PDNETs) (medium grade </p><p id="p0341" num="0341">malignancy), and poorly differentiated (usually small cell) NECs (PDNECs) (high-grade malignancy), based on size, proliferative rate, localization, differentiation, and hormone production. Metastatic sub-types follow the same nomenclature and classification strategy (MET-WDNET; MET-WDNEC, MET-PDNET, MET-PDNEC). Proposed alternatives to classification can be subjective. There is a need for molecular or gene-based classification schemes. The provided methods and systems, including GEP-NEN- specific predictive gene- based models, address these issues, and may be used in identifying and analyzing molecular parameters that are predictive of biologic behavior and prediction based on such parameters. </p><p id="p0342" num="0342"> [00290] Among the provided diagnostic, prognostic, and predictive methods are those which employ statistical analysis and biomathematical algorithms and predictive models to analyze the detected information about expression of GEP-NEN biomarkers and other markers such as housekeeping genes. In some embodiments, expression levels, detected binding or other information is normalized and assessed against reference value(s), such as expression levels in normal samples or standards. Provided embodiments include methods and systems for classification and prediction of GEP-NENs using the detected and measured information about 
<!-- EPO <DP n="66"/>-->
 the expression of the GEP-NEN biomarkers, for example, in classification, staging, prognosis, treatment design, evaluation of treatment options, and prediction of GEP-NEN disease outcomes, e.g., predicting development of metastases. </p><p id="p0343" num="0343"> Detection and diagnosis of GEP-NEN </p><p id="p0344" num="0344"> [00291] In some embodiments, the methods are used to establish GEP-NEN diagnosis, such as diagnosis or detection of early-stage disease or metastasis, define or predict the extent of disease, identify early spread or metastasis, predict outcome or prognosis, predict progression, classify disease, monitor treatment responsiveness, detect or monitor for recurrence, and to facilitate early therapeutic intervention. For example, among the provided methods and algorithms are those for use in classification, staging, prognosis, treatment design, evaluation of treatment options, and prediction of GEP-NEN disease outcomes, e.g., predicting development of metastases. </p><p id="p0345" num="0345"> [00292] In one embodiment, the methods, algorithms and models are useful for diagnostic surveillance, such as routine surveillance. In some embodiments, the methods, algorithms and models provide for early diagnosis; in one aspect, the methods are capable of detection of low- volume tumors, and detection of circulating tumor cells, including at early stages of disease, such as detection of as few as at or about 3 circulating GEP-NEN cells per milliliter of blood. In some embodiments, early detection allows early therapeutic intervention, at a time when therapies are more effective, which can improve survival rates and disease outcomes. </p><p id="p0346" num="0346"> [00293] For example, in one embodiment, the methods useful for early detection of the recurrence and/or metastasis of GEP-NEN, such as after treatment for example following surgical or chemical intervention. In some aspect, the methods are performed weekly or monthly following therapeutic intervention, for example, on human blood samples. In some aspects, the methods are capable of detecting micrometastases that are too small to be detected by conventional means, such as by imaging methods. For example, in one aspect the methods are capable of detecting metastases less than one centimeter (cm), such as at or about 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1 cm metastases, such as in the liver. </p><p id="p0347" num="0347"> [00294] For example, among the provided methods and systems are those that determine the presence or absence (or both) of a GEP-NEN in a subject or sample with a correct call rate of between 56 and 92 %, such as at least or at least about a 65, 70, 75, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 % correct call rate. In some cases, the 
<!-- EPO <DP n="67"/>-->
 methods are useful for diagnosis with a specificity or sensitivity of at least or at least about 70, 75, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 %. </p><p id="p0348" num="0348"> [00295] In other aspects, the methods are capable of detecting the recurrence, metastasis, or spread of GEP-NEN following treatment or during initial disaease progression at an earlier stage as compared with other diagnostic methods, such as imaging and detection of available biomarkers. In some aspects, the detected expression levels and/or expression signature of the biomarkers correlate significantly with the progression of disease, disease severity or aggressiveness, lack of responsiveness of treatment, reduction in treatment efficacy, GEP-NEN- associated events, risk, prognosis, type or class of GEP-NEN or disease stage. </p><p id="p0349" num="0349"> [00296] For example, in some embodiments, the methods are capable of predicting or monitoring the effects of therapeutic intervention. In one aspect, the methods provide are capable of detecting an improvement in disease as a result of treatment sooner or more effectively than available methods for detection and diagnosis, such as detection of tumors and metastasis by imaging and detection of available biomarkers, such as CgA. </p><p id="p0350" num="0350"> Development and monitoring of treatment and therapeutic uses </p><p id="p0351" num="0351"> [00297] Among the provided embodiments are methods that use the provided biomarkers and detection thereof in treatment development, strategy, and monitoring, including evaluation of response to treatment and patient-specific or individualized treatment strategies that take into consideration the likely natural history of the tumor and general health of the patient. </p><p id="p0352" num="0352"> [00298] GEP-NEN management strategies include surgery— for cure (rarely achieved) or cytoreduction— radiological intervention— for example, by chemoembolisation or </p><p id="p0353" num="0353">radiofrequency ablation— chemotherapy, cryoablation, and treatment with somatostatin and somatostatin analogues (such as Sandostatin LAR® (Octreotide acetate injection)) to control symptoms caused by released peptides and neuroamines, C PET-CT, and met resection. </p><p id="p0354" num="0354">Biological agents, including interferon, and hormone therapy, and somatostatin-tagged radionucleotides are under investigation. </p><p id="p0355" num="0355"> [00299] In one example, Cryoablation liberates GEP-NEN tissue for entry into the blood, which in turn induces symptoms, as described by Mazzaglia PJ, et ah, "Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival," Surgery 2007;142(l): 10-9. </p><p id="p0356" num="0356"> [00300] Chemo therapeutic agents, e.g., systemic cytotoxic chemo therapeutic agents, include etoposide, cisplatin, 5-fluorouracil, streptozotocin, doxorubicin; vascular endothelial growth 
<!-- EPO <DP n="68"/>-->
 factor inhibitors, receptor tyrosine kinase inhibitors (e.g., sunitinib, sorafenib, and vatalanib), and mammalian target of rapamycin (mTOR) inhibitors (e.g. , temsirolimus and everolimus), and combinations thereof, for example to treat disseminated and/or poorly differentiated disease. Other treatment approaches are well known. </p><p id="p0357" num="0357"> [00301] In some embodiments, the detection and diagnostic methods are used in conjunction with treatment, for example, by performing the methods weekly or monthly before and/or after treatment. In some aspects, the expression levels and profiles correlate with the progression of disease, ineffectiveness or effectiveness of treatment, and/or the recurrence or lack thereof of disease. In some aspects, the expression information indicates that a different treatment strategy is preferable. Thus, provided herein are therapeutic methods, in which the GEP-NEN biomarker detection methods are performed prior to treatment, and then used to monitor therapeutic effects. </p><p id="p0358" num="0358"> [00302] At various points in time after initiating or resuming treatment, significant changes in expression levels or expression profiles of the biomarkers (e.g. , as compared to expression or expression profiles before treatment, or at some other point after treatment, and/or in a normal or reference sample) indicates that a therapeutic strategy is or is not successful, that disease is recurring, or that a different therapeutic approach should be used. In some embodiments, the therapeutic strategy is changed following performing of the detection methods, such as by adding a different therapeutic intervention, either in addition to or in place of the current approach, by increasing or decreasing the aggressiveness or frequency of the current approach, or stopping or reinstituting the treatment regimen. </p><p id="p0359" num="0359"> [00303] In another aspect, the detected expression levels or expression profile of the biomarkers identifies the GEP-NEN disease for the first time or provides the first definitive diagnosis or classification of GEP-NEN disease. For example, in some aspects the method distinguishes between one or more of GEP-NEN classifications, such as WDNEC, WDNET, PDNEC, PDNET, and metastatic forms thereof, and/or distinguishes between GEP-NEN and other cancers, including other intestinal cancers. In some aspects of this embodiment, a treatment approach is designed based upon the expression levels or expression profiles, and/or the determined classification. The methods include iterative approaches, whereby the biomarker detection methods are followed by initiation or shift in therapeutic intervention, followed by continued periodic monitoring, reevaluation, and change, cessation, or addition of a new therapeutic approach, optionally with continued monitoring. 
<!-- EPO <DP n="69"/>-->
 [00304] In some aspects, the methods and systems determine whether or not the assayed subject is responsive to treatment, such as a subject who is clinically categorized as in complete remission or exhibiting stable disease. In some aspects, the methods and systems determine whether or not the subject is untreated (or treatment-naive, i.e., has not received treatment) or is non-responsive (i.e., clinically categorized as "progressive." For example, methods are provided for distinguishing treatment-responsive and non-responsive patients, and for distinguishing patients with stable disease or those in complete remission, and those with progressive disease. In various aspects, the methods and systems make such calls with at least at or about 65, 70, 75, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 % correct call rate (i.e., accuracy), specificity, or sensitivity. </p><p id="p0360" num="0360"> [00305] In some aspects, the sensitivity or correct call rate for the diagnostic or predictive or prognostic outcome is greater than, e.g., significantly greater than, that obtained using a known diagnosis or prognostic method, such as detection and measurement of circulating CgA or other single protein. </p><p id="p0361" num="0361"> Statistical analysis, mathematical algorithms and predictive models </p><p id="p0362" num="0362"> [00306] Typically, the diagnostic, prognostic, and predictive methods include statistical analysis and mathematical modeling. Thus, provided are supervised learning algorithms useful for the construction of predictive models, based on the GEP-NEN biomarkers identified herein, and methods and uses thereof for the prediction and classification of GEP-NENs. </p><p id="p0363" num="0363"> [00307] Any of a number of well-known methods for evaluating differences in gene expression may be used. Such methods range from simple comparisons of mean expression levels in each population e.g., using ANOVA (which is limited as the relevance of changes are complex to quantify) to mathematical analyses that are based on topographic, pattern-recognition based protocols e.g., support vector machines (SVM) (Noble WS. What is a support vector machine? Nat Biotechnol. 2006;24(12): 1565-7). Machine-learning based techniques are typically desirable for developing sophisticated, automatic, and/or objective algorithms for analyzing high-dimensional and multimodal biomedical data. </p><p id="p0364" num="0364"> [00308] In some examples, SVM— a variant of the supervised learning algorithm— is used in connection with the provided methods and systems. SVMs have been used to predict the grading of astrocytomas with a &gt;90 accuracy, and prostatic carcinomas with an accuracy of 74-80% (Glotsos D, Tohka J, Ravazoula P, Cavouras D, Nikiforidis G. Automated diagnosis of brain tumours astrocytomas using probabilistic neural network clustering and support vector 
<!-- EPO <DP n="70"/>-->
 machines. Int J Neural Syst 2005;15(l-2): 1-11; Glotsos D, Tohka J, Ravazoula P, Cavouras D, Nikiforidis G. Automated diagnosis of brain tumours astrocytomas using probabilistic neural network clustering and support vector machines. Int J Neural Syst 2005; 15(1 -2): 1-11). </p><p id="p0365" num="0365"> [00309] Other algorithms for use with the provided methods and systems include linear discriminant analysis (LDA), naive Bayes (NB), and K-nearest neighbor (KNN) protocols. Such approaches are useful for identifying individual or multi-variable alterations in neoplastic conditions (Drozdov I, Tsoka S, Ouzounis CA, Shah AM. Genome-wide expression patterns in physiological cardiac hypertrophy. BMC Genomics. 2010;11: 55; Freeman TC, Goldovsky L, Brosch M, et al. Construction, visualisation, and clustering of transcription networks from microarray expression data. PLoS Comput Biol 2007;3(10): 2032-42; Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6): 810-7. Epub 2010 Jul 22; Dhawan M, Selvaraja S, Duan ZH. Application of committee kNN classifiers for gene expression profile classification. Int J Bioinform Res Appl. 2010;6(4): 344-52; Kawarazaki S, Taniguchi K, Shirahata M, et al. Conversion of a molecular classifier obtained by gene expression profiling into a classifier based on real-time PCR: a prognosis predictor for gliomas. BMC Med </p><p id="p0366" num="0366">Genomics. 2010;3: 52; Vandebriel RJ, Van Loveren H, Meredith C. Altered cytokine (receptor) mRNA expression as a tool in immunotoxicology. Toxicology. 1998; 130(1): 43-67; Urgard E, Vooder T, Vosa U, et al. Metagenes associated with survival in non-small cell lung cancer. Cancer Inform. 2011;10: 175-83. Epub 2011 Jun 2; Pimentel M, Amichai M, Chua K, Braham L. Validating a New Genomic Test for Irritable Bowel Syndrome Gastroenterology 2011; 140 (Suppl 1): S-798; Lawlor G, Rosenberg L, Ahmed A, et al. Increased Peripheral Blood GATA-3 Expression in Asymptomatic Patients With Active Ulcerative Colitis at Colonoscopy. </p><p id="p0367" num="0367">Gastroenterology 2011;140 (Suppl 1)). </p><p id="p0368" num="0368"> [00310] In some embodiments, the provided methods and systems analyze expression of the GEP-NEN biomarkers as a group, with outputs dependent on an expression signature, such as expression signatures or profiles that are distinct between normal or reference samples and samples obtained from a subject with a "GEP-NEN." In such embodiments, pattern recognition protocols generally are used. Such approaches are useful, for example, to identify malignant signatures and signaling pathways in GEP-NEN tumor tissue (such as those described in Drozdov I, Kidd M, Nadler B, et al. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer. 2009; 115(8): 1638-50) and 
<!-- EPO <DP n="71"/>-->
 determining whether individual plasma samples were obtained from normal control or GEP- NENs (for example, as described in Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R, Kidd M. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Ann Surg Oncol 2009; 16(2): 487-98).. </p><p id="p0369" num="0369"> [00311] Methods using the predictive algorithms and models use statistical analysis and data compression methods, such as those well known in the art. For example, expression data may be transformed, e.g., In-transformed, and imported into a statistical analysis program, such as Partek® Genomic Suite ("Partek," Partek® Genomics SuiteTM, ed. Revision 6.3 St. Louis: Partek Inc, 2008) or similar program, for example. Data are compressed and analyzed for comparison. </p><p id="p0370" num="0370"> [00312] Statistical analyses include determining mean (M), e.g., geometric mean, of gene expression levels for individual sample types, standard deviations (SD) among types of samples, Geometric Fold Change (FC) between different sample types or conditions, calculated as the ratio of geometric means for two groups of samples or values, comparison of expression levels by 2-tailed Fisher' s test, or two-sample t-test, e.g., to identify biomarker genes differentially expressed between various samples and tissue types. Analysis of Variance (ANOVA) is used to evaluate differences in biomarker expression levels between expression in different samples and/or values. In one example, a two-class unpaired algorithm is implemented, such as by expression levels from a test and normal sample or reference value defining the two groups. </p><p id="p0371" num="0371"> [00313] Whether differences in expression levels, amounts, or values are deemed significant may be determined by well-known statistical approaches, and typically is done by designating a threshold for a particular statistical parameter, such as a threshold p-value (e.g. , p &lt; 0.05), threshold S-value (e.g. , +0.4, with S &lt; -0.4 or S &gt; 0.4), or other value, at which differences are deemed significant, for example, where expression of a biomarker is considered significantly down- or up-regulated, respectively, among two different samples, for example, representing two different GEP-NEN sub-types, tumors, stages, localizations, aggressiveness, or other aspect of GEP-NEN or normal or reference sample. </p><p id="p0372" num="0372"> [00314] In one aspect, the algorithms, predictive models, and methods are based on biomarkers expressed from genes associated with regulatory genotypes (i.e. , adhesion, migration, proliferation, apoptosis, metastasis, and hormone secretion) underlying various GEP- NEN subtypes. 
<!-- EPO <DP n="72"/>-->
 [00315] In one aspect, the methods apply the mathematical formulations, algorithms or models identify specific cutoff points, for example, expression levels or amounts, which distinguish between normal and GEP-NEN samples, between GEP-NEN and other cancers, and between various sub-types, stages, and other aspects of disease or disease outcome. In another aspect, the methods are used for prediction, classification, prognosis, and treatment monitoring and design. In one aspect, the predictive embodiments are useful for identifying molecular parameters predictive of biologic behavior, and prediction of various GEP-NEN-associated outcomes using the parameters. In one aspect of these embodiments, machine learning approaches are used, e.g., to develop sophisticated, automatic and objective algorithms for the analysis of high-dimensional and multimodal biomedical data. </p><p id="p0373" num="0373"> Compression of data and determining expression profiles </p><p id="p0374" num="0374"> [00316] For the comparison of expression levels or other values, and to identify expression profiles (expression signatures) or regulatory signatures based on GEP-NEN biomarker expression, data are compressed. Compression typically is by Principal Component Analysis (PCA) or similar technique for describing and visualizing the structure of high-dimensional data. PCA allows the visualization and comparison of GEP-NEN biomarker expression and determining and comparing expression profiles (expression signatures, expression patterns) among different samples, such as between normal or reference and test samples and among different tumor types. </p><p id="p0375" num="0375"> [00317] In some embodiments, expression level data are acquired, e.g., by real-time PCR, and reduced or compressed, for example, to principal components. </p><p id="p0376" num="0376"> [00318] PCA is used to reduce dimensionality of the data (e.g., measured expression values) into uncorrelated principal components (PCs) that explain or represent a majority of the variance in the data, such as about 50, 60, 70, 75, 80, 85, 90, 95 or 99 % of the variance. </p><p id="p0377" num="0377"> [00319] In one example, the PCA is 3-component PCA, in which three PCs are used that collectively represent most of the variance, for example, about 75%, 80%, 85%, 90%, or more variance in the data (Jolliffe IT, "Principle Component Anlysis," Springer, 1986). </p><p id="p0378" num="0378"> [00320] PCA mapping, e.g., 3-component PCA mapping is used to map data to a three dimensional space for visualization, such as by assigning first (1<sup>st</sup>), second (2<sup>nd</sup>) and third (3<sup>rd</sup>) PCs to the X-, y-, and z-axes, respectively. </p><p id="p0379" num="0379"> [00321] PCA may be used to determine expression profiles for the biomarkers in various samples. For example, reduced expression data for individual sample types (e.g., each tumor 
<!-- EPO <DP n="73"/>-->
 type, sub-type or grade, or normal sample type) are localized in a PCA coordinate system and localized data used to determine individual transcript expression profiles or signatures. </p><p id="p0380" num="0380"> [00322] In one aspect, the expression profile is determined for each sample by plotting or defining a centroid (center of mass; average expression), corresponding to or representing the sample's individual transcript expression profile (regulatory signature), as given by the principal component vector, as determined by PCA for the panel of biomarkers. </p><p id="p0381" num="0381"> [00323] Generally, two centroids or points of localization separated by a relatively large distance in this coordinate system represent two relatively distinct transcript expression profiles. Likewise, relatively close centroids represent relatively similar profiles. In this representation, the distance between centroids is inversely equivalent to the similarity measure (greater distance = less similarity) for the different samples, such that large distances or separation between centroids indicates samples having distinct transcript expression signatures. Proximity of centroids indicates similarity between samples. For example, the relative distance between centroids for different GEP-NEN tumor samples represents the relative similarity of their regulatory signatures or transcript expression profiles. </p><p id="p0382" num="0382"> Correlation, linear relationships and regulatory clusters </p><p id="p0383" num="0383"> [00324] In one aspect, the statistical and comparative analysis includes determining the inverse correlation between expression levels or values for two biomarkers. In one example, this correlation and the cosine of the angle between individual expression vectors (greater angle = less similarity), is used to identify related gene expression clusters (Gabriel KR, "The biplot graphic display of matrices with application to principal component analysis," Biometrika 1971;58(3):453). </p><p id="p0384" num="0384"> [00325] In some embodiments, there is a linear correlation between expression levels of two or more biomarkers, and/or the presence or absence of GEP-NEN, sub-type, stage, or other outcome. In one aspect, there is an expression-dependant correlation between the provided GEP-NEN biomarkers and characteristics of the biological samples, such as between biomarkers (and expression levels thereof) and various GEP-NEN sub-types (primary or metastatic), normal versus GEP-NEN samples, and/or primary versus metastatic or aggressive disease. </p><p id="p0385" num="0385"> [00326] Pearson's Correlation (PC) coefficients (R<sup>2</sup>) may be used to assess linear </p><p id="p0386" num="0386">relationships (correlations) between pairs of values, such as between expression levels of a biomarker for different biological samples (e.g., tumor sub-types) and between pairs of biomarkers. This analysis may be used to linearly separate distribution in expression patterns, 
<!-- EPO <DP n="74"/>-->
 by calculating PC coefficients for individual pairs of the biomarkers (plotted on x- and y- axes of individual Similarity Matrices). Thresholds may be set for varying degrees of linear correlation, such as a threshold for highly linear correlation of (R &gt; 0.50, or 0.40). Linear classifiers can be applied to the datasets. In one example, the correlation coefficient is 1.0. </p><p id="p0387" num="0387"> [00327] In one embodiment, regulatory clusters are determined by constructing networks of correlations using statistical analyses, for example, to identify regulatory clusters composed of subsets of the panel of biomarkers. In one example, PC correlation coefficients are determined and used to construct such networks of correlations. In one example, the networks are identified by drawing edges between transcript pairs having R above the pre-defined threshold. Degree of correlation can provide information on reproducibility and robustness. </p><p id="p0388" num="0388"> Predictive Models and Supervised Learning Algorithms </p><p id="p0389" num="0389"> [00328] Also provided herein are objective algorithms, predictive models, and topographic analytical methods, and methods using the same, to analyze high-dimensional and multimodal biomedical data, such as the data obtained using the provided methods for detecting expression of the GEP-NEN biomarker panels. As discussed above, the objective algorithms, models, and analytical methods include mathematical analyses based on topographic, pattern-recognition based protocols e.g., support vector machines (SVM) (Noble WS. What is a support vector machine? Nat Biotechnol. 2006;24(12): 1565-7), linear discriminant analysis (LDA), naive Bayes (NB), and K-nearest neighbor (KNN) protocols, as well as other supervised learning algorithms and models, such as Decision Tree, Perceptron, and regularized discriminant analysis (RDA), and similar models and algorithms well-known in the art (Gallant SI, "Perceptron-based learning algorithms," Perceptron-based learning algorithms 1990; 1(2): 179-91). </p><p id="p0390" num="0390"> [00329] In some embodiments, biomarker expression data is analyzed in biological samples, using feed-forward neural networks; best transcripts-predictors are selected. </p><p id="p0391" num="0391"> [00330] In some embodiments, Feature Selection (FS) is applied to remove the most redundant features from a dataset, such as a GEP-NEN biomarker expression dataset. FS enhances the generalization capability, accelerates the learning process, and improves model interpretability. In one aspect, FS is employed using a "greedy forward" selection approach, selecting the most relevant subset of features for the robust learning models. (Peng H, Long F, Ding C, "Feature selection based on mutual information: criteria of max-dependency, max- relevance, and min-redundancy," IEEE Transactions on Pattern Analysis and Machine </p><p id="p0392" num="0392">Intelligence, 2005;27(8): 1226-38). 
<!-- EPO <DP n="75"/>-->
 [00331] In some embodiments, Support Vector Machines (SVM) algorithms are used for classification of data by increasing the margin between the n data sets (Cristianini N, Shawe- Taylor J. An Introduction to Support Vector Machines and other kernel-based learning methods. Cambridge: Cambridge University Press, 2000). </p><p id="p0393" num="0393"> [00332] In some embodiments, the predictive models include Decision Tree, which maps observations about an item to a conclusion about its target value (Zhang H, Singer B. "Recursive Partitioning in the Health Sciences," (Statistics for Biology and Health): Springer, 1999.). The leaves of the tree represent classifications and branches represent conjunctions of features that devolve into the individual classifications. It has been used effectively (70-90%) to predict prognosis of metastatic breast cancer (Yu L et al "TGF-beta receptor- activated p38 MAP kinase mediates Smad-independent TGF-beta responses.," Embo J 2002;21(14):3749-59), as well as colon cancer (Zhang H et al "Recursive partitioning for tumor classification with gene expression microarray data.," Proc Natl Acad Sci U SA 2001;98(12):6730-5.), to predict the grading of astrocytomas (Glotsos D et al "Automated diagnosis of brain tumours astrocytomas using probabilistic neural network clustering and support vector machines.," Int J Neural Syst 2005; 15(1-2): 1-11.) with a &gt;90% accuracy, and prostatic carcinomas with an accuracy of 74- 80% (Mattfeldt T et al. "Classification of prostatic carcinoma with artificial neural networks using comparative genomic hybridization and quantitative stereological data.," Pathol Res Pract 2003;199(12):773-84.). The efficiency of this technique has been measured by 10-fold cross- validation (Pirooznia M et al "A comparative study of different machine learning methods on microarray gene expression data.," BMC Genomics 2008;9 Suppl 1:S13.). </p><p id="p0394" num="0394"> [00333] The predictive models and algorithms further include Perceptron, a linear classifier that forms a feed forward neural network and maps an input variable to a binary classifier (Gallant SI. "Perceptron-based learning algorithms," Perceptron-based learning algorithms 1990; 1(2): 179-91). It has been used to predict malignancy of breast cancer (Markey MK et al. "Perceptron error surface analysis: a case study in breast cancer diagnosis.," Comput Biol Med 2002;32(2):99-109). In this model, the learning rate is a constant that regulates the speed of learning. A lower learning rate improves the classification model, while increasing the time to process the variable (Markey MK et al. "Perceptron error surface analysis: a case study in breast cancer diagnosis.," Comput Biol Med 2002;32(2):99-109). In one example, a learning rate of 0.05 is used. In one aspect, a Perceptron algorithm is used to distinguish between localized or 
<!-- EPO <DP n="76"/>-->
 primary tumors and corresponding metastatic tumors. In one aspect, three data scans are used to generate decision boundaries that explicitly separate data into classes. </p><p id="p0395" num="0395"> [00334] The predictive models and algorithms further include Regularized Discriminant Analysis (RDA), which can be used as a flexible alternative to other data mining techniques, including Linear and Quadratic Discriminant Analysis (LDA, QDA) (Lilien RH, Farid H, Donald BR. "Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum.," J Comput Biol 2003;10(6):925-46.; Cappellen D, Luong- Nguyen NH, Bongiovanni S, et al. "Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony- stimulating factor and the ligand for the receptor activator of NFkappa B. " J Biol Chem 2002;277(24):21971-82.). RDA's regularization parameters, γ and λ, are used to design an intermediate classifier between LDA and QDA. QDA is performed when γ=0 and λ^Ο while LDA is performed when γ=0 and λ=1 (Picon A, Gold LI, Wang J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta 1. Cancer Epidemiol Biomarkers Prev 1998;7(6):497-504). </p><p id="p0396" num="0396"> [00335] To reduce over-fitting, RDA parameters are selected to minimize cross-validation error while not being equal 0.0001, thus forcing RDA to produce a classifier between LDA, QDA, and L2 (Pima I, Aladjem M., "Regularized discriminant analysis for face recognition," Pattern Recognition 2003;37(9): 1945-48). Finally, regularization itself has been used widely to overcome over-fitting in machine learning (Evgeniou T, Pontil M, Poggio T. "Regularization Networks and Support Vector Machines.," Advances in Computational Math 2000;13(l): l-50.; Ji S, Ye J. Kernel "Uncorrelated and Regularized Discriminant Analysis: A Theoretical and Computational Study.," IEEE Transactions on Knowledge and Data Engineering </p><p id="p0397" num="0397">2000;20(10): 1311-21.). </p><p id="p0398" num="0398"> [00336] In one example, regularization parameters are defined as γ = 0.002 and λ = 0. In one example, for each class pair, S-values are assigned to all transcripts which are then arranged by a decreasing S-value. RDA is performed, e.g., 21 times, such that the Ν<sup>ώ</sup> iteration consists of top N scoring transcripts. Error estimation can be carried out by a 10-fold cross-validation of the RDA classifier. This can be done by partitioning the tissue data set into complementary subsets, performing the analysis on one subset (called the training set), and validating the analysis on the other subset (called the validation set or testing set). </p><p id="p0399" num="0399"> Calculating misclassification error 
<!-- EPO <DP n="77"/>-->
 [00337] In one example, misclassification error is averaged to reduce variability in the overall predictive assessment, which can provide a more accurate approach to error estimation compared to other approaches, including bootstrapping and leave-one-out cross-validation (Kohavi R. "A study of cross-validation and bootstrap for accuracy estimation and model selection.," Proceedings of the Fourteenth International Joint Conference on Artificial </p><p id="p0400" num="0400">Intelligence, 1995;2(12): 1137-43.). </p><p id="p0401" num="0401"> [00338] In one example, selection for tissue classification is performed, for example, by computing the rank score (S) for each gene and for each class pair as: </p><p id="p0402" num="0402">[00339] s <sup>Mc2 ~Mcl</sup>\ </p><p id="p0403" num="0403">[00340] where /<sub>cl</sub> and /<sub>C2</sub> represent means of first and second class respectively and a<sub>cl</sub> and</p><p id="p0404" num="0404">C7<sub>C2</sub> are inter-class standard deviations. A large S value is indicative of a substantial differential expression ("Fold Change") and a low standard deviation ("transcript stability") within each class. Genes may be sorted by a decreasing S-value and used as inputs for the regularized discriminant analysis algorithm (RDA). </p><p id="p0405" num="0405"> [00341] The algorithms and models may be evaluated, validated and cross-validated, for example, to validate the predictive and classification abilities of the models, and to evaluate specificity and sensitivity. In one example, radial basis function is used as a kernel, and a 10- fold cross-validation used to measure the sensitivity of classification (Cristianini N, Shawe- Taylor J. "An Introduction to Support Vector Machines and other kernel-based learning methods.," Cambridge: Cambridge University Press, 2000.). Various classification models and algorithms may be compared by the provided methods, for example, using training and cross- validation, as provided herein, to compare performance of the predictive models for predicting particular outcomes. </p><p id="p0406" num="0406"> [00342] Embodiments of the provided methods, systems, and predictive models are reproducible, with high dynamic range, can detect small changes in data, and are performed using simple methods, at low cost, e.g., for implementation in a clinical laboratory. </p><p id="p0407" num="0407">F. KITS </p><p id="p0408" num="0408"> [00343] For use in the diagnostic, prognostic, predictive, and therapeutic applications described or suggested above, kits and other articles of manufacture are provided. In some 
<!-- EPO <DP n="78"/>-->
 embodiments, the kits include a carrier, package, or packaging, compartmentalized to receive one or more containers such as vials, tubes, plates, and wells, in which each of the containers includes one of the separate elements for use in the methods provided herein, and in some aspects further include a label or insert with instructions for use, such as the uses described herein. In one example, the individual containers include individual agents for detection of the GEP-NEN biomarkers as provided herein; in some examples, individual containers include agents for detection of housekeeping genes and/or normalization. </p><p id="p0409" num="0409"> [00344] For example, the container(s) can comprise an agent, such as a probe or primer, which is or can be detectably labeled. Where the method utilizes nucleic acid hybridization for detection, the kit can also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence. Kits can comprise a container comprising a reporter, such as a biotin- binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, fluorescent, or radioisotope label; such a reporter can be used with, e.g., a nucleic acid or antibody. </p><p id="p0410" num="0410"> [00345] The kits will typically comprise the container(s) described above and one or more other containers associated therewith that comprise materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use. </p><p id="p0411" num="0411"> [00346] A label can be present on or with the container to indicate that the composition is used for a specific therapeutic or non-therapeutic application, such as a prognostic, prophylactic, diagnostic or laboratory application, and can also indicate directions for either in vivo or in vitro use, such as those described herein. Directions and or other information can also be included on an insert(s) or label(s) which is included with or on the kit. The label can be on or associated with the container. A label a can be on a container when letters, numbers or other characters forming the label are molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. The label can indicate that the composition is used for diagnosing, treating, prophylaxing or prognosing a condition, such as GEP-NEN. </p><p id="p0412" num="0412"> [00347] In another embodiment, an article(s) of manufacture containing compositions, such as amino acid sequence(s), small molecule(s), nucleic acid sequence(s), and/or antibody(s), e.g., materials useful for the diagnosis, prognosis, or therapy of GEP-NEN is provided. The article of 
<!-- EPO <DP n="79"/>-->
 manufacture typically comprises at least one container and at least one label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers can be formed from a variety of materials such as glass, metal or plastic. The container can hold amino acid sequence(s), small molecule(s), nucleic acid sequence(s), cell population(s) and/or antibody(s). In one embodiment, the container holds a polynucleotide for use in examining the mRNA expression profile of a cell, together with reagents used for this purpose. In another </p><p id="p0413" num="0413">embodiment a container comprises an antibody, binding fragment thereof or specific binding protein for use in evaluating protein expression of GEP-NEN biomarkers in cells and tissues, or for relevant laboratory, prognostic, diagnostic, prophylactic and therapeutic purposes; </p><p id="p0414" num="0414">indications and/or directions for such uses can be included on or with such container, as can reagents and other compositions or tools used for these purposes. </p><p id="p0415" num="0415"> [00348] The article of manufacture can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and/or dextrose solution. It can further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, stirrers, needles, syringes, and/or package inserts with indications and/or instructions for use. </p><p id="p0416" num="0416">EXAMPLES </p><p id="p0417" num="0417"> [00349] Various aspects of the invention are further described and illustrated by way of the several examples which follow, none of which are intended to limit the scope of the invention. </p><p id="p0418" num="0418">EXAMPLE 1: DETECTION AND DETERMINING EXPRESSION LEVELS OF </p><p id="p0419" num="0419"> BIOMARKERS IN GEP-NEN AND NORMAL SAMPLES </p><p id="p0420" num="0420">Sample preparation, RNA extraction, real-time PCR </p><p id="p0421" num="0421"> [00350] Normal and neoplastic samples were obtained for detection and determination of GEP-NEN biomarker expression levels by real-time PCR. Normal samples included twenty- seven (27) normal small intestinal (SI) mucosa samples (NML), and thirteen (13) normal human enterochromaffin (EC) cell preparations (NML_EC; obtained through fluorescence-activated cell sorting (FACS) of normal mucosa; &gt;98 pure EC cells (Modlin IM et ah, "The functional characterization of normal and neoplastic human enterochromaffin cells," J Clin Endocrinol Metab 2006;91(6):2340-8). 
<!-- EPO <DP n="80"/>-->
 [00351] Neoplastic samples included fifty-three (53) primary SI GEP-NENs and twenty-one (21) corresponding liver metastases collected from a frozen biobank (all tissues microdissected). The GEP-NEN samples were obtained from patients enrolled according to protocols approved by the Institutional Review Board of Yale University. Each was classified as functional, with greater than 80% pure neoplastic cells and as positive for TPH1, confirming it was EC cell- derived (Modlin IM et al., "The functional characterization of normal and neoplastic human enterochromaffin cells," J Clin Endocrinol Metab 2006;91(6):2340-8). Patient samples also were collected from adenocarcinomas of the breast (n=53), colon (n=21), and pancreas (w=16). </p><p id="p0422" num="0422"> [00352] Primary GEP-NENs were classified pathologically according to the 2000 World Health Organization (WHO) standard, as well differentiated NETs ((WDNETs) (w=26) (benign behavior or uncertain malignant potential)); well differentiated neuroendocrine carcinomas ((WDNECs) (n=20) (low-grade malignancy)); poorly differentiated neuroendocrine tumors ((PDNETs) (n=5) (medium grade malignancy)); and poorly-differentiated (typically small-cell) neuroendocrine carcinomas ((PDNECs) (n=2) (high grade malignancy)). Metastatic GEP-NEN tissue samples (metastases; MET) (collected from liver resections from corresponding tumor types), were classified using a similar standard, as: WDNET MET (n=6), WDNEC MET (n=12), and PDNEC MET (n=3). Metastatic PDNETs (PDNET METs) are classified using the same method. </p><p id="p0423" num="0423"> [00353] For real-time PCR, RNA was extracted from various normal and neoplastic samples (27 samples of normal SI mucosa, 13 preparations of normal human EC cells, 53 primary SI GEP-NENs, 21 corresponding liver metastases, and 53 adenocarcinoma samples) using TRIzol® reagent (ready-to-use, monophasic solution of phenol and guanidine isothiocyanate; </p><p id="p0424" num="0424">Invitrogen™, Carlsbad, California). </p><p id="p0425" num="0425"> [00354] Transcript expression levels were measured by real-time PCR using Assays-on- Demand™ gene expression products and the ABI 7900 Sequence Detection System (both from Applied Biosystems) according to the manufacturer's suggestions (Kidd M et al, "Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors," Cancer 2005;103(2):229-36). Cycling was performed under standard conditions using the TaqMan® Universal PCR Master Mix Protocol (Applied </p><p id="p0426" num="0426">Biosystems). </p><p id="p0427" num="0427"> [00355] GEP-NEN biomarkers were detected and expression levels measured by real-time PCR, using sets of polynucleotide primer pairs, where each set contained primer pairs designed 
<!-- EPO <DP n="81"/>-->
 to specifically bind to and amplify a panel of GEP-NEN biomarkers. The GEP-NEN biomarker panel included products (transcripts) of genes implicated in typical primary and metastatic GEP- NEN phenotypes, for example, genes involved in adhesion, migration, proliferation, apoptosis, metastasis, and hormone secretion, and neuroendocrine marker genes. Housekeeping gene (ALG9, TFCP2 and ZNF410) expression levels also were measured. Raw AC<sub>T</sub> values for biomarker expression were normalized using the geNorm algorithm (Vandesompele J et al., "Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes," Genome Biol 2002;3(7):RESEARCH0034) and the </p><p id="p0428" num="0428">housekeeping expression levels. </p><p id="p0429" num="0429"> [00356] Normalized data were natural log (ln)-transformed for compression and imported into Partek® Genomic Suite (Partek, "Partek® Genomics SuiteTM," ed. Revision 6.3 St. Louis: Partek Inc, 2008). Mean gene expression levels (M) of the various biomarker transcripts and Standard Deviations (SD) were calculated. All statistical computations were carried out using R 2.9 language for statistical computing (R Development Core Team. R, "A language and environment for statistical computing," Vienna, Austria: R Foundation for Statistical </p><p id="p0430" num="0430">Computing, 2008). </p><p id="p0431" num="0431">Detection and determination of transcript expression levels of a 9 -biomarker panel </p><p id="p0432" num="0432"> [00357] Expression levels were determined by real-time PCR as described above using a set of primer pairs specific for a panel of nine GEP-NEN biomarkers (MAGE-D2, MTAl, NAPILI, Ki-67, Survivin, FZD7, Kissl, NRP2, and CgA (see Kidd M et al., "The role of genetic markers— NAPILI, MAGE-D2, and MTAl— in defining small-intestinal carcinoid neoplasia," Ann Surg Oncol 2006;13(2):253-62; Kidd M et al., "Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease," Ann Surg 2006;243(2):273-80) transcripts. The sequences of the primer pairs are listed in Table 1A, below, with other information about primer pairs listed in Table IB. Expression of the nine biomarkers </p><p id="p0433" num="0433">(transcripts) was measured in samples from primary SI GEP-NEN (AKA SI NET) (n = 53), corresponding liver metastases (n = 21), and normal EC cell preparations (n = 13). Expression levels in the tumor samples were compared for each biomarker to corresponding average expression levels in the normal enterochomaffin (EC) cell preparations. Based on this 
<!-- EPO <DP n="82"/>-->
 comparison, expression levels in the tumor samples were classified as Upregulated, Downregulated, or Baseline. </p><p id="p0434" num="0434"> Table 1: Sets of primers for GEP-NEN biomarkers and housekeeping genes </p><p id="p0435" num="0435"> Table 1A: Primer sequences </p><p id="p0436" num="0436"><img id="imgf000082_0001" he="204" wi="145" file="imgf000082_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/><!-- EPO <DP n="83"/>--><img id="imgf000083_0001" he="234" wi="146" file="imgf000083_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="84"/>--><img id="imgf000084_0001" he="234" wi="146" file="imgf000084_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="85"/>--><img id="imgf000085_0001" he="234" wi="146" file="imgf000085_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="86"/>--><img id="imgf000086_0001" he="234" wi="146" file="imgf000086_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="87"/>--></p><p id="p0437" num="0437"><img id="imgf000087_0001" he="215" wi="146" file="imgf000087_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0438" num="0438"> agaagg- a- 
<!-- EPO <DP n="88"/>-->
 Table IB: other information </p><p id="p0439" num="0439"><img id="imgf000088_0001" he="130" wi="275" file="imgf000088_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="89"/>--></p><p id="p0440" num="0440"><img id="imgf000089_0001" he="146" wi="275" file="imgf000089_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="90"/>--></p><p id="p0441" num="0441"><img id="imgf000090_0001" he="144" wi="275" file="imgf000090_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="91"/>--></p><p id="p0442" num="0442"><img id="imgf000091_0001" he="142" wi="275" file="imgf000091_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="92"/>--></p><p id="p0443" num="0443"><img id="imgf000092_0001" he="146" wi="275" file="imgf000092_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="93"/>--></p><p id="p0444" num="0444"><img id="imgf000093_0001" he="146" wi="275" file="imgf000093_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="94"/>--></p><p id="p0445" num="0445"><img id="imgf000094_0001" he="146" wi="275" file="imgf000094_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="95"/>--></p><p id="p0446" num="0446"><img id="imgf000095_0001" he="146" wi="275" file="imgf000095_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="96"/>--></p><p id="p0447" num="0447"><img id="imgf000096_0001" he="143" wi="275" file="imgf000096_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="97"/>--></p><p id="p0448" num="0448"><img id="imgf000097_0001" he="50" wi="275" file="imgf000097_0001.tif" img-format="tif" img-content="table" orientation="landscape" inline="yes"/><!-- EPO <DP n="98"/>--></p><p id="p0449" num="0449">[00358] The results are presented in FIG. 1, with each of the figures nine panels showing average expression levels for an individual biomarker in normal EC (left), malignant/metastatic (center) and localized (right) samples. Ellipsoids correspond to a +2 Standard Deviation (SD) threshold. All p-values: p &lt; 0.05. The results demonstrate significantly higher expression levels of MAGE-D2. MTAl, NAPILI, Ki-67. FZD7, CgA and NRP2, and reduced levels of survivin and Kissl in SI GEP-NEN (AKA SI NETs), confirming differential expression of these GEP-NEN biomarkers in GEP-NEN samples compared to normal cells, and between different GEP-NEN tumor grades. </p><p id="p0450" num="0450">Detection and expression level determination for transcripts of 21 -biomarker panel </p><p id="p0451" num="0451"> [00359] Quantitative real-time PCR (QPCR) was carried out as described above, using a set of primer pairs to measure expression levels of transcripts from a 21 -gene GEP-NEN biomarker panel (including MAGE-D2, MTAl, NAPILI, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCK1, HOXC6, CTGF, PTPRN2, SCG5, and Tphl). The primer sequences and information are listed in Tables 1A and IB, above. </p><p id="p0452" num="0452">Expression of the 21 biomarkers was measured in 167 human tissue samples, including normal EC cell (n=l3) normal SI mucosa (n=27), and primary (n=53) and metastatic (n=2l liver METs) GEP-NEN subtype and 53 adenocarcinoma (colon, breast, and pancreatic) samples. This study demonstrated that each of the 21 biomarkers is significantly differentially expressed in GEP- NEN tumor samples. </p><p id="p0453" num="0453"> [00360] For each of the 21 biomarkers, the proportion of GEP-NEN samples versus adenocarcinoma samples in which transcript levels were detected was calculated and compared using a 2-tailed Fisher's test (GraphPad Prizm 4; FIG. 8B: *p&lt;0.002 SI GEP-NENs versus adenocarcinomas (Fisher's exact test)). As shown in FIG. 8B, a significantly higher proportion (&gt;95%) of the GEP-NEN samples in this study expressed (i.e., were positive for) 16 of the 21 GEP-NEN biomarker genes (76%), as compared to adenocarcinomas (p&lt;0.002). Genes highly expressed in both tumor types included CTGF, FZD7, NRP2, PNMA2 and survivin. </p><p id="p0454" num="0454"> [00361] In contrast to different GEP-NEN sub-types, the various normal EC cell samples exhibited homogeneous transcript expression, with low transcript variation (57%) between samples. Different neoplastic SI GEP-NEN (a.k.a. SI NET) subtypes showed heterogeneity at 
<!-- EPO <DP n="99"/>-->
 the transcript level, indicating that different GEP-NEN sub-types could be differentiated by detecting and determining expression levels of transcripts in the 21-biomarker panel. </p><p id="p0455" num="0455">EXAMPLE 2: Principal Component Analysis (PCA) </p><p id="p0456" num="0456"> [00362] After natural log (ln)-transformation, and importation into Partek® Genomic Suite, Principal Component Analysis (PCA) was performed to describe the structure of the high- dimensional expression data. PCA allowed visualization and comparison of transcript expression patterns among various samples (e.g., normal, neoplastic, GEP-NEN vs. other tumor, GEP-NEN subtypes, primary vs. metastatic/malignant). PCA reduced dimensionality of the expression data— obtained with each of the nine-biomarker and twenty-one biomarker panels— to three uncorrelated principal components (PCs), which explained most variations (Jolliffe ΓΓ, "Principle Component Anlysis," Springer, 1986.). PCA mapping was visualized in a 3- dimentional space, with the first (1<sup>st</sup>), second (2<sup>nd</sup>) and third (3<sup>rd</sup>) PCs assigned to the x-, y-, and z-axes, respectively. </p><p id="p0457" num="0457"> [00363] For the nine and the twenty-one gene panels, average expression data for various samples were superimposed in this PCA coordinate system. The centroid (center of mass (average expression)) of each sample represented its individual transcript expression profile (regulatory signature) as given by the principal component vector. In this representation, the distance between centroids inversely equivalent to the similarity measure (greater distance = less similarity). Thus, large distances or separation between centroids indicated samples with distinct transcript expressions signatures; proximity of centroids indicated similarity between samples. For example, distance between centroids for different tumor type samples represented the relative similarity of their regulatory signatures (transcript expression levels). </p><p id="p0458" num="0458">9-biomarker panel </p><p id="p0459" num="0459"> [00364] PCA was carried out, as described above, for the real-time PCR expression data for the nine-gene biomarker panel (MAGE-D2, MTA1, NAP1L1, Ki-67, Survivin, FZD7, Kissl, NRP2, and CgA). Three PCs (PC#1, PC#2, PC#3) reflected most of the expression variance between primary SI GEP-NENs, normal EC cell preparations, and respective metastases. </p><p id="p0460" num="0460">Reduced data were mapped to a three dimensional space (FIG. 2). As shown in FIG. 2, for primary SI GEP-NENs and normal EC cell preparations, PC#1, PC#2, and PC#3 represented 
<!-- EPO <DP n="100"/>-->
 31.7%, 26.5%, and 17.4% of the variance, respectively; overall, the three PCs represented 75.6% of the variance. </p><p id="p0461" num="0461"> [00365] The three PCs represented 75.6% of variance for primary tumor subtypes and normal EC cell preparations (FIG. 2A), and 73.2% of variance for primary GEP-NEN tumor subtypes and corresponding metastases (FIG. 2C). For metastases, PC#1, PC#2, and PC#3 represented 40.4%, 19.9%, and 12.9% of the variance, respectively; overall 73.2% of the variance in the data was represented by all 3 PCs (FIG. 2C). </p><p id="p0462" num="0462"> [00366] The inverse correlation between biomarker expression levels and the cosine of the angle between individual expression vectors (greater angle = less similarity) was used to identify related gene expression clusters. The clusters are shown in FIG. 2B for primary SI GEP-NENs ((1) CgA, NRP2, NAP1L1, FZD7; (2) MAGE-D2, MTA1, Kissl; and (3) Ki-67, Survivin)) and in FIG. 2D for corresponding metastases ((1) NAP 1 LI, FZD7, CgA, Survivin, Ki-67, Kissl; (2) MTA1, MAGE-D2, NRP2) (Gabriel KR, "The biplot graphic display of matrices with application to principal component analysis," Biometrika 1971;58(3):453). </p><p id="p0463" num="0463">21 -biomarker panel PCA </p><p id="p0464" num="0464"> [00367] PCA also was carried out as described above for the 21 -biomarker panel (MAGE-D2, MTA1, NAP1L1, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCK1, HOXC6, CTGF, PTPRN2, SCG5, and Tphl). Three principal components captured most of the variance (83%) within the dataset. Reduced data were mapped to a three dimensional space. </p><p id="p0465" num="0465"> [00368] FIG. 8A shows a comparison of expression profiles for GEP-NENs (including various primary and metastatic sub-types), adenocarcinomas (sub-types), and normal tissues (EC and SI). As shown, centroids for the three adenocarcinoma types were separate from those for both normal SI mucosa and neoplastic GEP-NEN tissue subtypes. This observation confirms significant difference in expression levels in this other (epithelial) tumor type, shown using the Fisher's exact test, described above (FIG. 8B). The various neoplastic (SI GEP-NEN) subtypes displayed heterogeneous expression profiles, showing they could be distinguished using this panel of biomarkers. </p><p id="p0466" num="0466"> [00369] All normal EC preparations displayed homogeneous transcript expression (with low variation (57%) within samples). Further, the normal sample expression profiles were 
<!-- EPO <DP n="101"/>-->
 substantially different compared to those of other tissue types, including normal SI mucosa. The genetic profile for normal EC cells was substantially different compared to normal SI mucosa and neoplastic tissue. </p><p id="p0467" num="0467"> [00370] The results demonstrate differences in expression profiles for the GEP-NEN biomarkers and distinct regulatory expression signatures for primary SI GEP-NEN tumor subtypes, normal EC cell preparations, and SI GEP-NEN metastases. This study confirms that measuring expression of the 21 biomarkers can successfully distinguish between GEP-NEN subtypes, adenocarcinoma types, normal SI mucosa, normal EC cells, and between primary and metastatic GEP-NEN subtypes. </p><p id="p0468" num="0468">EXAMPLE 3: Tumor profiling and analysis. </p><p id="p0469" num="0469"> [00371] Statistical analyses and tumor profiling were performed on transformed expression data obtained with the nine- and twenty-one biomarker panels described above. </p><p id="p0470" num="0470">9-biomarker panel </p><p id="p0471" num="0471"> [00372] Mean (M) transcript expression levels and standard deviations (SD) were calculated for the nine-biomarker panel, for primary tumor subtypes and normal EC cell preparations. Mean normal expression of CgA (M<sub>No</sub>rmai = -9.2, SD = 4.2), Ki-67 (M<sub>No</sub>rmai = -4.5, SD<sub>No</sub>rmai = 1.1), Kissl (M<sub>Norma</sub>i = -4.0, SD<sub>Norma</sub>i = 3.2), NAP1L1 (M<sub>Norma</sub>i = -8.3, SD<sub>Normid</sub> = 1.1), NRP2 (M<sub>Norma</sub>i = -9.3, SD = 3.8), and Survivin (M<sub>Norma</sub>i = -6.0, SD<sub>Norma</sub>i = 1.0) was significantly different compared to mean expression in primary tumors, both overall (All Tumors) and among individual subtypes. See p values and Fold Change (FC), listed in Table 2, below. Transcript expression level measurements were reevaluated in a subset of samples (n=35). The data were highly correlated (R =0.93, p=0.001), demonstrating this approach was both highly reproducible and robust. </p><p id="p0472" num="0472"> [00373] Analysis of Variance (ANOVA) was carried out to evaluate differences in biomarker expression levels between tumor and normal samples, and between normal samples and individual tumor subtype samples. Specifically, ANOVA compared expression between normal EC cell preparations and primary tumor tissues, and between normal EC cell </p><p id="p0473" num="0473">preparations and individual primary tumor types (Table 2). A two-class unpaired algorithm was implemented, with tumor sample data (total or individual sub-type) and normal sample expression data defining the two groups. As there were no missing values in the datasets, 
<!-- EPO <DP n="102"/>-->
 imputation was unnecessary. For each biomarker transcript, geometric Fold Change (FC) was calculated as the ratio of geometric means for the Tumor Group and the Normal Group. </p><p id="p0474" num="0474"> [00374] Biomarker genes calculated to have differences in expression between normal and tumor groups, with /?&lt;0.05, were considered significantly changed. Transcripts with /?&lt;0.05 and absolute FC&gt;2.0 were considered differentially expressed between groups. CgA, FZD7, Ki-67, NAP1L1, NRP2, and Survivin were significantly altered in WDNETs compared to normal EC cell preparations. Transcript levels of CgA, Ki-67, MAGE-D2, and NRP2 were significantly changed in WDNECs. PDNETs displayed alternatively expressed levels of CgA, Ki-67, NAP1L1, NRP2, and Survivin. Finally, PDNECs were different only in expressions of NAP1L1 and NRP2. </p><p id="p0475" num="0475"> Table 2: </p><p id="p0476" num="0476"> ANOVA comparing biomarker expression levels in SI-GEP-NENs, and individual SI-GEP- NEN sub-types, to expression levels in normal EC cell samples </p><p id="p0477" num="0477"><img id="imgf000102_0001" he="73" wi="171" file="imgf000102_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0478" num="0478"> WDNET = Well Differentiated Neuroendocrine Tumors, WDNEC = Well Differentiated Neuroendocrine </p><p id="p0479" num="0479"> Carcinomas, PDNET = Poorly Differentiated Neuroendocrine Tumors, PDNEC = Poorly Differentiated </p><p id="p0480" num="0480"> Neuroendocrine Carcinomas; NS = /?&gt;0.05, FC = Fold Change </p><p id="p0481" num="0481">[00375] Pearson's Correlation (PC) coefficients (R<sup>2</sup>) were calculated for the nine-biomarker panel to assess linear relationships between pairs of biomarkers and between tumor sub-type differentiation and expression of the biomarkers. The distribution of biomarker expression among primary GEP-NEN subtypes and normal EC samples was linearly separated by calculating PC coefficients for individual pairs of the biomarkers (plotted on x- and y- axes of individual Similarity Matrices shown in FIG. 3). The study determined highly linear (R<sup>2</sup> &gt; 0.50) correlation of expression for four pairs of biomarkers (MTA1. MAGE-D2, MTA1: Kissl, 
<!-- EPO <DP n="103"/>-->
 FZD7.NAP1L1, and Survivin: Ki-67 (highly correlated (R<sup>2</sup> &gt; 0.50)). Additionally, distribution of expression profiles for WDNETs, WDNEC, and PDNETs was linearly correlated to pair- wise expressions of Kiss 1: Survivin, FZD7.NAP1L1, Survivin: MTA1, and MTA1.MAGE-D2, indicating a linear classifier could be applied to the dataset. The data further suggest an expression-dependant correlation between the biomarkers and primary tumor subtypes. </p><p id="p0482" num="0482"> 21-biomarker panel </p><p id="p0483" num="0483"> [00376] Pearson's Correlation (PC) coefficients were used to identify linear relationships between expression levels of biomarkers in the 21 -gene panel. PC coefficients were calculated for each pair of the 21 biomarkers, across all tissue types (FIG. 9A). FIG. 9 shows the results in a heatmap, with the pairs with the lowest (-0.03), medium (0.4), and highest (1) correlations indicated in black, dark grey, and light grey, respectively. The 21-biomarker panel contained 27 highly correlated (R 2 &gt;0.40) transcript pairs, with the highest correlation coefficient (R 2 =1.00) between MTA1, NRP2, and Kissl. </p><p id="p0484" num="0484"> [00377] From these data, a network of correlations was constructed by drawing an edge between any transcript pair having an R<sup>2</sup> above a pre-defined threshold (R<sup>2</sup> &gt;0.40) (FIG. 9B, with actual R<sup>2</sup> values superimposed on each edge). As shown in FIG. 9B, five distinct regulatory clusters were identified within the network, each having a unique set of biomarkers: (1) MAGE-D2, NRP2, Kissl, MTA1, and CgA (most tightly-connected cluster (every R<sup>2</sup>- value&gt;0.79)); (2) GRIA2, OR51E1, SPOCK1, and SCG5; (3), CXCL14, NKX2-3, HOXC6, CTGF, PTPRN2; (4) NAP 1 LI, FZD7 , and PNMA2; and (5) Survivin and Tphl. In FIG. 9B, the R2 values are superimposed on individual edges. The lowest R - value is 0.40 within each cluster; the highest value is 1.0. The results demonstrate expression levels of the panel of biomarkers are biologically relevant to GEP-NEN. </p><p id="p0485" num="0485"> [00378] A two- sample t-test computation was used to identify biomarker genes that are differentially expressed between: 1) EC cells, normal SI mucosa, and primary and metastatic tissues; 2) primary GEP-NEN subtypes; and 3) metastatic GEP-NEN subtypes (FIG. 10). </p><p id="p0486" num="0486"> [00379] Calculated S-values for each subset ranged from -1.4 to 1.1. Based on the number of genes (n=2l) and the sample size (n=l 14), the threshold for statistical significance for the S- value was set at +0.4 (Nadler B, "Discussion of "On consistency and sparsity for principal component analysis in high dimensions,"" Journal of the American Statistical Association 2009;104:694-97). Transcripts with S &lt; -0.4 or S &gt; 0.4, and /?&lt;0.05, were considered 
<!-- EPO <DP n="104"/>-->
 significantly down- or up-regulated, respectively. Results are presented in FIG. 10, with volcano plots of gene ranks and significance (p) values for the t-test. </p><p id="p0487" num="0487"> [00380] FIG. 10A shows the comparison between normal SI mucosa, normal EC cells and SI GEP-NENs. Compared to normal mucosa, transcript expression of the classic neuroendocrine marker Tphl, was significantly higher (/?&lt;0.001, S=0.7; FIG. 10A) in SI GEP-NEN samples. Compared to normal SI mucosa, neoplastic tissue expressed higher transcript levels of CgA and GRIA2 (FIG. 10B); expression of CgA was not significantly altered (p=0.07, S=0.39) between neoplastic tissue and normal EC cells. </p><p id="p0488" num="0488"> [00381] FIG. 10B shows the comparison between all GEP-NEN (tumor) samples and all normal samples, all metastatic GEP-NEN samples and all normal samples, and all metastatic GEP-NEN samples and all primary GEP-NEN samples. None of the biomarker transcripts were differentially expressed in the collective metastatic GEP-NEN samples, when analyzed as an entire group, compared to the collective primary GEP-NEN samples, analyzed as a group. </p><p id="p0489" num="0489"> [00382] FIG. IOC shows the comparison between primary GEP-NEN subtypes and all metastases as a group. No biomarker transcripts were differentially expressed in PDNET samples as compared to PDNEC samples (PDNET-PDNEC), or WDNET samples as compared to PDNEC (WDNET-PDNEC) samples. Between WDNEC and PDNEC (WDNEC-PDNEC), MAGE-D2 was the only significant differentiating marker (p=0.009, S=1.03; FIG. IOC). </p><p id="p0490" num="0490"> [00383] FIG. 10D shows comparison between primary tumors and metastatic subtypes. CgA, Kissl, NRP2, and Tphl were differentially expressed between all metastasis subtypes (FIG. 10D). </p><p id="p0491" num="0491">EXAMPLE 4: Predictive Models for classifying GEP-NENs </p><p id="p0492" num="0492"> [00384] Expression levels of GEP-NEN biomarkers obtained in the studies in Examples 1-4 were further analyzed with supervised learning algorithms and models, including Support Vector Machines (SVM), Decision Tree, Perceptron, and regularized discriminant analysis RDA (Gallant SI, "Perceptron-based learning algorithms," Perceptron-based learning algorithms 1990;1(2): 179-91)). </p><p id="p0493" num="0493">EXAMPLE 4A: Prediction and modeling with detected expression of the nine -biomarker panel </p><p id="p0494" num="0494"> [00385] Expression data obtained in the nine-biomarker study were analyzed using the Feature Selection (FS) classification model. The model was employed using a "greedy forward" 
<!-- EPO <DP n="105"/>-->
 selection approach, selecting the most relevant subset of features for the robust learning models, as described by Peng H, Long F, Ding C, "Feature selection based on mutual information: </p><p id="p0495" num="0495"> criteria of max-dependency, max -relevance, and min-redundancy," IEEE Transactions on Pattern Analysis and Machine Intelligence, 2005;27(8): 1226-38. </p><p id="p0496" num="0496"> [00386] FS determined that for this study, expression levels of NAP 1 LI, FZD7, Kissl and MAGE-D2 were the best variables (of the nine biomarkers) for SVM classification. Thus, SVM was carried out by comparing expression levels for these biomarkers in normal EC cell preparations (n=l3) and primary STGEP-NENs (n=36). For SVM, radial basis function was used as a kernel and a 10-fold cross-validation was used to measure the sensitivity of classification. See Cristofanilli M et al. "Circulating tumor cells, disease progression, and survival in metastatic breast cancer," N Engl J Med 2004. The results are shown in Table 3, below, and in FIG. 4. As shown, SMV predicted SI GEP-NENs in this study with 100% sensitivity, and 92% class specificity; normal EC cell preparations were accurately predicated with 77% sensitivity, with a class specificity of 100%. </p><p id="p0497" num="0497">Table 3: Class predictions produced by the Support Vector Machines classification model using transcript expression levels of N API LI, FZD7, Kissl, and MAGE-D2 
<img id="imgf000105_0001" he="22" wi="171" file="imgf000105_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 </p><p id="p0498" num="0498">[00387] Density maps in FIG. 4 display distributions between SI GEP-NENs and normal EC cells, colorized to the density of the samples produced differential zones that depended on the individual gene expressions. Expression levels of NRP2, MAGE-D2, Kissl, and FZD7 transcripts as identified by the Feature Selection algorithm were plotted on the X- and Y-axis. Normal and neoplastic sample data were scattered according to their respective gene pair expressions. Distribution densities based on average Euclidean distance (difference in expression) between samples were colorized green (normal) and red (neoplastic). Blue areas indicate a region of transition between normal and neoplastic groups. The distinct separation between normal EC cells and primary small intestinal tumors indicates the utility of the selected transcripts as malignancy markers. 
<!-- EPO <DP n="106"/>-->
 [00388] Feature Selection identified NAPILI and Ki-67 expression levels as principle discriminators in the Decision Tree classifier. Based on this result, Decision Trees classification model was constructed on expression data for individual primary SI GEP-NEN subtypes by correlating NAPILI and Ki-67 expression level values to the corresponding expression levels for primary tumor subtypes, as determined above. The results are displayed in FIG. 5, with the leaves of the tree representing classifications and branches representing conjunctions of features that devolve into the individual classifications. A 10-fold cross-validation was used to measure the efficiency of this technique, as described by Pirooznia M, et ah, "A comparative study of different machine learning methods on microarray gene expression data," BMC Genomics 2008;9 Suppl 1 :S 13. Percentages shown in parenthesis in FIG. 5 indicate the occurrence frequencies of primary SI GEP-NEN subtypes. As shown in Table 4, below, Decision Trees classification predicted WDNETs in this study with 78% sensitivity and 82%; predicted </p><p id="p0499" num="0499"> WDNECs in this study with 78% sensitivity and 64%; and predicted PDNETs in this study with 71% sensitivity and 63% specificity. With the nine biomarker panel, PDNECs were </p><p id="p0500" num="0500"> misclassified in this study as either WDNETs or PDNETs. (FIG. 5; Table 4). </p><p id="p0501" num="0501">Table 4: Class predictions produced by the Decision Trees classification model using transcript expression of Ki-67 and NAPILI. </p><p id="p0502" num="0502"><img id="imgf000106_0001" he="56" wi="152" file="imgf000106_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0503" num="0503">[00389] ANOVA was performed to identify transcripts differentially expressed in primary SI GEP-NEN subtypes and corresponding metastases (Table 5). Significant gain of Kissl </p><p id="p0504" num="0504"> (p&lt;0.005) was associated with metastasis in all tumor subtypes. </p><p id="p0505" num="0505">Table 5: ANOVA results across Small Intestinal Neuroendocrine Tumor subtypes and corresponding metastases. </p><p id="p0506" num="0506"> WDNET vs. WDNET WDNEC vs. WDNEC PDNEC vs. PDNEC 
<!-- EPO <DP n="107"/>-->
 
<img id="imgf000107_0001" he="52" wi="155" file="imgf000107_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0507" num="0507"> MET = Metastasis; FC = Fold Change; "p" = p value; NS = p≥ 0.05 </p><p id="p0508" num="0508"> [00390] Detected expression levels of MAGE-D2, NAPILI, and Kissl (as identified by FS) were analyzed in primary and corresponding metastatic WDNETs, using SVM to construct a classifier. To evaluate expression of biomarkers as compared to metastatic potential of primary tumors, samples were plotted in correlation with the selected gene expression levels and distribution densities were colorized to outline the separation of primary and metastatic samples (FIG. 6A). </p><p id="p0509" num="0509"> [00391] WDNETs and metastatic WDNET results scattered according to their respective gene pair expressions, with distribution densities based on the average Euclidean distance (difference in expression) between samples colorized blue (primary tumors) and red (metastases), green areas indicating a region of transition between primary and metastatic tumors). As shown, WDNETs and WDNET METs were predicted with 100% sensitivity and specificity. WDNET could be predicted to metastasize if transcript levels of 1) NAPILI &gt; -2.71 and Kissl &gt; -2.50; 2) NAPILI &gt; -3.82 and MAGE-D2 &gt; -4.42; 3) MAGE-D2 &gt; -3.21 and Kissl &gt; -2.12. </p><p id="p0510" num="0510"> [00392] A perceptron classifier (Markey MK et ah, "Perceptron error surface analysis: a case study in breast cancer diagnosis," Comput Biol Med 2002;32(2):99-109) of 0.05 was used to distinguish between localized tumors and the corresponding metastases. This methodology has been shown to effectively predict malignancy of breast cancer (Markey MK et ah, "Perceptron error surface analysis: a case study in breast cancer diagnosis" Comput Biol Med 2002;32(2):99- 109). A Perceptron classifier (using three data scans to generate the decision boundaries that explicitly separate data into classes, with a learning rate of 0.05) was used to predict metastases of WDNECs and PDNECs. </p><p id="p0511" num="0511"> [00393] The FS algorithm predicted that NAPILI and Kissl were highly expressed specifically in WDNEC METs and that CgA was highly expressed specifically in PDNEC METs. Metastatic potential of primary tumors was visualized by plotting expressions of 
<!-- EPO <DP n="108"/>-->
 featured genes and colorizing the distribution densities of primary tumors and their metastases. Data are presented in FIG. 6B and FIG. 6C, showing data from primary tumor subtypes and respective metastases scattered according to their respective gene pair expressions, with distribution densities based on the average Euclidean distance (difference in expression) between samples colorized blue (primary tumors) and red (metastases), and green areas indicating regions of transition between primary tumor subtypes and respective metastases. WDNECs were predicted to metastasize with values of NAPILI &gt; -5.28 and Kissl &gt; -2.83, while PDNECs could be predicted to metastasize when CgA &gt; -3.5. These results show distinct separation of primary SI GEP-NEN subtypes and the respective metastases, demonstrating the utility of the provided biomarkers as metastasis markers. </p><p id="p0512" num="0512">EXAMPLE 4B: Evaluating classification and predictive capabilities of the nine-biomarker panel </p><p id="p0513" num="0513"> [00394] To evaluate classification and predictive capabilities using the nine-biomarker panel, real-time PCR was performed on samples obtained from an independent set of SI GEP-NEN tissues (n=37), including normal EC cell preparations (n=17), localized SI GEP-NENs (w=8), and malignant SI GEP-NENs (n=12), to measure the marker gene transcript expression. All WDNETs were considered as "localized" while other tumor subtypes were considered </p><p id="p0514" num="0514">"malignant". Assessment of linearly correlated transcript pairs identified a pattern similar to the training set whereas MTA1:MAGE-D2, MTAl:Kissl, FZD7:NAP1L1, and Survivin:Ki-67 transcript pairs were highly correlated (R2&gt;0.50). The trained SVM model was applied to differentiate normal EC cell preparations from neoplasia with 76% accuracy. </p><p id="p0515" num="0515"> [00395] The results (shown in FIG. 7) indicated that in this study (using subsets of the nine- biomarker panel), normal EC cells were cross-validated with only 77% accuracy and predicted in an independent test set with 76% accuracy (p = 0.84). Localized GEP-NENs were cross- validated with only 78% accuracy and predicted with 63% accuracy in the test set (p = 0.25). Malignant GEP-NENs were cross-validated with only 83% accuracy and predicted with 83% accuracy in an independent set (p = 0.80). The Decision tree model could predict localized and malignant GEP-NENs with only 63% and 83% accuracy respectively (FIG. 7). The F-test statistic was computed to confirm that the classification results of the training and the independent sets were not significantly different. The p-values for normal, localized, and malignant subgroups were 0.84, 0.25, and 0.80 respectively. 
<!-- EPO <DP n="109"/>-->
 EXAMPLE 4C: Prediction and modeling using expression levels from the 21-biomarker panel </p><p id="p0516" num="0516"> [00396] A regularized discriminant analysis (RDA) algorithm was designed and applied to expression data for the twenty-one biomarker panel (MAGE-D2, MTA1, NAP1L1, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCK1, HOXC6, CTGF, PTPRN2, SCG5, and Tphl), described above. Gene selection for tissue classification was performed by computing the rank score (S) for each gene and for each class air as: 
<img id="imgf000109_0001" he="8" wi="26" file="imgf000109_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0517" num="0517">[00397] where μ<sub>€1</sub> and μ<sub>€2</sub> represent means of first and second class respectively and &lt;T<sub>C1</sub> and</p><p id="p0518" num="0518">C7<sub>C2</sub> are inter-class standard deviations. A large S value was indicative of a substantial differential expression ("Fold Change") and a low standard deviation ("transcript stability") within each class. Genes were sorted by a decreasing S-value and used as inputs for the RDA. </p><p id="p0519" num="0519"> [00398] RDA's regularization parameters, γ and λ were used to design an intermediate classifier between LDA (performed when γ=0 and ^Ι) and QDA (performed when γ=0 and λ^Ο) (Picon A, Gold LI, Wang J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor betal. Cancer Epidemiol Biomarkers Prev 1998;7(6):497-504). To reduce over-fitting, RDA parameters were selected to minimize cross-validation error while not being equal 0.0001, thus forcing RDA to produce a classifier between LDA, QDA, and L2 (Pima I, Aladjem M. Regularized discriminant analysis for face recognition. Pattern Recognition 2003;37(9): 1945-48). </p><p id="p0520" num="0520"> [00399] Regularization parameters were defined as γ = 0.002 and λ = 0. For each class pair, S-values were assigned to expression data for individual transcripts, which were then arranged by a decreasing S-value. RDA was performed 21 times, such that the N<sup>th</sup> iteration consisted of top N scoring transcripts. Error estimation was done by a 10-fold cross-validation of the RDA classifier, by partitioning the tissue data set into complementary subsets, performing the analysis on one subset (called the training set), and validating the analysis on the other subset (called the validation set or testing set). This operation was performed for all permutations of test- train sets and misclassification error was averaged to reduce variability in the overall predictive assessment. 
<!-- EPO <DP n="110"/>-->
 EXAMPLE 4D: Sensitive, accurate mathematical classification of unknown tissues and GEP-</p><p id="p0521" num="0521">NENs, differentiation of GEP-NEN sub-types and staging ofGEP-NENs using expression data from a twent -one-biomarker panel </p><p id="p0522" num="0522"> [00400] This RDA algorithm was applied to expression data obtained as described above for the panel of 21-biomarkers (MAGE-D2, MTAl, NAPILI, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCK1, HOXC6, CTGF, PTPRN2, SCG5, and Tphl). The algorithm was used to distinguish samples of unknown tissue types (ECs (normal enterochromaffin cells); "Normal" (normal small intestinal mucosa); </p><p id="p0523" num="0523">"Tumor" (aggregation of primary and metastatic GEP-NENs and carcinomas (NET/NEC)); and primary WDNET; WDNEC; PDNET; PDNEC), for mathematical classification of GEP-NENs, as follows. </p><p id="p0524" num="0524"> [00401] For each sample, it first was determined whether the tissue was normal or neoplastic. Tissues deemed neoplastic then were assessed to determine whether they were primary or metastatic. GEP-NEN subtypes (primary or metastatic) then were characterized. The RDA algorithm was applied in every step using the same set of learning parameters (γ=0.002 and λ^Ο). Performance of the classifier was measured by calculating misclassification rate (overall proportion of false -positives between any two classes). </p><p id="p0525" num="0525"> [00402] Results are shown in Tables 6A-C (listing misclassification rate versus numbers of gene (biomarker) transcripts detected, beginning with the highest ranked transcript for each distinction). </p><p id="p0526" num="0526">Table 6A: Misclassification Rates versus number of transcripts detected </p><p id="p0527" num="0527"> (normal vs. GEP-NEN; primary vs. Metastasis) </p><p id="p0528" num="0528"><img id="imgf000110_0001" he="48" wi="150" file="imgf000110_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/><!-- EPO <DP n="111"/>-->
 7 0.01 0.07 0.18 </p><p id="p0529" num="0529"> 8 0 0.09 0.14 </p><p id="p0530" num="0530"> 9 0 0.06 .14. </p><p id="p0531" num="0531"> 10 0 0.07 0.11 </p><p id="p0532" num="0532"> 11 0.01 0.05 0.12 </p><p id="p0533" num="0533"> 12 0.01 0.04 0.07 </p><p id="p0534" num="0534"> 13 0 0.03 0.08 </p><p id="p0535" num="0535"> 14 0.01 0.03 0.05 </p><p id="p0536" num="0536"> 15 0 0.02 0.03 </p><p id="p0537" num="0537"> 16 0 0.01 0.02 </p><p id="p0538" num="0538"> 17 0 0.01 0.02 </p><p id="p0539" num="0539"> 18 0 0.01 0 </p><p id="p0540" num="0540"> 19 0 0.01 0 </p><p id="p0541" num="0541"> 20 0 0 0.02 </p><p id="p0542" num="0542"> 21 0 0 0.02 </p><p id="p0543" num="0543">Table 6B: Misclassification rates versus number of transcripts detected (primary GEP-</p><p id="p0544" num="0544">NENs) </p><p id="p0545" num="0545"><img id="imgf000111_0001" he="121" wi="169" file="imgf000111_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/><!-- EPO <DP n="112"/>-->
 Number of </p><p id="p0546" num="0546"> Misclassification Rates </p><p id="p0547" num="0547"> Transcripts </p><p id="p0548" num="0548"> 20 0 0 0 0 0 </p><p id="p0549" num="0549"> 21 0 0 0 0 0 </p><p id="p0550" num="0550"> Table 6C: Misclassification rates versus number of transcripts detected (metastatic GEP-</p><p id="p0551" num="0551">NENs) </p><p id="p0552" num="0552"><img id="imgf000112_0001" he="135" wi="150" file="imgf000112_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0553" num="0553">[00403] As shown in Tables 6A-C, the methods and RDA algorithm was able to detect the presence, stage, and classification (sub-type), with zero misclassification rates across pair- wise iterations of normal EC cells, normal small intestinal mucosa, and GEP-NEN subtypes. </p><p id="p0554" num="0554"> [00404] As shown in Table 6A, the RDA algorithm distinguished normal EC cells from neoplastic tissue. Detection and analysis of expression levels of just the single highest ranked biomarker transcript (PNMA2) was able to make this distinction with a misclassification rate of 0.08; detection and analysis of the respective single highest ranked biomarker (CgA) was able to 
<!-- EPO <DP n="113"/>-->
 make the distinction between normal SI mucosa from neoplastic tissue with a misclassification rate of 0.21 (Table 6A). </p><p id="p0555" num="0555"> [00405] Applying the method to data for pluralities of biomarkers (detecting expression of levels of biomarker panels and applying the RDA algorithm to the data) was able to detect and distinguish GEP-NENs from normal samples with zero misclassification. Distinguishing EC cells from tumor tissue with a misclassification rate of zero was achieved using a panel of eight (8) biomarker transcripts. Distinguishing normal SI mucosa from tumor tissue with a misclassification rate of zero was achieved using a panel of twenty (20) biomarker transcripts (Table 7). In this study, misclassification rates were higher with fewer transcripts. These results demonstrate the biomarker specificity for different tissue groups and confirm the ability of the present methods to detect GEP-NEN disease and distinguish GEP-NEN tissue from different normal tissue types, with high specificity. </p><p id="p0556" num="0556"> [00406] Likewise, applying the RDA algorithm to expression levels of panels of biomarkers could determine with 100% accuracy whether an unknown tissue sample was primary or metastatic. For this determination, expression levels were detected for eighteen (18) biomarker transcripts and the data included in the RDA model (Table 7), with higher misclassification rates using fewer transcripts. Detecting expression of and applying the algorithm to only the highest ranked transcript (MAGE-D2) distinguished primary and metastatic samples with a 0.28 misclassification rate. (Table 6A). </p><p id="p0557" num="0557"> [00407] Primary GEP-NEN subtypes also could be differentiated with 100 % accuracy using the RDA algorithm. Misclassification rates when only the single highest ranked transcripts were detected ranged from 0.07 (PTPRN2, for distinguishing between PDNEC and WDNEC) to 0.37 (NRP2, for distinguishing between WDNEC and WDNET). Applying the RDA algorithm to expression levels of all 21 biomarker transcripts, the methods distinguished between WDNETs and WDNECs with a zero misclassification rate (Table 6B), with higher misclassification rates using fewer biomarkers. </p><p id="p0558" num="0558"> [00408] As shown in Table 6C the RDA algorithm also was used to distinguish with 100% accuracy between metastatic GEP-NEN subtypes. Misclassification rates with only the single highest ranked transcripts were 0.22 (CXCL14, for distinguishing between WDNET MET and WDNEC MET), 0.2 (NAP1L1, for distinguishing between PDNEC MET and WDNEC MET), and 0.17 (NRP2, for distinguishing between PDNEC MET and WDNET MET), respectively (Table 6C). 
<!-- EPO <DP n="114"/>-->
 [00409] </p><p id="p0559" num="0559"> Table 7. Misclassification rates with detection of various numbers of transcripts; achieving minimal misclassification; SVM, decision trees (DT), and multi-layer perceptron (MLP) classifiers. </p><p id="p0560" num="0560"><img id="imgf000114_0001" he="108" wi="170" file="imgf000114_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0561" num="0561"> "Normal" = normal small intestinal mucosa; </p><p id="p0562" num="0562"> "Tumor"= aggregation of primary and metastatic NETs and carcinomas (NET/NEC) </p><p id="p0563" num="0563">[00410] Table 8 summarizes the numbers of in NET biomarkers able to distinguish between indicated samples using the RDA algorithm in this example. In this example, all 21 biomarkers distinguished WDNEC from WDNET with zero misclassification (higher misclassification with fewer transcripts). By contrast, as few as two biomarkers could differentiate between PDNEC and WDNET (MAGE-D2, CXCL14), and between PDNEC and PDNET (PTPRN2, MTA1) with zero misclassification. In this example, 11 biomarkers distinguished normal enterochromaffin (EC) cells from normal SI mucosa with zero misclassification (PNMA2, CXCL14, PTPRN2, Tphl, FZD7, CTGF, X2BTB48, NKX2-3, SCG5, Kissl, SPOCKl, with a higher misclassification rate using fewer biomarkers). Fewer transcripts were able to distinguish normal EC cells from neoplastic tissue (w=8, PNMA2, Tphl, PTPRN2, SCG5, SPOCKl, X2BTB48, GRIA2, OR51E1). Expression of twenty of the biomarkers (with the exception of CXCL14) could differentiate 
<!-- EPO <DP n="115"/>-->
 normal SI mucosa from neoplastic tissue with zero misclassification (higher misclassification rates with fewer transcripts). </p><p id="p0564" num="0564">Table 8: Numbers of biomarker transcripts used for pairwise distinctions with zero classification rate by RDA </p><p id="p0565" num="0565"><img id="imgf000115_0001" he="104" wi="115" file="imgf000115_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0566" num="0566">[00411] Finally, SVM, decision trees (DT), and MLP classifiers were applied, as described above, using data for transcripts of the twenty-one biomarker panel, in a similar fashion as RDA. The performance of RDA was compared to performance of SVM, decision trees, and multi-layer perceptron (MLP), for classification of GEP-NEN subtypes by detecting expression of the twenty-one biomarker panel. All classifiers were subject to the training and cross-validation protocol outlined in Example 4A. Misclassification rates were calculated (Table 7). SVM was able to achieve a zero misclassification to distinguish PDNET from WDNEC. Decision trees distinguished with misclassification rates ranging from 0.03 (between EC and Tumor sample) to 0.33 (between WDNEC MET and WDNET MET, and between PDNEC MET and WDNET MET). Somewhat comparable to RDA, the MLP classifier produced zero misclassification rates with 7/13 iterations, with a high overall accuracy. The RDA approach was most reliable in this example with the 21 marker gene panel, achieving zero misclassification rates in all iterations. 
<!-- EPO <DP n="116"/>-->
 EXAMPLE 5: Detection of circulating GEP-NEN cells (CNC) and identification of biomarker transcripts (mRNA) from plasma </p><p id="p0567" num="0567"> [00412] Circulating GEP-NEN cells (CNCs) were detected in human blood using the provided methods and biomarkers. For this process, human blood samples (plasma, buffy coat, and whole blood) were obtained and subjected to staining, cell sorting, and real-time PCR (to detect GEP-NEN biomarkers and housekeeping genes). </p><p id="p0568" num="0568">EXAMPLE 5A: Sample preparation and RNA isolation from plasma, buffy coat, and whole blood </p><p id="p0569" num="0569"> [00413] In the following studies for detection of biomarkers in human plasma and buffy coat, human blood samples were obtained from a blood databank, with samples from healthy controls («=85) or patients («=195) who had been treated for GEP-NEN disease, at Yale New Haven Hospital, Uppsala or Berlin. See Kidd M, et ah, "CTGF, intestinal stellate cells and carcinoid fibrogenesis," World J Gastroenterol 2007;13(39):5208-16. Five mL of blood were collected in tubes containing ethylenediaminetetraacetic acid (EDTA). Plasma was separated from buffy coat following 2 spin cycles (5 min at 2,000rpm) and then stored at -80°C prior to nucleic acid isolation and/or hormone (CgA) analysis. </p><p id="p0570" num="0570">RNA isolation from various blood samples </p><p id="p0571" num="0571"> [00414] For isolation of RNA from buffy coat, samples were incubated with TRIZOL®, followed by RNA clean-up. RNA was dissolved in diethyl pyrocarbonate water and measured spectrophotometrically, and an aliquot analyzed on a Bioanalyzer (Agilent Technologies, Palo Alto, CA) to assess the quality of the RNA (Kidd M, et al. "The role of genetic markers— NAP1L1, MAGE-D2, and MTA1— in defining small-intestinal carcinoid neoplasia," Ann Surg Oncol 2006;13(2):253-62). </p><p id="p0572" num="0572"> [00415] For isolation of RNA from GEP-NEN patient and control plasma, the QIAamp RNA Blood Mini Kit was used (FIG. 11A), which in this study allowed real-time PCR detection of housekeeping genes in significantly more samples compared to the TRIZOL® approach (FIG. 11B) (8/15 versus 2/15, /?=0.05). For isolation of RNA directly from whole blood, the QIAamp RNA Blood Mini Kit was used, following the manufacturer's guidelines. 
<!-- EPO <DP n="117"/>-->
 Stability and reproducibility of samples </p><p id="p0573" num="0573"> [00416] The blood test is based on identifying the GEP-NEN molecular signature in 1ml of whole blood, collected in an EDTA-tube. It was determined that the gene signature is stable for up to four hours (refrigeration at 4-8°C, following phlebotomy) prior to freezing (FIG. 13). It is unaffected by fasting/feeding. Analysis of inter-assay reproducibility (same samples processed on separate days) ranged from 98.8-99.6% while intra-assay reproducibility was 99.1-99.6%. </p><p id="p0574" num="0574"> [00417] These studies identify that the gene signature is highly reproducible (-99%), is stable for up to four hours in refrigeration (prior to freezing) and is unaffected by fasting/feeding. </p><p id="p0575" num="0575">Real-time PCR </p><p id="p0576" num="0576"> [00418] Total RNA obtained from plasma, buffy coat, and whole blood as described above was subjected to reverse transcription with the High Capacity cDNA Archive Kit (Applied Biosystems (ABI), Foster City, CA) following the manufacturer's suggested protocol. Briefly, 2 micrograms of total RNA in 50 microliters of water was mixed with 50 uL of 2XRT mix containing Reverse Transcription Buffer, deoxynucleotide triphosphate solution, random primers, and Multiscribe Reverse Transcriptase. The RT reaction was performed in a thermal cycler for 10 mins at 25°C followed by 120 mins at 37°C, as described by Kidd M, et ah, "The role of genetic markers— NAP 1 LI, MAGE-D2, and MTA1— in defining small-intestinal carcinoid neoplasia," Ann Surg Oncol 2006;13(2):253-62. Transcript levels of the marker genes were measured using Assays-on-Demand™ products and the ABI 7900 Sequence Detection System according to the manufacturer's suggestions {see Kidd M, Eick G, Shapiro MD, et al. </p><p id="p0577" num="0577">Micro satellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005;103(2):229-36). </p><p id="p0578" num="0578"> [00419] Cycling was performed under standard conditions, using the TaqMan® Universal PCR Master Mix Protocol. Briefly, complementary DNA in 7.2 uL of water was mixed with 0.8 uL of 20· Assays-on-Demand primer and probe mix and 8 uL of 2X TaqMan Universal Master mix in a 384-well optical reaction plate. The following PCR conditions were used: 50°C for 2 mins and then 95°C for 10 mins, followed by 50 cycles at 95°C for 15 mins and 60° for 1 min, as described by Kidd M, et al, "The role of genetic markers-NAPlLl, MAGE-D2, and MTA1- -in defining small-intestinal carcinoid neoplasia," Ann Surg Oncol 2006;13(2):253-62. Raw AC<sub>T</sub> (delta C<sub>T</sub> = change in cycle time as a function of amplification) normalized using geNorm {see 
<!-- EPO <DP n="118"/>-->
 Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol </p><p id="p0579" num="0579">2002;3(7):RESEARCH0034), and expression of the house-keeping genes ALG9, TFCP2 and ZNF410. See Kidd M, et ah, "GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR," Physiol Genomics 2007;30(3):363-70. Normalized data were natural log (ln)-transformed for compression. ALG-9 was used as the housekeeping gene, its expression detected and used to normalize GEP-NEN biomarker expression data. </p><p id="p0580" num="0580"> [00420] For statistical analysis, all computations were carried out using R 2.9 language for statistical computing. See R Development Core Team. R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing, 2008. GraphPad (Prizm 4) and SPSS 16.0 were used for all statistical analyses, by receiver- operator characteristic (ROC) curves, Fisher's exact test and/or ANOVA, using 2-tailed tests, with /?&lt;0.05, considered significant. </p><p id="p0581" num="0581">EXAMPLE 5B: Detection of housekeeping genes and detection in whole blood </p><p id="p0582" num="0582"> [00421] Transcript expression levels of three (3) housekeeping genes (ALG9, TFCP2 and ZNF410) were determined in mRNA isolated using the TRIZOL® approach, described above, from buffy coat from five healthy donors. All three genes were detected with AC<sub>T</sub> levels between 30 and 35. Sequences and information for exemplary primer pairs are listed in Tables 1A and IB. </p><p id="p0583" num="0583"> [00422] Transcript expression levels of the same 3 housekeeping genes and 11 GEP-NEN biomarker genes were evaluated in mRNA prepared from whole blood from 3 healthy donors (normal samples). For this process, mRNA was isolated, cDNA synthesized, and PCR performed by different people on different days, on separate plates, using independently- prepared reagents, made on different days. Detected gene expression levels across samples were highly correlated (FIG. 11C; R&gt;0.99, p&lt;0.0001). </p><p id="p0584" num="0584"> [00423] Expression of 5 housekeeping genes (18S, ALG9, GAPDH, TFCP2 and ZNF410) was detected by real-time PCR on mRNA isolated using TRIZOL®, from whole blood samples, from 5 healthy donors. Primer pairs are listed in Tables 1A and IB. In this study, ALG9 expression was the least variable between samples (coefficient of variation = 1.6%) (FIG. 13A). ALG9 transcript levels were determined by real-time PCR on RNA isolated from whole blood 
<!-- EPO <DP n="119"/>-->
 from five healthy control patients, before and at thirty-minute intervals after feeding. The results showed that expression levels of ALG9 were not significantly altered up to 4 hours </p><p id="p0585" num="0585">postprandially (as determined by nANOVA: /?&gt;0.05) (FIG. 13B). These results demonstrate that detection of gene products according to the provided methods produces consistent results and is useful for comparison of data from patient samples acquired and prepared on different days by distinct investigators. </p><p id="p0586" num="0586">Delineation of A House-Keeping Gene </p><p id="p0587" num="0587"> [00424] To identify the most useful house-keeping genes for normalization, a panel (n=l9) of candidate markers was examined that comprised those identified from GEP-NEN tissue (n=9), and those through screening of the GEP-NEN blood transcriptomes (n=!0). In order to select "house-keeper" markers, a number of criteria were used including: topological importance when mapped to the blood interactome (7,000 genes, 50,000 interactions)_ENREF_3, stability (M- value) following real-time PCR, and efficiency of transcription in the blood. In addition, the presence of efficiencies between the target genes and the house-keeping gene were examined. Such a correlation supports a relative quantitation-based algorithm for calculation. The 19 genes included in the analysis were tissue-derived: 18S, GAPDH, ALG9, SLC25A3, VAPA, TXNIP, ADD3, DAZAP2, ACTG1, and blood microarray-derived: ACTB, ACTG4B, ARF1, HUWE1, MORF4L1 RHOA, SERP1, SKP1, TPT1, and TOX4. Targets that were considered appropriate house-keepers exhibited &gt;3 characteristics. </p><p id="p0588" num="0588">Topological importance in blood microarray </p><p id="p0589" num="0589"> [00425] Three topological features were examined: "Degree" = number of connections in each gene; "Betweenness" = importance of a gene in signal transduction, and "Clustering" = clustering coefficient or the extent to which a gene's neighbors are interconnected. A high "degree" indicates many connections per gene, a high "betweenness" indicates a more critical role in the information flow within the interactome while a "high" clustering coefficient means that more of a gene's neighbors are connected to each other. The most appropriate gene would have low values for Degree, Betweeness and Clustering. Genes that fulfill all these </p><p id="p0590" num="0590">characteristics include ACTB, TOX4, TPT1 and TXNIP (FIG. 14A-C). The order of genes is: 
<!-- EPO <DP n="120"/>-->
 [00426] TXNIP=ACTB=T0X4=TPT1&gt;ALG9=ARF1&gt;GAPDH&gt;DAZAP2&gt;VAPA=ATG4B= HUWE1=M0RF4L1=RH0A=SERP1&gt;ADD3. </p><p id="p0591" num="0591">Variability (Coefficient of variation and M-value) </p><p id="p0592" num="0592"> [00427] Two approaches were used to assess variation in house-keeping gene expression, firstly variability and secondly robustness (the "M" value) measured by geNorm. Raw CT values were examined for variation (FIG. 15) and whether expression passed the D'Agostino and Pearson normality test (Table 9). </p><p id="p0593" num="0593">Table 9. Candidate House-keeping genes and normality of expression </p><p id="p0594" num="0594"><img id="imgf000120_0001" he="48" wi="159" file="imgf000120_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0595" num="0595"> CV = coefficient of variation, DP = D'Agostino and Pearson omnibus normality test. N = not normally distributed, Y = passed the normality test. </p><p id="p0596" num="0596">[00428] Variability analysis identified that ALG9, ARF1, ATG4B, RHDA and SKP1 were the least variable genes. Genes selected by geNorm as showing the least variation between samples (and hence the greatest stability or robust expression) are indicated in FIG. 16. The "M"-value is a measure of gene stability and defined as the average pair-wise variation of a particular gene with all other potential reference genes. The most stable genes included: ALG9, ACTB, ARF1, ATG4B, HUWE4, MORF4L1, RHDA, SKP1, TPT1 and TOX4. </p><p id="p0597" num="0597">PCR efficiency </p><p id="p0598" num="0598"> [00429] PCR efficiency was examined to evaluate which candidate house -keeping genes fulfilled adequate amplification criteria. This was undertaken in two independent samples using a standard curve (dilution: 2000 - O.Olng/ul). The PCR efficiency was calculated using the Fink equation: 
<!-- EPO <DP n="121"/>-->
 Efficiency = 10<sup>A</sup>(-l/slope) - 1 </p><p id="p0599" num="0599"> [00430] Analysis identified that 18S and ALG9 were the most efficiently transcribed tissue- derived genes while TPT1 was the most efficiently transcribed blood-derived candidate housekeeping gene (FIG. 17). </p><p id="p0600" num="0600">Efficacy of amplification compared to target genes </p><p id="p0601" num="0601"> [00431] Finally, the amplification kinetics of the target and reference genes were examined for similarities. This is a necessary pre-requisite for any appropriate PCR amplification protocol otherwise a correction factor is required in quantitation algorithms to deal with over-estimated expression calculations. It is also important for any comparative C<sub>T</sub> method e.g., AAC<sub>T</sub> </p><p id="p0602" num="0602">particularly as estimations from raw data are more accurate than from standard curves. </p><p id="p0603" num="0603"> [00432] In general, a house-keeping gene is considered appropriate if the difference in C<sub>T</sub> for the target-reference gene across a series of dilutions is &lt;0.1. One house-keeping gene identified that shared similar PCR efficacies with target genes was ALG9 (FIG. 18). </p><p id="p0604" num="0604"> [00433] None of the blood-microarray derived candidate house-keeping genes exhibited the appropriate features necessary to act as a house-keeping gene. ALG9, the tissue-derived candidate house-keeping gene, in contrast, exhibited low variability (M-value and DP test), appropriate topological features, was efficiently transcribed and shared similar amplification features with the target genes of interest. This gene was therefore selected as an appropriate house-keeping gene to normalize circulating tumor transcripts. </p><p id="p0605" num="0605">Target Normalization </p><p id="p0606" num="0606"> [00434] There are a two major methods for normalizing target gene expression: absolute and relative quantitation. The former requires a standard curve (and therefore uses up plate space), is more labor-intensive and is less accurate than protocols based on raw C<sub>T</sub> values. This study focused on relative quantitation approaches. A number of algorithms have been developed for relative quantification including the Gentle model, the Pfaffl model, models based on amplification plots, Q-Gene and geNorm. The majority of methods include mechanisms to estimate for differences in PCR efficiencies, use multiple house-keepers e.g., geNorm, or can only be commercially acquired (e.g., qBase<sup>PLUS</sup> from Biogazelle). One method that is easy to use and does not require estimation factors is the AAC<sub>T</sub> protocol. This is a mathematical model that 
<!-- EPO <DP n="122"/>-->
 calculates changes in gene expression as a relative fold difference between an experimental and calibrator sample. It is dependent on similar amplification efficiencies for the house-keeper and target genes (a feature identified for ALG9), requires the amplification of small PCR products (&lt;150bprs - a feature of Applied Biosystems Taqman), and a PCR method that has been optimized (e.g., starting concentration of target has been established). The AAC<sub>T</sub> approach was selected for normalization of the 51 candidate genes in peripheral blood. The utility of this approach was demonstrated when this method (AAC<sub>T</sub> normalization with ALG9) was compared to geNorm (normalization with 18S, ALG9 and GAPDH) (FIG. 19). </p><p id="p0607" num="0607"> [00435] The variation in target gene expression was significantly lower in control samples using a AAC<sub>T</sub> protocol (p&lt;0.004 vs. geNorm) while the majority of targets exhibited a normal distribution (62% versus 0%, D'Agostino and Pearson omnibus normality test) following normalization with ALG9. A AAC<sub>T</sub> protocol (with ALG9) has been shown to successfully normalize target expression in GEP-NEN tumor tissue. A AAC<sub>T</sub> approach using ALG9 as a house-keeping gene was identified to be the most appropriate normalization protocol for the 51 candidate GEP-NEN marker genes. Accordingly, this approach was selected to profile transcript expression in blood samples. </p><p id="p0608" num="0608">Identification of Candidate Tumor Marker Genes </p><p id="p0609" num="0609"> [00436] To identify potential marker genes, both tissue- and blood-based tissue microarrays were from GEP-NEN samples as resources to detect candidate marker genes. Gene selection was optimized by applying and developing a number of biomathematical algorithms. </p><p id="p0610" num="0610"> [00437] Initially, GEP-NEN (obtained from the small intestine) transcriptomes were analyzed and compared this to normal small intestinal mucosa (U133A chips, n=&amp; tumors and n=4 controls). Using dCHIP (lower bound fold change &gt;1.2-fold, unpaired t-test, and hierarchical clustering based on Pearson correlation) 1,451 up-regulated genes in tumor samples were identified. Thirty-two candidate markers were chosen based on level of up-regulation (&gt;3-fold, e.g., NAPILI), known biological processes (proliferation e.g., Ki67; survival e.g., survivin), and clinical significance (e.g., somatostatin receptor expression, CgA). In a separate study, PCR- based expression in tumor tissue of nine of these candidate markers were confirmed as predictive of GEP-NEN malignancy. In the current study, the 32 candidate genes were examined further and 17 were included in the final gene panel. 
<!-- EPO <DP n="123"/>-->
 [00438] As a second strategy, two microarray data sets of tumor tissue (HUGE and U133A, a total of «=30 tumors and «=10 controls) were utilized, and compared GEP-NENs (obtained from small intestinal sites) to other tumors (breast, colon, prostate and liver cancers) from publicly available databases. Small bowel material from Crohn's disease, which is known to perturb local neuroendocrine cell activity and is associated with SI-NEN risk, was also assessed to further delineate the overall GEP-NEN gene landscape and help identify candidate markers. In order to assess the relationships of the genes involved, a graphic theoretical analysis of gene co- expression networks was constructed. This approach determined that the "GEP-NEN" gene network (generated by integrating the two platforms, U133A and HUGE) consisted of 6,244 genes and 46,948 links. The gene network was highly modular (i.e. genes tended to organize into interconnected communities) and therefore contained genes that were functionally related (as they occurred within the same community). An unbiased community detection algorithm identified 20 communities (collections of related genes) with &gt;20 genes each. Enrichment of each gene community for biological processes identified terms including Oxidation reduction' {Cluster 1/2), 'Immune response' (Cluster 5), and 'Cell cycle' (Cluster 18). Of importance was identification that the GEP-NEN gene network was topologically distinct from other common cancers (but shared similarity) to Crohn's disease (FIG. 20A). The latter may reflect the known proliferation of neuroendocrine cells in Crohn's disease. </p><p id="p0611" num="0611"> [00439] The topological distinction reflected unique connectivity patterns around each gene in the interactome providing information that a panel of genes or gene-interactions may be specific to the tumor (GEP-NEN). Such a tumor- specific signature was generated by eliminating gene- gene interactions found in breast, colon, prostate, and liver cancer gene networks from the GEP- NEN gene network. The resulting GEP-NEN- specific signature yielded 124 genes and 150 interactions (FIG. 20B). </p><p id="p0612" num="0612"> [00440] Mapping these 124 GEP-NEN- specific genes back to the U133A tissue-based microarray identified that 41 genes were differentially expressed, of which 21 were up-regulated (FIG. 20C) and could differentiate between GEP-NENs and controls (FIG. 20D). These 21 up- regulated genes were examined further, and 12 were included in the final gene panel. </p><p id="p0613" num="0613"> [00441] As a third strategy, circulating GEP-NEN transcriptomes were examined to identify additional candidate markers. For these studies, peripheral blood transcriptomes (n=l controls, n=l GEP-NENs) were compared to the "In-house" tissue array (n=3 controls, n=9 GEP-NENs [from the small intestine]) and one published array from the ArrayExpress database (accession 
<!-- EPO <DP n="124"/>-->
 number: E-TABM-389: n=6 controls, n=3 primary midgut NENs, and n=3 GEP-NEN </p><p id="p0614" num="0614">metastases [METs]). </p><p id="p0615" num="0615"> [00442] Tumor samples were clearly differentiated from controls (FIG. 21 A- C) and differentially expressed genes were identified for each of the groups: Blood (n=2,354), "In- house" (w=l,976) and Public datasets (w=4,353) (FIG. 21D-F). </p><p id="p0616" num="0616"> [00443] As expected, there was a large correlation between changes in gene expression for the "In-house" and Public tissue datasets (R=0.59, FIG. 22A). While the correlation between the Blood and "In-house" and Public datasets was low (R=-0.11 and -0.05, respectively) (FIG. 22A,B), 157 (33%) of the 483 significantly changed genes ("In-house'7blood) and 423 (45%) of the 947 significantly changed genes (Public/blood), were positively correlated. </p><p id="p0617" num="0617"> [00444] Overall, between the Blood, "In-house", and Public datasets, 85 genes were correlated in blood and tissue, while 196 were inversely or anti-correlated (FIG. 23A). The correlated genes encoded processes such as intracellular signaling, cell death, and regulation of transcription (FIG. 23B) while the anti-correlated genes encoded processes such as telomere maintenance, neural tube development, and protein complex assembly (FIG. 23C). </p><p id="p0618" num="0618"> [00445] Thirty-nine of the 85 (46%) concordantly expressed genes in both blood and tissue were up-regulated and 46 transcripts are down-regulated. An analysis of the up-regulated genes identified that 22 had 0-3 paralogs and were expressed at levels &gt;3-fold. Integration of these genes with the blood interactome confirmed that they were highly inter-connected (more central in the interactome), demonstrating their "putative" biological relevance in the context of GEP- NENs (FIG. 24). </p><p id="p0619" num="0619"> [00446] These approaches, including analysis and integration of tumor tissue and circulating peripheral blood transcripts, enabled identification of a panel of 75 candidate marker genes associated with GEP-NENs. The utility of these genes to identify GEP-NENs was then studied in peripheral blood samples. </p><p id="p0620" num="0620">The Circulating GEP-NEN Fingerprint (51 Marker Gene Panel) </p><p id="p0621" num="0621"> [00447] In order to develop a useable marker panel, transcript levels of each of the 75 candidate markers in mRNA isolated from 77 blood samples (controls: «=49; GEP-NENs: w=28) were measured. A 2-step protocol (RNA isolation, cDNA production and PCR) was developed as this is more accurate than 1-step protocols. The reproducibility of 2-step protocols is high 
<!-- EPO <DP n="125"/>-->
 (Pearson's correlation &gt;0.97; for the 2-step approach, the correlation is 0.987-0.996). In preliminary studies, the preferred method for mRNA isolation from blood samples was the mini blood kit (Qiagen: RNA quality &gt;1.8 A<sub>2</sub>60:28o ratio, RIN&gt;5.0, appropriate for PCR applications</p><p id="p0622" num="0622">37 ) with cDNA produced using the High Capacity Reverse transcriptase kit (Applied Biosystems: cDNA production 2000-2500ng/ul). Real-time PCR was consistently performed with 200ng/ul of cDNA on a HT-7900 machine using 384-well plates and 16ul of reagents/well (Fast Universal PCR master mix, Applied Biosystems). The limit of detection for PCR was determined as 40 cycles (200ng/ul cDNA positively amplified in 95.3+0.2% of cases). Increasing the number of cycles to 45-50 cycles identified positive expression in &lt;1% of target samples; the false negative rate was calculated using a C<sub>T</sub> cut-off of 40 to be 0.8%. This cycle number is more stringent than the accepted European approach for leukemia detection, but is consistent with other PCR-based detection protocols. Primers were exon spanning to minimize genomic DNA amplification and were &lt;150bprs. Commercially available Applied Biosystems primers (5 '-nuclease assay) were used. The consistent parameters for RNA isolation, cDNA synthesis and real-time PCR provide a stable platform for target and house-keeping gene analysis. </p><p id="p0623" num="0623"> [00448] 51 of the 75 candidate markers were as identified as producing detectable product (C<sub>T</sub> &lt; 40 cycles) in blood. This 51 gene panel included: AKAP8L, APLP2, ARAF1, ATP6V1H, BNIP3L, BRAF, C21orf7, CD59, COMMD9, CTGF, ENPP4, FAM13A, FLJ10357, FZD7, GLT8D1, HDAC9, HSF2, Ki67, KRAS, LEOl, MORF4L2, NAP1L1, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PNMA2, PQBP1, RAF1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SST1, SST3, SST4, SST5, TECPR2, TPH1, TRMT112, VMAT1, VMAT2, VPS13C, WDFY3, ZFHX3, ZXDC, ZZZ3. Thirteen of these 51 marker genes have previously been associated with GEP-NENs, either of the previous studies, or in those of others. </p><p id="p0624" num="0624"> [00449] Having defined a potentially useful marker gene panel, the GEP-NEN transcriptomic resources were examined to identify preferred house-keeping genes and determine preferred methods for normalization of the data. Identifying appropriate house-keeping genes and applying normalization protocols would facilitate quantification of each of the 51 candidate transcripts and determine whether they represented a panel of GEP-NEN marker genes. 
<!-- EPO <DP n="126"/>-->
 EXAMPLE 5C: Detection of circulating GEP-NEN cells and biomarker expression in whole blood </p><p id="p0625" num="0625"> [00450] Using real-time PCR, flow cytometry, and florescence-activated cell sorting (FACS)- sorting, CD 164 was identified as a marker capable of detecting circulating GEP-NEN cells in whole blood. Detection of CD 164 transcript expression levels by real-time PCR demonstrated that this biomarker is consistently overexpressed (300-10,000 x) in GEP-NEN patient samples (29/29 GEP-NEN cells and 4 GEP-NEN cell lines) compared to normal EC cells and leukocytes, demonstrating CD 164 is useful as a biomarker for identification of GEP-NEN cells in human samples, e.g., whole blood. </p><p id="p0626" num="0626"> [00451] Multi-parameter flow cytometry was performed on whole blood samples obtained from 10 GEP-NEN patients and 10 age- and sex- matched controls. A population of GEP-NEN cell-sized cells (FIG. 25A), which was double-positive for acridine orange (AO)-PE-CY7 and CD164-APC was detected in GEP-NEN samples, but absent in normal control samples (FIG. 25B). Collection and immuno staining of these cells for TPH expression confirmed they were serotonin-positive GEP-NEN cells (FIG. 25C, inset). </p><p id="p0627" num="0627"> [00452] After dual labeling with AO and CD164, 3-12 GEP-NEN cells, per mL of blood, were sorted by FACS and collected. Real-time PCR identified elevated (&gt;2-fold, /?&lt;0.03) expression levels of the 21 GEP-NEN biomarkers described above (MAGE-D2, MTAl, NAP 1 LI, Ki67, Survivin, FZD7, Kissl, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, PNMA2, SPOCK1, HOXC6, CTGF, PTPRN2, SCG5, and Tphl), normalized to house-keeping genes compared to normal whole blood samples, confirming that these cells were GEP-NEN tumor cells. Significantly higher expression levels (3-5 fold, /?&lt;0.05) were identified in samples obtained from six patients with metastatic disease, as compared to four patients with local disease. </p><p id="p0628" num="0628"> [00453] Expression of a thirteen GEP-NEN biomarker panel was detected by real-time PCR on RNA prepared directly from whole blood obtained from 12 patients. For comparison, PCR was performed in parallel on RNA purified from FACS-purified circulating blood GEP-NEN cells (as described above), and tumor mucosa from 12 patients from same study. The expression levels of the biomarker transcripts detected in whole blood were highly correlated with levels detected in purified circulating GEP-NEN cells (R<sup>2</sup>=0.6, /?&lt;0.0001) (FIG. 26A) and in tumor tissue (R<sup>2</sup>=0.81, /?&lt;0.0001) (FIG. 26B). 
<!-- EPO <DP n="127"/>-->
 [00454] These results confirm that circulating GEP-NEN cells (CNCs) exist in blood and can be detected by PCR using RNA prepared from whole blood and other blood samples for the detection, staging, prognosis and prediction with the methods and compositions provided herein. </p><p id="p0629" num="0629">EXAMPLE 5D: Detection of GEP-NEN biomarker expression and statistical analysis using whole blood samples </p><p id="p0630" num="0630"> [00455] Expression levels of individual biomarker transcripts (VMAT2, NAP 1 LI, and </p><p id="p0631" num="0631">PNMA2), as well as the summed expression levels of a panel of thirteen (13) GEP-NEN biomarkers (APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT2) were determined by real-time PCR as described above, on whole blood samples from 3 groups of human samples obtained from: 1) a training group from Yale New Haven Hospital, including 55 GEP-NEN patients (all comers, including patients with high level disease as well as those considered disease-free) and 47 control patients, 2) an independent test group from Berlin («=144 («=120 patients, n=24 controls)) and 3) an independent test group from Uppsala (n=34 («=20 patients; n=l4 controls))), respectively. The primer pair sequences and other information about primers are listed in Tables 1A and IB. </p><p id="p0632" num="0632"> [00456] To facilitate representation, detected expression levels of the 13 biomarker transcripts were vectorally summed (&gt;+l=∑ over-expressed genes; &gt;-l=∑ genes whose expression is decreased) and plotted. </p><p id="p0633" num="0633"> [00457] An ROC curve strategy was employed for identification of GEP-NENs, in group (1) samples. Results demonstrated areas under the curve (AUCs) for the three individual biomarker transcripts ranging from 0.66 to 0.90 (0.92 for summed transcripts (VI: /?&lt;0.0001)) in GEP-NEN patient samples (FIG. 27, showing ROCs for each). The sensitivity, specificity, positive predictive value and negative predictive value for determining GEP-NEN disease using the summed transcript expression levels were 96.1%; 90.2%; 83.3%, and 97.9%, respectively. Use of predicted cutoffs was tested in the two independent test sets (2) and (3). The sensitivities and specificities for VI ranged from 95-97% and 81-87%. It was also observed that gender was not associated with transcript expression (Mann Whitney score = 0.11, /?=0.19) levels detected in blood. Storage at -80°C had no significant effect on the transcript expression levels of the detected 13 biomarkers (R=0.987-0.996, /?&lt;0.0001). 
<!-- EPO <DP n="128"/>-->
 [00458] Housekeeping and summed GEP-NEN biomarker transcript expression levels were detected in 29 control and patient samples (Yale and Berlin), assayed on separate days in two separate PCR runs. Expression of the ALG9 housekeeping gene and the FZD7 GEP-NEN marker were each highly correlated when assayed on separate days: R : 0.92-0.97, p&lt;0.0001 in two separate runs (FIG. 28A-B) and no significant differences were noted between normalized FZD7 in controls and tumor samples on separate days (FIG. 28C-D). Intra- and inter-assay reproducibility was high for FDZ7 (C.V. = 2.28-3.95%) demonstrating that blood measurements of target genes are highly reproducible. The results demonstrate intra- and inter-assay </p><p id="p0634" num="0634">reproducibility for housekeeping and GEP-NEN biomarker detection using real-time PCR on RNA obtained from whole blood. </p><p id="p0635" num="0635"> [00459] These data demonstrated that detection of GEP-NEN biomarker transcript expression levels in whole blood can be used to identify circulating GEP-NEN cells (CNCs), that the detected expression levels in whole blood correlate well with tissue expression levels and can identify GEP-NEN patients with high sensitivity and specificity, and with high reproducibility. </p><p id="p0636" num="0636">EXAMPLE 5E: Detection of lesions and treatment response </p><p id="p0637" num="0637">[00460] To evaluate the utility of the 51 marker gene panel both as a technique as a circulating GEP-NEN signature to detect these lesions as well as treatment response, a test set of 130 samples (controls: «=67, GEP-NENs: «=63 [untreated disease, «=28, treated, «=35]) was established. PCR was performed on all markers, and values normalized to ALG9 (AACT), using the control group as the population control (calibrator sample). The work- flow for identifying the utility of the marker panel included normalization (ANOVA identified 39 of 51 genes to be differentially expressed in all 3 sets) and the support-machine bases mathematical assessments of gene expression. </p><p id="p0638" num="0638"> [00461] Using the four algorithms, an average 88% correct call rate was determined (FIG. 29), while the performance metrics are included in Table 10. The data of the molecular test for differentiating normal samples from GEP-NENs (both treated and untreated) are as follows: overall sensitivity (94.0%), specificity (85.7%), positive predictive value (PPV) (87.5%) and negative predictive value (NPV) (93.1%). </p><p id="p0639" num="0639">Table 10. Performance evaluation of distinguishing normal samples from GEP-NENs. </p><p id="p0640" num="0640"> Normal (True) | GEP-NENs 
<!-- EPO <DP n="129"/>-->
 (True) </p><p id="p0641" num="0641"> Normal (Predicted) 63 9 </p><p id="p0642" num="0642"> GEP-NENs (Predicted) 4 54 </p><p id="p0643" num="0643">[00462] Using the same gene panel, it was determined that treated and un-treated GEP-NENs could be distinguished with the following performance metrics (Table 11): Sensitivity = 85.7%, Specificity = 85.7%, PPV = 88.2% and NPV = 82.8%. </p><p id="p0644" num="0644">Table 11. Performance evaluation of distinguishing Treated from Untreated GEP-NEN s. </p><p id="p0645" num="0645"><img id="imgf000129_0001" he="31" wi="142" file="imgf000129_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0646" num="0646">[00463] For overall performance as a test to differentiate NENs from controls, the call rate was 94%, while the ability to identify treated samples was 85%. </p><p id="p0647" num="0647"> [00464] These results indicate that pattern recognition protocols which enable analysis of expression of 51 candidate markers (as a group) have utility for differentiating between </p><p id="p0648" num="0648">"normal" or "GEP-NENs". This confirmed that approaches e.g., SVM used in tumor tissue, are applicable to peripheral blood transcript analysis and identification of neuroendocrine tumor disease. </p><p id="p0649" num="0649">EXAMPLE 5F: Evaluation of the Molecular Fingerprint as a Predictor of GEP-NENs </p><p id="p0650" num="0650"> [00465] The efficacy of this 51 marker gene panel as a potential test was examined in four independent datasets to establish whether it could correctly identify GEP-NENs versus controls. Four independent sets were constructed: Independent set 1 included 35 GEP-NENs and 36 controls; Independent set 2 included 33 GEP-NENs and 31 controls; Independent set 3 included 47 GEP-NENs and 24 controls; and Independent set 4 included 89 GEP-NENs and no controls. </p><p id="p0651" num="0651"> [00466] The four algorithms were assessed: SVM, LDA, KNN and Bayes for utility in determining whether a blood sample was a GEP-NEN or a control in each of the independent sets. Tabulated results identified that overall correct call rates (identifying both GEP-NENs and 
<!-- EPO <DP n="130"/>-->
 controls correctly) ranged from 56-68% in independent set 1, 53-78% in set 2, 82-92% in set 3 and 48-74% in set 4 (Table 12). The average rates over all sets were 67-69% for SVM, LDA and Bayes; KNN scored higher: 73%. </p><p id="p0652" num="0652">Table 12. Overall call rates (percentage) for each of the algorithms in each of the independent sets </p><p id="p0653" num="0653"><img id="imgf000130_0001" he="32" wi="118" file="imgf000130_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0654" num="0654">[00467] Further analysis of the calls identified whether the correct call rates corresponded to identifying controls or tumor samples (Table 13). Most consistent correct calls for controls were the SVM (90% overall) and LDA (91%) algorithms. The highest correct call rates for GEP- NENs were identified with the Bayes algorithm (85%). </p><p id="p0655" num="0655">Table 13. Call rates (percentage) for each of the groups, control or GEP-NENs, in each of the independent sets </p><p id="p0656" num="0656"><img id="imgf000130_0002" he="42" wi="157" file="imgf000130_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0657" num="0657"> NA = not applicable (no controls included in this set) </p><p id="p0658" num="0658">[00468] Sensitivities, specificities, positive predictive values and negative predictive values calculated for each of the algorithms in the 3 independent sets are included in Table 14. </p><p id="p0659" num="0659">Table 14. Performance metrics for each of the algorithms in each of the independent sets 
<img id="imgf000130_0003" he="22" wi="163" file="imgf000130_0003.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 
<!-- EPO <DP n="131"/>-->
 Set 70 87 85 73 76 77 78 75 81 58 68 75 100 3 52 100 2 </p><p id="p0660" num="0660"> Set 85 100 100 77 87 100 100 80 83 100 100 75 79 88 93 68 3 </p><p id="p0661" num="0661"> A= sensitivity, B= specificity, expositive predictive value, D-negative predictive value. Set 4 had no controls. </p><p id="p0662" num="0662">[00469] The Bayes algorithm performed best for detecting GEP-NENs (sensitivity = 83%), while the SVM algorithm performed best for determining controls (specificity = 96%). The weakness of Bayes is a high false-positive; the weakness of SVM is that it does not perform adequately in sample sets that exhibit a majority of well-treated (complete remission/stable disease) samples. </p><p id="p0663" num="0663"> [00470] For overall performance as a test to differentiate NENs from controls, algorithms SVM, LDA and KNN had positive predictive values of -90% and negative predictive values of 70%. </p><p id="p0664" num="0664">EXAMPLE 5G: 51 marker gene panel for GEP-NEN Identification </p><p id="p0665" num="0665"> [00471] To confirm that the 51 marker gene panel was effective, correct call rates for the panel were compared in each of the independent sets (Table 12) and compared this with a 13 marker and 25 marker subsets. The 13 marker subset was limited to genes confirmed as predictive of GEP-NEN malignancy in tissue; the 25 marker panel included these genes as well as an additional 12 GEP-NEN specific genes identified in FIG. 20D. Examining correct calls in each of the 4 independent sets identified that the 51 marker panel performed significantly better than either the 13 or 25 marker panel (FIG. 30). </p><p id="p0666" num="0666"> [00472] These results indicate that a number of pattern recognition protocols based on the 51 candidate marker genes can distinguish between control samples and GEP-NENs with high efficiency and sensitivity. </p><p id="p0667" num="0667">Example 5H: Detection of GEP-NEN-biomarker expression levels in whole blood, for evaluation of therapeutic responsiveness and prediction of metastases (comparison to CgA) </p><p id="p0668" num="0668"> [00473] Detection of summed GEP-NEN biomarker transcript expression levels (13- biomarker panel) in whole blood, before and following therapeutic intervention (resection and 
<!-- EPO <DP n="132"/>-->
 Octreotide LAR) was carried out, demonstrating the clinical utility of embodiments of the provided methods and systems. Moreover, comparison to detection of CgA expression alone demonstrated improved sensitivity of the provided methods in GEP-NEN detection, risk determination, and monitoring of therapeutic responses. CgA is an SI GEP-NEN marker present in 60-80% of GEP NETs, as described by Modlin IM et ah, Chromogranin A-Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease, Ann Surg Oncol. 2010 Sep;17(9):2427-43. Epub 2010 Mar 9. </p><p id="p0669" num="0669">Detection of GEP-NEN biomarkers following surgical intervention: </p><p id="p0670" num="0670"> [00474] Nine patients underwent small bowel and hepatic met resection (resulting in an approximately 90% reduction in tumor volume). Expression levels of the 13 summed GEP- NEN biomarker transcripts (APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAPILI, PNMA2, RAFl, TPHl, VMAT2) were determined as described above using real-time PCR on samples prepared from whole blood samples, taken one day before surgery and then two weeks post-operatively. </p><p id="p0671" num="0671"> [00475] The results are shown in FIG. 31 (horizontal bars representing mean expression levels pre and post surgery). Two weeks following surgery, summed expression levels (as described above) of the GEP-NEN Biomarkers levels were significantly decreased (from a mean of 84 before surgery to a mean of 19 after surgery, greater than 75% reduction, with /?&lt;0.02) (FIG. 31A). As shown in FIG. 31B, detection of CgA expression levels alone did not show a significant decrease (20 % reduction in mean expression). </p><p id="p0672" num="0672"> [00476] These results demonstrate that biomarker expression levels detected with the provided methods and systems accurately reflect tumor removal and can be used to evaluate responsiveness and efficacy of surgical intervention. </p><p id="p0673" num="0673">Detection of GEP-NEN -biomarkers following somatostatin analogue (Sandostatin LAR® (Octreotide acetate injection)) drug therapy </p><p id="p0674" num="0674"> [00477] Summed expression levels (as described above) for the thirteen biomarkers also were detected in eight patient samples by real-time PCR, before, one month after, and two months after treatment with Sandostatin LAR® (Octreotide acetate injection), a somatostatin analog. The results are shown in FIG. 32. 
<!-- EPO <DP n="133"/>-->
 [00478] Results showed a significant (p=0.017) reduction in expression of the summed biomarker transcripts one month after continuous treatment. After six months of continued treatment, transcript levels were reduced by an additional 50% (p=0.06 vs. 1 month) and were in the normal range (FIG. 32A). In contrast, no significant change in CgA expression levels, alone, was observed at one month post-LAR® treatment (FIG. 32B); in this study, detected levels of CgA expression alone decreased only at the 6 month time-point. These results show that as for surgical intervention, the provided systems and methods for biomarker detection can be used to monitor LAR® treatment, providing a higher sensitivity as compared to detection of a single GEP-NEN biomarker alone, e.g. CgA. </p><p id="p0675" num="0675"> Early detection of low volume micrometastasis and evaluation of treatment efficacy in individual patients </p><p id="p0676" num="0676"> [00479] The summed 13 GEP-NEN biomarker expression levels (as described above) were monitored to evaluate treatment efficacy and predict risk in two individual patients, treated with Cryo Ablation and hepatic met resection, respectively. </p><p id="p0677" num="0677"> [00480] Patient SK, a male of 63 yrs, with metastatic small intestinal (SI) GEP-NEN was evaluated as normal by stereotactic radiosurgery (SRS) / computed tomography (CT), and was considered disease free. Summed expression of transcripts in whole blood was evaluated using real-time PCR as described above. The results, presented in FIG. 33, showed normal expression levels of CgA. In contrast, summed expression levels of the panel of 13 GEP-NEN biomarkers (APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT2) ("PCR(+)") were elevated (FIG. 33). Based on this information, the patient underwent <sup>U</sup>C<sup>"</sup>PET-CT in Sweden, demonstrating he had a liver metastasis of approximately 0.5 cm. </p><p id="p0678" num="0678">Subsequently, the patient underwent cryoablation, which liberates GEP-NEN tissue for entry into the blood, inducing symptoms, as described by Mazzaglia PJ, et ah, "Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival," Surgery 2007;142(l): 10-9. </p><p id="p0679" num="0679"> [00481] Expression levels were monitored monthly for six months following cryoablation, by real-time PCR on RNA prepared from whole blood. The results demonstrated elevated expression levels of the biomarker panel, but not of CgA alone, after cryoablation. Between four and five months following cryoablation, bone micrometastases were identified; PCR </p><p id="p0680" num="0680">demonstrated the appearance of these micrometastases correlated with elevated GEP-NEN biomarker panel transcript expression levels; CgA expression alone was detected as normal. 
<!-- EPO <DP n="134"/>-->
 Following LAR® therapy (which blocks secretion and proliferation of GEP-NEN cells), biomarker panel expression levels in the blood were determined to normalize (real-time PCR). </p><p id="p0681" num="0681"> [00482] This study demonstrates that detection of GEP-NEN biomarker panels by the provided methods can accurately reflect acute GEP-NEN-associated events, demonstrating the impmroved sensitivity of the provided methods (e.g., as compared to detection of an available biomarker, CgA alone) and systems for detecting GEP-NEN biomarkers in prognostic and predictive analysis and evaluation of treatment efficacy and detection of relapse or early-stage disease, particularly when disease is limited to rare micrometastases. </p><p id="p0682" num="0682"> [00483] Patient BG, a 69-year old female with metastatic small intestinal GEP-NEN, Grade T2N1M1, underwent surgical small bowel and hepatic met resection, followed by 9 months of treatment with Octreotide LAR®. Expression levels of CgA and the 13-GEP-NEN biomarkers ("PCR(+)") were monitored by real-time PCR on whole blood samples as described above, prior to surgery, two weeks post-op, and monthly for twelve months. All symptoms resolved after twelve months of treatment. As shown in FIG. 34, detection of CgA expression levels alone revealed dramatic fluctuations, not correlating with treatment or symptom reduction. Biomarker panel expression levels ("PCR(+)"), by contrast, were detected as significantly reduced following surgical tumor excision, measured two weeks post-op, and significantly reduced following LAR® treatment, remaining reduced out to twelve months (at which point all symptoms remained resolved). </p><p id="p0683" num="0683"> [00484] This study demonstrates that detection of GEP-NEN biomarker panels by the provided methods can sensitively reflect disease severity and responsiveness to treatment, providing an improvement over available biomarker detection methods. The provided methods and systems are useful for monitoring treatment responsiveness and relapse, and can detect both the presence (FIG. 33) and the absence (FIG. 34) of GEP-NEN disease with high fidelity. These results demonstrate that detection of the provided biomarkers in blood provides added diagnostic and treatment value, for example, as surrogate markers for treatment efficacy to monitor the effects of surgery (removal of tumors) or targeted medical therapy ( inhibition of tumor secretion/ proliferation). See Arnold R, et ah, "Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group," ASCO 2009, Gastrointestinal Cancers Symposium, Abstract #121. 2009. 
<!-- EPO <DP n="135"/>-->
 EXAMPLE 6: Evaluation of the Molecular Fingerprint as an Indicator of Treatment Efficacy </p><p id="p0684" num="0684"> [00485] The efficacy of this 51 marker gene panel as a potential test was examined in the four independent datasets to establish whether it could differentiate between treatment-responsive (those that were clinically categorized as in complete remission or as exhibiting stable disease) and untreated (treatment-naive) or non-responsive (clinically categorized as "progressive") tumors. In addition, a 13 marker subset of the 51 marker gene panel was evaluated to determine if it could be used to provide additional information regarding response to therapy, specifically if it could provide more specific information in progressive, untreated disease compared to stable disease. </p><p id="p0685" num="0685"> [00486] Independent set 1 included 35 GEP-NENs. Full clinical details were available for all patients; 33 of the samples were considered in complete remission or had stable disease. Sixty percent of samples were under treatment (predominantly LAR: 96%). </p><p id="p0686" num="0686"> [00487] Independent set 2 included 32 GEP-NENs. Full clinical details were available for all; 28 of the samples were considered in complete remission or had stable disease. Eighty-four percent of samples were under treatment (LAR: -40%, surgery -25%). </p><p id="p0687" num="0687"> [00488] Independent set 3 included 47 NENs. Full clinical details were available for all; 30 of the samples were considered in complete remission or had stable disease. Fifty-six percent of samples were under treatment (LAR: -75%). </p><p id="p0688" num="0688"> [00489] Independent set 4 included 89 GEP-NENs. Full clinical details were available for all patients; 71 of the samples were considered in complete remission or had stable disease. Forty- six percent of samples were under treatment (predominantly LAR: 85%). </p><p id="p0689" num="0689"> [00490] The four algorithms were assessed: SVM, LDA, KNN and Bayes for utility in determining whether a blood sample was associated with a "treated" phenotype (clinically responsive/stable disease) or could identify untreated/progressive disease. Tumor samples that were called "normal" or "treated" were considered to exhibit a "treated" or clinically responsive ("responder") phenotype. Those considered "untreated" were classified as being non-responsive (or "non-responders"). The algorithms as a group ("voting" algorithm) were examined for utility and include correct call rates from best 3 of 4 algorithms. </p><p id="p0690" num="0690"> [00491] Tabulated results indicate that overall correct call rates (identifying both </p><p id="p0691" num="0691">appropriately treated and non-responsive samples) was 73-94% in independent set 1, 81-89% in 
<!-- EPO <DP n="136"/>-->
 set 2, 82-94% in set 3 and 72-94% in set 4 (Table 15). The average rates were 83-88% for each of the algorithms. A combination, best "3 of 4", resulted in similar (88%) correct call rate. </p><p id="p0692" num="0692">Table 15. Overall call rates (%)for each of the algorithms in each of the independent sets </p><p id="p0693" num="0693"><img id="imgf000136_0001" he="32" wi="142" file="imgf000136_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0694" num="0694">[00492] Further analysis of the calls identified whether the correct call rates corresponded to identifying clinically responsive patients or samples from those individuals that were not responding to treatment (Table 16). </p><p id="p0695" num="0695">Table 16. Call rates (%)for each of the groups, clinically responsive or non-responders, in each of the independent sets </p><p id="p0696" num="0696"><img id="imgf000136_0002" he="42" wi="158" file="imgf000136_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0697" num="0697"> * = excluded from analysis as only two and four patients were classified as "non-responders " in each of these two sets. </p><p id="p0698" num="0698">[00493] The most consistent correct calls for "responders" were identified with the KNN algorithm (-97%). The highest correct call rates for "non-responders" were the SVM and LDA algorithms (-80%). </p><p id="p0699" num="0699"> [00494] Sensitivities, specificities, positive predictive values and negative predictive values calculated for each of the algorithms in the 3 independent sets are included in Table 17. </p><p id="p0700" num="0700">Table 17. Performance metrics for each of the algorithms in each of the independent sets 
<img id="imgf000136_0003" he="12" wi="161" file="imgf000136_0003.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 
<!-- EPO <DP n="137"/>-->
 Set 1 97 0 97 0 97 0 97 0 100 0 100 0 100 0 100 0</p><p id="p0701" num="0701">Set 2 88 * 100 0 88 * 100 0 88 * 100 0 88 * 100 0</p><p id="p0702" num="0702">Set 3 100 62 86 100 96 86 94 92 97 85 94 92 89 55 76 77</p><p id="p0703" num="0703">Set 4 95 56 83 83 94 52 82 77 88 56 90 50 85 88 98 39</p><p id="p0704" num="0704">AVE 95 39 92 46 94 46 93 42 93 47 96 36 90 48 94 29</p><p id="p0705" num="0705">SENS = sensitivity, SPEC = specificity, PPV = positive predictive value, NPV </p><p id="p0706" num="0706">predictive value, * no value (cannot be calculated) </p><p id="p0707" num="0707">[00495] The SVM, LDA and KNN algorithms performed best for detecting patients that were considered to be either in complete remission or exhibiting stable disease (sensitivity = 93-95%). The SVM algorithm was also the most sensitive algorithm for detecting individuals with untreated or progressive disease (80%). The combination, best "3 of 4", resulted in an average 99% correct call rate for determining remission/disease stability and 75% for detecting untreated or progressive disease. </p><p id="p0708" num="0708"> [00496] The best algorithms to differentiate treatment-responsive samples from those classified as non-responders were LDA and KNN with PPVs of -98% and NPVs of -92%. </p><p id="p0709" num="0709"> [00497] Thereafter, the association between clinical description and PCR-based scores was examined. To delineate individual groups, the following descriptors were used: </p><p id="p0710" num="0710"> [00498] "Complete remission" = all investigations negative; </p><p id="p0711" num="0711"> [00499] "Stable disease after surgery" = abnormal investigations but no change in serial evaluation; and </p><p id="p0712" num="0712"> [00500] "Stable disease after surgery + LAR" = abnormal investigations but no change in serial evaluation. </p><p id="p0713" num="0713"> [00501] Analysis by clinical criteria (examination, biochemistry, scanning) of all treated samples in the 4 independent sets as a group identified: </p><p id="p0714" num="0714"> 1) Patients considered in complete remission (i.e. following surgery for removal of an appendiceal tumor (n=3) or a hemicolectomy for a &lt; 1.5cm ileo-cecal NEN with no lymph node metastases (w=8) or &lt;2 lymph node metastases (n=2) were correctly identified in 100% of cases by the algorithms (FIG. 35). All 13 samples were called "normal" by the algorithm. </p><p id="p0715" num="0715"> 2) Patients considered as stable disease (following surgery for removal of tumor </p><p id="p0716" num="0716"> (hemicolectomy: n=24, gastrectomy: n=l, appendectomy: n=3, hemicolectomy and liver resection: n=T, ileal/colonic resection: n=3, hemicolectomy, liver resection and lymph 
<!-- EPO <DP n="138"/>-->
 node dissection: n=2, embolization: n=2) were correctly called (called tumor "treated" by the mathematical algorithms) in 95% of cases (40/42) (FIG. 35). </p><p id="p0717" num="0717"> 3) Patients considered as stable disease following drug therapy (long-acting </p><p id="p0718" num="0718"> somatostatin analog (SI-NENs=72, PNENs=13, rectal NENs=2, gastric NENs=2), pasireotide (SI-NEN=1) or RAD001 (SI-NEN=4) were correctly called in 90% of cases (70/78) (FIG. 35). </p><p id="p0719" num="0719">EXAMPLE 7: Use of a 13 marker panel gene panel subset to evaluate disease responses </p><p id="p0720" num="0720"> [00502] A subset of genes that were highly correlated with untreated, progressive disease was evaluated to determine if they could be used to further define patient groups and be used to provide additional information regarding response to therapy, particularly in patients undergoing treatment but considered to be "progressive". </p><p id="p0721" num="0721"> [00503] An analysis of clinical samples in the test set identified 13 genes selectively over- expressed in the untreated, progressive group compared to those considered to exhibit stable disease. The genes identified were: AKAP8L, BRAF, CD59, COMMD9, Ki67, MORF4L2, OAZ2, RAF1, SST1, SST3, TECPR2, ZFHX3 and ZXDC. Inclusion of these genes in an algorithm resulted in correct call rates to differentiate stable from progressive disease in -73% of cases in the test set (FIG. 36). </p><p id="p0722" num="0722"> [00504] An analysis of this gene panel in independent sets 1-4 (as a group; progressive disease - irrespective of treatment: n=26 [50% of patients on treatment, 50% treatment stopped because considered untreatable] ; stable disease: w=143) identified that the correct call rate for samples from patients considered to exhibit "progressive" disease was 65% (KNN). The sensitivities, specificities, PPV and NPV for the four different algorithms in this group were 34- 65%, 96-100%, 64-100%, and 89-94% respectively. The best algorithm to detect "progressive" disease was KNN; the best algorithm for detecting "stable" disease was SVM. This indicates that a 13 marker panel subset is useful as an adjunct to the 51 marker panel particularly for identifying GEP-NENs that are not responding to therapy and are considered clinically </p><p id="p0723" num="0723">"progressive". </p><p id="p0724" num="0724"> [00505] These approaches demonstrate that treatment responsiveness can be accurately defined by the 51 marker panel in 90-100%. Samples that are considered clinically progressive and therefore not responsive to therapy (e.g., LAR or everolimus) can be identified in 65-80%. 
<!-- EPO <DP n="139"/>-->
 EXAMPLE 8: Comparison of the 51 -marker gene panel with plasma Chromogranin A levels for Disease Prediction </p><p id="p0725" num="0725"> [00506] The utility of the PCR-based approach was compared to Chromogranin A levels measured in plasma for identifying GEP-NENs and differentiating between treated and untreated samples. </p><p id="p0726" num="0726"> [00507] CgA is widely utilized as a generalized NEN marker and elevated levels are generally considered to be a sensitive, -70-90% accurate as a marker for GEP-NENs. Measurements of this peptide, however, are non-specific (10-35% specificity) as it is also elevated in other neoplasia e.g., pancreatic and small cell lung neoplasia and prostate carcinomas as well as in a variety of cardiac and inflammatory diseases, by proton pump inhibitor usage and in renal failure. CgA is a component of neuroendocrine cell secretion, not proliferation, and therefore its use as a surrogate for tumor growth has obvious significant limitations. In general, the sensitivity of this biomarker for predicting GEP-NENs is dependent on the degree of differentiation of the tumor, the location of the tumor and whether it is metastatic or not. Despite modest correlations between CgA levels and hepatic tumor burden, the low (&lt;60%) sensitivity for detecting metastases, the absence of a standardization of measurement in the USA, as well as that the FDA does not accept CgA as a supportable biomarker, it is currently the only marker "routinely" used to evaluate treatment efficacy (surgery, liver transplantation, bio-/chemo-therapy, chemo- /embolization, radiofrequency ablation). CgA levels were therefor used as the best available equivalent of a "gold- standard" against which to assess the PCR-based test. </p><p id="p0727" num="0727"> [00508] CgA values were measured using the DAKO ELISA kit in the initial test set of 130 samples (controls: «=67, GEP-NENs: «=63 [untreated disease, «=28, treated, «=35]) used to develop the 51 marker gene panel. The DAKO kit is art recognized to detect CgA in plasma samples from GEP-NENs. </p><p id="p0728" num="0728"> [00509] CgA levels were elevated (p&lt;0.05) in both untreated (63%) and treated GEP-NENs (32%) using either the Student's t-test (FIG. 37A) or non-parametric tests (FIG. 37B). </p><p id="p0729" num="0729"> [00510] The efficacy of CgA to identify GEP-NENs compared to controls identified a correct call rate of 74% (Table 18). The efficacy for correctly identifying a GEP-NEN, irrespective of treatment, was lower at -45%. </p><p id="p0730" num="0730">Table 18: Diagnostic capacity of CgA levels to discriminate controls from all GEP-NENs (treated and untreated). 
<!-- EPO <DP n="140"/>-->
 Normal (True) GEP-NENs </p><p id="p0731" num="0731"> (True) </p><p id="p0732" num="0732"> Normal (Predicted) 65 30 </p><p id="p0733" num="0733"> GEP-NENs (Predicted) 2 26 </p><p id="p0734" num="0734"> The performance metrics of this test were: Sensitivity = 97%, Specificity = 46%, PPV = 68% and NPV = 93%. </p><p id="p0735" num="0735">[00511] DAKO uses a cut-off of 19 Units/L as the upper limit of normal. Using this value, a total of 25 (45%) of 56 GEP-NENs were considered positive compared to 1 (1.4%) of 67 controls for performance metrics of Sensitivity = 45%, Specificity = 98%, PPV = 96% and NPV = 68% (FIG. 38). The correct call rate for this cut-off was 70%. </p><p id="p0736" num="0736"> [00512] Using CgA levels with the PCR transcript expression (51 marker panel) was next evaluated for the ability to provide additional value to the predictions. Inclusion of CgA levels did not increase the prediction ability of the marker genes, and reduced the efficacy, particularly of the KNN classifier (FIG. 39A-B). It was conclude that inclusion of CgA levels do not improve the quality of the candidate marker gene panel. </p><p id="p0737" num="0737"> [00513] These results demonstrate that quantification of a circulating multi-transcript molecular signature (tumor transcripts) is more sensitive than measurement of a single, circulating protein (CgA). Inclusion of CgA measurement in the molecular fingerprint provides no "added" predictive value. </p><p id="p0738" num="0738">EXAMPLE 9: Comparison of the 51 -marker gene panel with plasma Chromogranin A levels for Assessment of Disease Efficacy </p><p id="p0739" num="0739"> [00514] The utility of the PCR-based approach was directly compared to CgA levels measured in plasma for identifying GEP-NENs and differentiating between treated and untreated samples. Analyses of the efficacy of CgA to differentiate between treated and untreated GEP- NENs identified that the correct call rate was 66% (Table 19). The performance metrics were: Sensitivity = 69%, Specificity = 63%, PPV = 67% and NPV = 65%. </p><p id="p0740" num="0740">Table 19: Diagnostic capacity of CgA levels to discriminate between un-treated and treated GEP-NEN samples 
<img id="imgf000140_0001" he="16" wi="123" file="imgf000140_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="141"/>-->
 Illustrative Cases </p><p id="p0741" num="0741"> [00515] To facilitate clinical usage, a scoring system was developed based on the calls from the mathematical algorithm. This is a "Distance" score that measures the Euclidean distance of an unknown sample to gene expression profiles of the different calls "Normal" versus "Tumor", and "Treated" versus "Untreated". A low score: 0-25 converts to "normal", 26-50 is "tumor - treated" (or stable) and 51-100 is "tumor untreated". This provides a physician-friendly visualization since it is clear where an individual patient value falls in the disease spectrum (diagnosis of "normal" versus "tumor" and clinical interpretation of "treated" versus </p><p id="p0742" num="0742">"untreated"). It also provides the opportunity to graph how treatment influences the transcript index of the disease. An example is provided in FIG. 40. These terms and scores are used for the individual, illustrative cases provided below. </p><p id="p0743" num="0743">Index case 1: Incidentally identified Appendiceal NEN, with subsequent development of a mesenteric metastasis </p><p id="p0744" num="0744"> [00516] JPP (45 yo male with hypertension and previous splenectomy [1998]), underwent left hemicolectomy for an abscess and perforation [12/2009]. At surgery, a well differentiated 0.8cm NEN was identified with lymphatic invasion and extension to the meso-appendix [T7N1M1]. The tumor exhibited low proliferative capacity: Ki67&lt;2 and mitotic count &lt;1/10HPF). A subsequent MRI scan (1/2010) identified residual mesenteric implants and repeat surgery (4/2010) was undertaken for colostomy closure. At this time a mesenteric lymph node metastasis (&lt;lcm) was removed (Ki67&lt;2 ). </p><p id="p0745" num="0745"> Table 20 </p><p id="p0746" num="0746"><img id="imgf000141_0001" he="55" wi="159" file="imgf000141_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0747" num="0747"> PCR score: 0-100 (0-25=normal, 26-50=treated; 51-100=untreated disease): Diagnosis = normal or tumor, interpretation = treated versus untreated. CgA values: Units/liter (U/L) (DAKO ELISA) </p><p id="p0748" num="0748">ABNML = abnormal (elevated): NML = normal range 
<!-- EPO <DP n="142"/>-->
 [00517] The PCR test is more sensitive than CgA for identifying residual (untreated) disease (diagnosis = "tumor", interpretation = "untreated", PCR score 68) and for demonstrating surgical removal of the metastasis (diagnosis = "tumor", interpretation = "treated", PCR score 40). The identification that the blood PCR test did not revert to a call of "Normal" following surgical excision indicates the presence of residual metastatic disease (PCR score remains above normal: -40). Since the PCR value has not changed between 2010 and 2011 to an "untreated" phenotype it is likely that the disease is clinically "stable". </p><p id="p0749" num="0749">Index case 2: SI-NEN, surgical resection. </p><p id="p0750" num="0750"> [00518] BA (65 yr female, history of coronary artery disease, type II diabetes and glaucoma exhibited with anemia in 1996 and 2006. Colonoscopy and CT scan identified a terminal ileal NEN [5/2009]. She underwent a right hemicolectomy (2/2010) for removal of a 1cm SI-NEN which exhibited lymphatic invasion but no nodes were positive [T1N0M0]. Tumor exhibited low proliferative index: Ki67=2 and mitotic count &lt;2/10HPF). </p><p id="p0751" num="0751">Table 21 </p><p id="p0752" num="0752"><img id="imgf000142_0001" he="48" wi="138" file="imgf000142_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0753" num="0753"> PCR score: 0-100 (0-25=normal, 26-50=treated; 51-100=untreated disease); Diagnosis = normal or tumor, interpretation = treated versus untreated. CgA values: Units/liter (U/L) (DAKO ELISA) </p><p id="p0754" num="0754">ABNML = abnormal (elevated); NML = normal range </p><p id="p0755" num="0755">[00519] The PCR test identifies a small mass, low proliferation small intestinal NEN </p><p id="p0756" num="0756">(diagnosis = "tumor", interpretation = "untreated", PCR score 61). The identification that the blood PCR test did not revert to a call of "Normal" following surgical excision indicates the presence of residual disease (PCR score 26-30) suggesting incomplete resection (non-R0). 
<!-- EPO <DP n="143"/>-->
 Index case 3: Metastatic rectal NEN (endoscopically removed), pan-segmental liver metastases, treated with LAR </p><p id="p0757" num="0757"> [00520] AJ (47 yo male, with an incidentally identified rectal NEN (on endoscopy - 5/2010)). Extensive pan-segmental liver metastases were noted on follow-up (CT/MRI scan 6/2010). Sandostatin was initiated [7/2011]. Surgical resection for residual disease (primary and rectal lymph node metastasis) with removal of 2 liver metastases was undertaken [10/2010]. A 1.5cm rectal lymph node metastasis), with a Ki67&lt;15 was identified. The liver metastases had a Ki67~3 (T2N1M1). Subsequent surgery was undertaken [2/2011] to close the ileostomy and remove additional liver metastases. Serial MRI scans demonstrated no change in hepatic burden. Sandosatin continued. </p><p id="p0758" num="0758"> Table 22 </p><p id="p0759" num="0759"><img id="imgf000143_0001" he="59" wi="167" file="imgf000143_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0760" num="0760"> PCR score: 0-100 (0-25=normal, 26-50=treated; 51-100=untreated disease); Diagnosis = normal or tumor, interpretation = treated versus untreated. CgA values: Units/liter (U/L) (DAKO ELISA) </p><p id="p0761" num="0761">ABNML = abnormal (elevated); NML = normal range </p><p id="p0762" num="0762">[00521] The PCR test identifies liver metastases as well as residual disease from a nonfunctional (non- secreting) lesion (diagnosis = "tumor", interpretation = "untreated", PCR score 78). The PCR test is more effective than CgA for both identifying the disease and monitoring treatment response. The failure of the PCR test to revert to a call of "Normal" is consistent with the presence of liver metastases. The values have not changed between 2010 and 2011 to an "untreated" phenotype suggesting the disease is "stable". This finding (PCR score: 26-44) is consistent with current imaging protocols which demonstrate stable non progressive disease. 
<!-- EPO <DP n="144"/>-->
 Index case 4: Metastatic SI-NEN, pan-segmental liver metastases, treated with hemicolectomy. lymph node dissection and liver resection and LAR </p><p id="p0763" num="0763"> [00522] BG (71 yo female, initially identified with hepatic nodules and ~4cm mesenteric mass (positive by octreoscan) confirmed to be a well-differentiated neuroendocrine carcinoma (by liver biopsy) [9/2008]. Underwent an ileal and liver wedge resections [12/2008]. An 8cm mesenteric nodule was removed as was a 1.5cm NEN, while 6/9 lymph nodes were positive for metastasis. The tumor had a low proliferative capacity, mitotic count = 2/10hpf, Ki67&lt;2 (T2N1M1). Octreotide was initiated 2/2009 with some control of symptoms but increasing right upper quadrant discomfort was noted. Octreoscan [4/2010] identified several small liver lesions with additional lesions confirmed in 2/2011 (Octreoscan). Underwent ERCP and sphincterotomy [4/2011] and cholecystectomy [6/2011]. </p><p id="p0764" num="0764">Table 23 </p><p id="p0765" num="0765"><img id="imgf000144_0001" he="63" wi="173" file="imgf000144_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0766" num="0766"> PCR score: 0-100 (0-25=normal, 26-50=treated; 51-100=untreated disease); Diagnosis = normal or tumor, interpretation = treated versus untreated. CgA values: Units/liter (U/L) (DAKO ELISA) </p><p id="p0767" num="0767">ABNML = abnormal (elevated); NML = normal range </p><p id="p0768" num="0768">[00523] The PCR test identifies extensive disease (diagnosis = "tumor", interpretation = "untreated", PCR score 70). Since the blood PCR test (PCR Score 27-35) did not revert to "Normal" after surgery the result is consistent with residual metastases. CgA results performed less effectively than the PCR test for both identifying the disease and monitoring treatment response. 
<!-- EPO <DP n="145"/>-->
 Index case 5: Recurrent liver metastasis (following hepatectomy), treated with LAR and embolization </p><p id="p0769" num="0769"> [00524] SK (64 yo male, with a history of atrial fibrillation, hyperlipedemia and kidney stones). SI-NEN diagnosed [12/2001] after developing flushing. He underwent resection of the ileal tumor and hepatic mets. Subsequent surgeries included re-resection of a mesenteric lymph node mass [3/2005] and lymph nodes [9/2006]. In [12/2008] cryoablation for a liver met. PET scan [4/2009] identified small liver nodules and a bone lesion. Sandostatin begun [6/2009], repeat scans [PET and MRI] identify no new lesions. </p><p id="p0770" num="0770">Table 24 </p><p id="p0771" num="0771"><img id="imgf000145_0001" he="71" wi="184" file="imgf000145_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0772" num="0772"> PCR score: 0-100 (0-25=normal, 26-50=treated; 51-100=untreated disease): Diagnosis = normal or tumor, interpretation = treated versus untreated. CgA values: Units/liter (U/L) (DAKO ELISA) </p><p id="p0773" num="0773">ABNML = abnormal (elevated): NML = normal range </p><p id="p0774" num="0774">[00525] The PCR test identified recurrence of the disease (diagnosis = "tumor", interpretation = "untreated", PCR score 63), demonstrated efficacy of cryoablation and detected residual disease. Becuase the blood PCR test did not revert to a call of "Normal", this result was considered evidence of metastases which were identified by 13C-PET (PCR score 49). CgA results were less effective than the PCR test for both identifying the disease and monitoring treatment response. 
<!-- EPO <DP n="146"/>-->
 EXAMPLE 10: Utility of the molecular signature to differentiate GEP-NEN subtypes (Small Intestine versus Pancreatic NENs) </p><p id="p0775" num="0775"> [00526] The 51 marker gene panel was used to examine the ability to distinguish GEP-NENs from controls and to differentiate whether a sample is from a patient responsive to treatment compared to a non-responder or treatment-naive individual. The marker panel was developed around information derived from small intestinal NEN tissue and blood microarrays. While the performance metrics are significantly better than for CgA ELISA, it was a goal of this work to establish whether the test could differentiate between GEP-NENs from two different sites, namely the small intestine and the pancreas. This is relevant in the case of a tumor of unknown primary location and is also relevant since tumors exhibit significantly different prognoses depending on their site of origin. The 5-year survival of a STNEN is -80% and -50% of the mortality is not disease-specific. In contrast, the 5-year survival of a PNEN is -40% and -95% of patients die from the disease. Determining the location of an unknown primary can therefore be an important variable in determining therapy; somatostatin analogs have demonstrated utility in SI-NENs 9 while sunitinib and everolimus have efficacy in PNENs_ENREF_10. </p><p id="p0776" num="0776"> [00527] Examination of the 51 marker gene panel identified that it exhibited a much larger expression variance (0.54+0.4 versus 0.38+0.14 in SI-NENs) indicating that the genes selected in the panel were not as specific for PNENs as for SI-NENs. Mapping expression identified that tumors were spatially separated (FIG. 41 A). </p><p id="p0777" num="0777"> [00528] Furthermore, the expression in the panel could differentiate with 92% accuracy between the two tumor sites (FIG. 41B). The test can thus accurately differentiate between a pancreatic and a small bowel tumor. </p><p id="p0778" num="0778">EXAMPLE 11: Ability of the 51 -marker gene panel to discriminate between GEP-NENs and GI Cancers </p><p id="p0779" num="0779"> [00529] To further evaluate the utility of this PCR-based approach, the molecular fingerprint in gastrointestinal adenocarcinomas, such as gastric and hepatic cancers (esophageal: n=2, pancreatic: «=11, gallbladder: n=3, colon: n=!0, rectal: n=l was examined. This was undertaken to assess whether some genes e.g., KRAS, BRAF, Ki67 over-expressed in GI adenocarcinoma and included in the panel, might perturb the accuracy. 
<!-- EPO <DP n="147"/>-->
 [00530] Examination of the 51 marker gene panel identified that it exhibited a larger expression variance (0.5+0.25 versus 0.44+0.17 in GEP-NENs) indicating that the NEN-specific genes selected in the panel were less specific for GI cancers than for GEP-NENs. PCA identified that tumors were spatially separated (FIG. 42A) and that the NEN panel could differentiate with 83% accuracy between GEP-NENs and GI cancers (FIG. 42B). </p><p id="p0780" num="0780"> [00531] The test therefore has the power to differentiate between GEP-NENs and GI cancers and the circulating molecular signature of NENs is different to that of GI adenocarcinomas. The minor overlap is consistent with the observation that ~ 40% of GI adenocarcinomas exhibit neuroendocrine elements. </p><p id="p0781" num="0781"> [00532] A direct comparison of the molecular test and CgA ELISA identified that the PCR- based method had a significantly more accurate call rate compared to measurement of CgA levels (χ<sup>2</sup>=12.3, /?&lt;0.0005) (FIG. 43). </p><p id="p0782" num="0782"> [00533] The sensitivities were similar for detecting a GEP-NEN (94% versus 97%) but the specificity of the PCR test was higher than CgA (85% versus 46%). For differentiating treated versus untreated samples, the PCR-based test exhibited higher performance metrics (85% versus -65%). </p><p id="p0783" num="0783"> [00534] CgA is less useful than the circulating molecular fingerprint for defining "treatment" in GEP-NENs. This reflects the fact that the protein (CgA) is a constitutive secretory product of all neuroendocrine cells and has no specific biological relationship to neuroendocrine tumors, their proliferation rate or their metastasis. </p><p id="p0784" num="0784"> [00535] Throughout this application, various website data content, publications, patent applications and patents are referenced. (Websites are referenced by their Uniform Resource Locator, or URL, addresses on the World Wide Web.) The disclosures of each of these references are hereby incorporated by reference herein in their entireties. </p><p id="p0785" num="0785"> [00536] The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention. 
</p></description><claims mxw-id="PCLM44851260" ref-ucid="WO-2012119013-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="148"/>--> Claims </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A system for gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) diagnosis or prognosis, comprising: a set of isolated polynucleotides or isolated polypeptides that specifically hybridize or bind to a panel of GEP-NEN biomarkers, wherein the panel comprises a plurality of GEP-NEN biomarkers, including a gene product selected from the group consisting of: AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, </claim-text><claim-text>FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PQBP1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SST1, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, ZZZ3, APLP2, CD59, ARAF1, BRAF1, KRAS, and RAF1 gene products. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The system of claim 1, wherein the panel of GEP-NEN biomarkers includes a gene product selected from the group consisting of: AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKD1, PLD3, PQBP1, RNF41, RSF1, RTN2, SMARCD3, SPATA7, SST1, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The system of claim 1 or claim 2, wherein the panel of GEP-NEN biomarkers includes at least three of the following biomarkers: APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT1, and VMAT2 gene products. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The system of any of claims 1-3, wherein the panel of GEP-NEN biomarkers comprises at least 3, at least 11, at least 13, at least 20, at least 21, at least 29, at least 37, at least 51, or at least 75 biomarkers. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The system of claim 4, wherein the panel of GEP-NEN biomarkers comprises at least 51 biomarkers. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The system of any of claims 1-5, wherein the panel of GEP-NEN biomarkers includes AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, <!-- EPO <DP n="149"/>--> PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The system of any of claims 1-6, wherein the panel of GEP-NEN biomarkers includes APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPHl, VMATl, and VMAT2 gene products. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The system of any of claims 1-7, wherein the panel of GEP-NEN biomarkers includes AKAP8L, APLP2, ARAF1, ATP6V1H, BNIP3L, BRAF, C21orf7, CD59, COMMD9, CTGF, ENPP4, FAM13A, FLJ10357, FZD7, GLT8D1, HDAC9, HSF2, Ki67, KRAS, LEOl, MORF4L2, NAP1L1, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PNMA2, PQBPl, RAF1, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TPHl, TRMT112, VMATl, VMAT2, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The system of any of claims 1-8, wherein the panel of GEP-NEN biomarkers comprises an APLP2 gene product, a CD59 gene product, an ARAF1 gene product, a BRAF1 gene product, a KRAS gene product, or a RAF1 gene product. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The system of any of claims 1-9, wherein: </claim-text><claim-text> the panel of GEP-NEN biomarkers includes APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPHl, and VMAT2 gene products; or </claim-text><claim-text> the panel of GEP-NEN biomarkers includes APLP2, ARAF1, BRAF1, CD59, KRAS, RAF1, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCK1, X2BTB48, CgA, CTGF, FZD7, Ki-67, Kissl, MAGE-D2, MTAl, NAP1L1, NRP2, Tphl, VMATl, VMAT2 and Survivin gene products. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>11. The system of any of claims 1-10, wherein: </claim-text><claim-text> the panel of GEP-NEN biomarkers further includes a gene product selected from the group consisting of MAGE-D2, MTAl, Survivin, Kissl, HOXC6, NRP2, X2BTB48, CXCL14, GRIA2, NKX2-3, OR51E1, CTGF, PTPRN2, SPOCK1, and SCG5 gene products. <!-- EPO <DP n="150"/>--> </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. A system for GEP-NEN diagnosis or prognosis, comprising: a set of isolated polynucleotides or isolated polypeptides that specifically hybridize or bind to a panel of GEP- NEN biomarkers, the panel comprising at least 21 GEP-NEN biomarkers, wherein the system is able to classify or detect a GEP-NEN in a human blood sample. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The system of claim 12, wherein the panel comprises at least 51 GEP-NEN biomarkers. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The system of any of claims 1-13, wherein the system can identify GEP-NEN in a human blood sample with a specificity and sensitivity of at least 80 %. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The system of any of claims 1-14, wherein the system can differentiate between a subject with GEP-NEN and a subject with another type of gastrointestinal (GI) cancer or can differentiate between a subject with small intestinal NEN and a subject with a pancreatic NEN. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. The system of any of claims 1-15, wherein the system can predict treatment responsiveness to, or determine whether a patient has become clinically stable following, or is responsive or non-responsive to, surgical intervention or somatostatin analog therapy, with at least 90 % accuracy. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. The system of any of claims 1-16, wherein the system can differentiate between treated and untreated GEP-NEN with a sensitivity and specificity of at least 85 %. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. The system of any of claims 1-18, wherein the system can determine whether or not a subject previously diagnosed with a GEP-NEN is in complete remission. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. The system of any of claims 13-18, wherein the system is capable of the identification, differentiation, or prediction with a greater sensitivity, specificity, or accuracy compared with detection of circulating CgA levels. </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. The system of any of claims 1-19, further comprising an isolated polynucleotide or polypeptide that specifically binds to a housekeeping gene product. <!-- EPO <DP n="151"/>--> </claim-text></claim><claim id="clm-0021" num="21"><claim-text>21. The system of claim 20, wherein the housekeeping gene product is selected from the group consisting of: ACTB, TOX4, TPT1 and TXNIP gene products. </claim-text></claim><claim id="clm-0022" num="22"><claim-text>22. The system of claim 20 or 21, wherein the housekeeping gene product is selected from the group consisting of: 18S, GAPDH, ALG9, SLC25A3, VAPA, TXNIP, ADD3, DAZAP2, ACTG1, ACTB, ACTG4B, ARF1, HUWE1, MORF4L1 RHOA, SERP1, SKP1, TPT1, TOX4, TFCP2, and ZNF410, gene products. </claim-text></claim><claim id="clm-0023" num="23"><claim-text>23. The system of claim 22, wherein the housekeeping gene product is selected from the group consisting of: 18S, GAPDH, ALG9, SLC25A3, VAPA, TXNIP, ADD3, DAZAP2, ACTG1, ACTB, ACTG4B, ARF1, HUWE1, MORF4L1 RHOA, SERP1, SKP1, TPT1, and TOX4 gene products. </claim-text></claim><claim id="clm-0024" num="24"><claim-text>24. The system of any of claims 1-23, wherein the panel of GEP-NEN biomarkers comprises a gene product having a nucleotide sequence with at least 90 % identity to a sequence selected from the group consisting of SEQ ID NOs: 1-29, 105, 201, 204-213, 215, 217-225, 227- 229, 232-240, and 243-246. </claim-text></claim><claim id="clm-0025" num="25"><claim-text>25. The system of any of claims 1-24, wherein the system distinguishes between subtypes of GEP-NEN and the panel of biomarkers comprises a set of biomarkers, wherein </claim-text><claim-text> (i) the expression profile of the set of biomarkers is significantly different in primary PDNEC and primary WDNET and the set comprises CXCL14 and MAGE-D2 gene products; </claim-text><claim-text> (ii) the expression profile of the set of biomarkers is significantly different in primary PDNEC and primary WDNEC and the set comprises three biomarkers, including a PTPRN2 gene product; </claim-text><claim-text> (iii) the expression profile of the set of biomarkers is significantly different in primary PDNEC and primary PDNET and the set comprises MTA1 and PNMA2 gene products; </claim-text><claim-text> (iv) the expression profile of the set of biomarkers is significantly different in primary PDNET and primary WDNET or in primary PDNET and primary WDNEC and the set comprises at least four biomarkers; </claim-text><claim-text> (v) the expression profile of the set of biomarkers is significantly different in primary WDNEC and primary WDNET and the set comprises twenty-one biomarkers; <!-- EPO <DP n="152"/>--> (vi) the expression profile of the set of biomarkers is significantly different in metastatic WDNEC and metastatic WDNET and the set comprises at least three biomarkers, including a CXCL14 gene product; </claim-text><claim-text> (vii) the expression profile of the set of biomarkers is significantly different in metastatic PDNEC and metastatic WDNEC and the set comprises at least four biomarkers, including a NAP1L1 gene product; or </claim-text><claim-text> (viii) the expression profile of the set of biomarkers is significantly different in metastatic PDNEC and metastatic WDNET and the set comprises g at least six biomarkers, including a NRP2 gene product. </claim-text></claim><claim id="clm-0026" num="26"><claim-text>26. A method for detection, diagnosis, classification, or prediction of an outcome of a gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN), GEP-NEN cell, or associated condition, comprising: </claim-text><claim-text> (a) obtaining a biological test sample; and </claim-text><claim-text> (b) detecting the presence, absence, expression levels, or expression profile of a panel of at least two GEP-NEN biomarkers, wherein the panel includes a gene product selected from the group consisting of: AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, </claim-text><claim-text>FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, ZZZ3, APLP2, CD59, ARAF1, BRAF1, KRAS, and RAF1 gene products. </claim-text></claim><claim id="clm-0027" num="27"><claim-text>27. The method of claim 26, wherein the panel includes a gene product selected from the group consisting of: AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, </claim-text><claim-text>FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </claim-text></claim><claim id="clm-0028" num="28"><claim-text>28. The method of claim 27 or 28, wherein the panel includes APLP2, ARAF1, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAP1L1, PNMA2, RAF1, TPH1, VMAT1, and VMAT2 gene products. <!-- EPO <DP n="153"/>--> </claim-text></claim><claim id="clm-0029" num="29"><claim-text>29. The method of any of claims 26-28, wherein the panel comprises at least 3, at least 11, at least 13, at least 20, at least 21, at least 29, at least 37, at least 51, or at least 75 biomarkers. </claim-text></claim><claim id="clm-0030" num="30"><claim-text>30. The method of claim 29, wherein the panel comprises at least 51 biomarkers. </claim-text></claim><claim id="clm-0031" num="31"><claim-text>31. The method of any of claims 26-30, wherein the panel includes AKAP8L, ATP6V1H, BNIP3L, C21orf7, COMMD9, ENPP4, FAM13A, FLJ10357, GLT8D1, HDAC9, HSF2, LEOl, MORF4L2, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PQBPl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TRMT112, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </claim-text></claim><claim id="clm-0032" num="32"><claim-text>32. The method of any of claims 26-31, wherein the panel includes APLP2, ARAFl, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAPILI, PNMA2, RAFl, TPH1, VMAT1, and VMAT2 gene products. </claim-text></claim><claim id="clm-0033" num="33"><claim-text>33. The method of any of claims 26-32, wherein the panel includes AKAP8L, APLP2, ARAFl, ATP6V1H, BNIP3L, BRAF, C21orf7, CD59, COMMD9, CTGF, ENPP4, FAM13A, FLJ10357, FZD7, GLT8D1, HDAC9, HSF2, Ki67, KRAS, LEOl, MORF4L2, NAPILI, NOL3, NUDT3, OAZ2, PANK2, PHF21A, PKDl, PLD3, PNMA2, PQBPl, RAFl, RNF41, RSFl, RTN2, SMARCD3, SPATA7, SSTl, SST3, SST4, SST5, TECPR2, TPH1, TRMT112, VMAT1, VMAT2, VPS13C, WDFY3, ZFHX3, ZXDC, and ZZZ3 gene products. </claim-text></claim><claim id="clm-0034" num="34"><claim-text>34. The method of any of claims 26-33, wherein the panel comprises an APLP2 gene product, a CD59 gene product, an ARAFl gene product, a BRAFl gene product, a KRAS gene product, or a RAFl gene product. </claim-text></claim><claim id="clm-0035" num="35"><claim-text>35. The method of any of claims 26-34, wherein: </claim-text><claim-text> the plurality of GEP-NEN biomarkers includes APLP2, ARAFl, BRAF, CD59, CTGF, FZD7, Ki67, KRAS, NAPILI, PNMA2, RAFl, TPH1, and VMAT2 gene products; or </claim-text><claim-text> the panel of GEP-NEN biomarkers includes APLP2, ARAFl, BRAFl, CD59, KRAS, RAFl, CXCL14, GRIA2, HOXC6, NKX2-3, OR51E1, PNMA2, PTPRN2, SCG5, SPOCK1, <!-- EPO <DP n="154"/>--> X2BTB48, CgA, CTGF, FZD7, Ki-67, Kissl, MAGE-D2, MTA1, NAP1L1, NRP2, Tphl, VMAT1, VMAT2 and Survivin gene products. </claim-text></claim><claim id="clm-0036" num="36"><claim-text>36. The method of any of claims 26-35, wherein the biological test sample is a blood, plasma, serum, tissue, saliva, serum, urine, or semen sample. </claim-text></claim><claim id="clm-0037" num="37"><claim-text>37. The method of claim 36, wherein the biological test sample is from blood. </claim-text></claim><claim id="clm-0038" num="38"><claim-text>38. The method of any of claims 26-37, wherein the detection in step (b) is carried out using the system of any of claims 1-25. </claim-text></claim><claim id="clm-0039" num="39"><claim-text>39. The method of any of claims 26-38, wherein the test sample is taken from a GEP- NEN patient. </claim-text></claim><claim id="clm-0040" num="40"><claim-text>40. The method of any of claims 26-39, further comprising comparing the expression levels or expression profile of the biomarkers detected in the test biological sample to a normal or reference level of expression or a normal or reference expression profile. </claim-text></claim><claim id="clm-0041" num="41"><claim-text>41. The method of claim 40, wherein the method further comprises, prior to the comparing, obtaining a normal or reference sample; and detecting the presence, absence, expression levels, or expression profile of the panel of GEP-NEN biomarkers in the normal sample, whereby the normal or reference level of expression or expression profile used in the comparison is determined. </claim-text></claim><claim id="clm-0042" num="42"><claim-text>42. The method of any of claims 26-41, wherein: </claim-text><claim-text> the detection in step (b) comprises contacting the test sample with a set of </claim-text><claim-text>polynucleotides that specifically bind to the panel of GEP-NEN biomarkers. </claim-text></claim><claim id="clm-0043" num="43"><claim-text>43. The method of claim 42, wherein the set of polynucleotides comprises DNA, RNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides. </claim-text></claim><claim id="clm-0044" num="44"><claim-text>44. The method of claim 42 or 43, wherein the polynucleotides comprise sense and antisense primers, and detection in step (b) is carried out by (i) producing cDNA from the test <!-- EPO <DP n="155"/>--> sample by reverse transcription; (ii) amplifying the cDNA so produced with pairs of sense and antisense primers, which specifically hybridize to the panel of GEP-NEN biomarkers; and (iii) detecting products of the amplification. </claim-text></claim><claim id="clm-0045" num="45"><claim-text>45. The method of any of claims 26-44, wherein the presence, absence, expression levels, or expression profile indicates the presence, absence, classification, prognosis, risk, responsiveness to treatment, aggressiveness, severity, or metastasis of the GEP-NEN, or whether a GEP-NEN subject is treated or untreated, is in complete remission, or is clinically stable, or indicates the efficacy of a GEP-NEN treatment. </claim-text></claim><claim id="clm-0046" num="46"><claim-text>46. The method of any of claims 26-45, wherein the method classifies or detects a GEP-NEN in a human blood sample with a specificity or sensitivity of at least 80 %. </claim-text></claim><claim id="clm-0047" num="47"><claim-text>47. The method of any of claims 26-46, wherein the method differentiates between a subject with GEP-NEN and a subject with another type of gastrointestinal (GI) cancer, or differentiates between a subject with small intestinal NEN and a subject with a pancreatic NEN. </claim-text></claim><claim id="clm-0048" num="48"><claim-text>48. The method of any of claims 26-47, wherein the method predicts treatment responsiveness to, or determine whether a patient has become clinically stable following, or is responsive or non-responsive to, surgical intervention or somatostatin analog therapy, with at least 90 % accuracy. </claim-text></claim><claim id="clm-0049" num="49"><claim-text>49. The method of any of claims 26-48, wherein the method differentiates between treated and untreated GEP-NEN with a sensitivity and specificity of at least 85 %. </claim-text></claim><claim id="clm-0050" num="50"><claim-text>50. The method of any of claims 26-49, wherein the method determines whether or not a subject diagnosed with a GEP-NEN is in complete remission. </claim-text></claim><claim id="clm-0051" num="51"><claim-text>51. The method of any of claims 26-50, wherein the test sample is a blood sample and the method detects at least at or about three GEP-NEN cells per milliliter (mL) of whole blood. <!-- EPO <DP n="156"/>--> </claim-text></claim><claim id="clm-0052" num="52"><claim-text>52. The method of any of claims 26-51, further comprising computing a mean expression level for the panel of GEP-NEN biomarkers in the test biological sample. </claim-text></claim><claim id="clm-0053" num="53"><claim-text>53. The method of claim 52, wherein the computing is carried out by vectorally summing the detected expression levels for each of the plurality of GEP-NEN biomarkers. </claim-text></claim><claim id="clm-0054" num="54"><claim-text>54. The method of claim 41, wherein: </claim-text><claim-text> the test biological sample is from the GEP-NEN patient after treatment and the reference sample is from the same GEP-NEN patient prior to treatment; </claim-text><claim-text> the reference sample is from a tissue or fluid not containing GEP-NEN cells; </claim-text><claim-text> the reference sample is from a healthy individual; </claim-text><claim-text> the reference sample is from a cancer other than GEP-NEN; </claim-text><claim-text> the reference sample is from an EC cell or SI tissue; </claim-text><claim-text> the test biological sample is from a metastatic GEP-NEN and the reference sample is from a non-metastatic GEP-NEN; or </claim-text><claim-text> the reference sample is from a GEP-NEN of a different classification compared to the GEP-NEN patient from which the test biological sample is obtained. </claim-text></claim><claim id="clm-0055" num="55"><claim-text>55. The method of any of claims 26-54, wherein the method identifies the presence or absence, classification, or stage of GEP-NEN with between 80 % to 100 % predictive value, sensitivity, or specificity. </claim-text></claim><claim id="clm-0056" num="56"><claim-text>56. The method of any of claims 26-55, further comprising compressing the detected expression levels from the test biological sample, thereby determining an expression profile. </claim-text></claim><claim id="clm-0057" num="57"><claim-text>57. The method of any of claims 26-56, wherein the test biological sample is a whole blood or saliva sample from a GEP-NEN patient and expression levels or expression profile detected or determined for the test biological sample correlate(s) with the expression levels or expression profile for the same GEP-NEN biomarkers for a GEP-NEN tissue sample or purified GEP-NEN cell sample obtained from the same patient, with an R of at least about 0.4. <!-- EPO <DP n="157"/>--> </claim-text></claim><claim id="clm-0058" num="58"><claim-text>58. The method of any of claims 26-57, further comprising analyzing the data using a predictive algorithm. </claim-text></claim><claim id="clm-0059" num="59"><claim-text>59. The method of claim 58, wherein the predictive algorithm is selected from the group consisting of support vector machines (SVM), linear discriminant analysis (LDA), K- nearest neighbor (KNN) and naive Bayes (NB). </claim-text></claim><claim id="clm-0060" num="60"><claim-text>60. The method of claim 58, wherein the predictive algorithm is selected from the group consisting of decision tree, SVM, RDA, and Perceptron. </claim-text></claim><claim id="clm-0061" num="61"><claim-text>61. A method for detecting neuroendocrine tumor cells in blood, comprising: </claim-text><claim-text> obtaining a blood sample; and contacting the blood sample with one or more agents, which specifically binds to a panel of GEP-NEN biomarkers, comprising at least two GEP-NEN biomarkers, wherein the method detects at least at or about one, two, or three GEP-NEN cells per mL blood. </claim-text></claim><claim id="clm-0062" num="62"><claim-text>62. The method of claim 61, wherein the agents comprise the system of any of claims</claim-text><claim-text>1-25. </claim-text></claim><claim id="clm-0063" num="63"><claim-text>63. A method for enriching or isolating neuroendocrine tumor cells from a mixture of cells, comprising: contacting the mixture of cells with an agent that specifically binds to CD164; and purifying cells bound by the agent. </claim-text></claim><claim id="clm-0064" num="64"><claim-text>64. The method of claim 63, wherein the contacting further comprises contacting the cells with another agent, which is a GEP-NEN- specific reagent. </claim-text></claim><claim id="clm-0065" num="65"><claim-text>65. The method of claim 63 or 64, wherein the mixture of cells is a cell culture or a blood sample or other biological fluid. </claim-text></claim><claim id="clm-0066" num="66"><claim-text>66. The method of any of claims 63-65, wherein the method enriches or isolates at least at or about three cells per mL of blood. </claim-text></claim><claim id="clm-0067" num="67"><claim-text>67. A method of treatment, comprising: <!-- EPO <DP n="158"/>--> (a) providing a treatment to a GEP-NEN patient; </claim-text><claim-text> (b) obtaining a sample from the GEP-NEN patient and detecting expression levels of a panel of GEP-NEN biomarkers in the sample. </claim-text></claim><claim id="clm-0068" num="68"><claim-text>68. The method of claim 67, wherein step (a) further comprises, prior to providing treatment, determining pre-treatment expression levels of the panel of GEP-NEN biomarkers in a sample from a patient. </claim-text></claim><claim id="clm-0069" num="69"><claim-text>69. The method of claim 68, further comprising a step (c): comparing the pre- treatment expression levels to the expression levels detected in step (b). </claim-text></claim><claim id="clm-0070" num="70"><claim-text>70. The method of claim 69, further comprising determining that there is a difference in expression levels between the pre-treatment expression levels and the expression levels in step (b), which indicates the efficacy of the treatment. </claim-text></claim><claim id="clm-0071" num="71"><claim-text>71. The method of any of claims 67-70, further comprising determining expression levels of the biomarkers in the GEP-NEN patient at a later time and comparing them to the expression levels in step (b), wherein a difference between expression levels indicates a recurrence or lack of treatment responsiveness. </claim-text></claim><claim id="clm-0072" num="72"><claim-text>72. The method of any of claims 67-71, wherein the expression levels are detected using the system of any of claims 1-25. </claim-text></claim><claim id="clm-0073" num="73"><claim-text>73. The method of any of claims 67-72, wherein the levels of CgA expression in the patient sample of step (b) are not significantly different compared to pre-treatment CgA expression levels or to CgA expression levels at the later time. </claim-text></claim><claim id="clm-0074" num="74"><claim-text>74. The method of any of claims 67-73, further comprising discontinuing the treatment or modifying the treatment that is provided to the patient. </claim-text></claim><claim id="clm-0075" num="75"><claim-text>75. The method of any of claims 67-74, wherein the detection indicates the presence of a GEP-NEN micrometastasis in the patient. <!-- EPO <DP n="159"/>--> </claim-text></claim><claim id="clm-0076" num="76"><claim-text>76. The method of claim 75, wherein the sample in step (b), the pre-treatment sample, or the sample taken at a later time is or was determined to be free of GEP-NEN, GEP-NEN metastases, or GEP-NEN recurrence by histology or detection of CgA alone. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
